Abstract
Definitions in psychopharmacology have been coined by the activity of special compounds or chemical classes found in patients. This is not only true for the term “neuroleptic” but also for the term “anxiolytic.” Other terms have been “ataractic” or “psycholeptic.” Anxiolytics are derived from “tranquilizers,” such as meprobamate, which was used widely until the advent of benzodiazepines. The property which these drugs have in common is the alleviation of anxiety, thus explaining the term “anxiolytic.” These agents are used for the relatively minor disorders of the nonpsychotic or neurotic type, whereas the antipsychotic agents (phenothiazines, butyrophenones) are given mainly to combat the more severe psychotic or schizophrenic reactions. Thus, the terms “antianxiety” and “antipsychotic” indicate a qualitative distinction in the clinical use and mode of action of the drug. Pathological anxiety in man has been defined by its interference with normal functions, by manifestations of somatic disorders, emotional discomfort, interference with productivity at work, etc. This complex characterization of anxiety in man already indicates the difficulties to find appropriate pharmacological models. Therefore, several tests have to be performed to find a spectrum of activities which can be considered to be predictive for therapeutic efficacy in patients. For in vivo studies, most investigators use a battery of anticonvulsive tests, antiaggressive tests, and evaluation of conditioned behavior.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References and Further Reading
General Considerations
Boissier JR, Simon P (1969) Evaluation of experimental techniques in the psychopharmacology of emotion. Ann N Y Acad Sci 159:898–914
Costa E, Corda MG, Epstein B, Forchetti C, Guidotti A (1983) GABA-benzodiazepine interactions. In: Costa E (ed) The Benzodiazepines. From molecular biology to clinical practice. Raven Press, New York, pp 117–136
Costall B, Naylor RJ, Tyers MB (1988) Recent advances in the neuropharmacology of 5-HT3 agonists and antagonists. Rev Neurosci 2:41–65
Cotman CW, Iversen LL (1987) Excitatory amino acids in the brain-focus on NMDA receptors. Trends Neurosci 10:263–265
Fonnum F (1987) Biochemistry, anatomy, and pharmacology of GABA neurons. In: Meltzer HY (ed) Psychopharmacology: the third generation of progress. Raven Press, New York, pp 173–182
Lippa AS, Priscilla A, Nash BA, Greenblatt EN (1979) Preclinical neuropharmacological testing procedures for anxiolytic drugs. In: Fielding S, Lal H (eds) Anxiolytics. Futura Publishing, New York, pp 41–81
Lloyd KG, Morselli PL (1987) Psychopharmacology of GABAergic drugs. In: Meltzer HY (ed) Psychopharmacology: the third generation of progress. Raven Press, New York, pp 183–195
Peroutka SJ (1988) 5-Hydroxytryptamine receptor subtypes: molecular, biochemical and physiological characterization. Trends Neurosci 11:496–500
Watkins JC, Olverman HJ (1987) Agonists and antagonists for excitatory amino acid receptors. Trends Neurosci 10:265–272
Zukin SR, Young AB, Snyder SH (1974) Gamma-aminobutyric acid binding to receptor sites in the rat central nervous system. Proc Natl Acad Sci U S A 71:4801–4807
GABA Receptor Binding
Bormann J (2000) The “ABC” of GABA receptors. Trends Pharmacol Sci 21:16–19
Chehib M (2004) GABAC receptor ion channels. Clin Exp Pharmacol Physiol 31:800–804
Enna SJ, Möller H (1987) γ-Aminobutyric acid (GABA) receptors and their association with benzodiazepine recognition sites. In: Meltzer HY (ed) Psychopharmacology: the third generation of progress. Raven, New York, pp 265–272
Fritschy JM, Brünig I (2003) Formation and plasticity of GABAergic synapses: physiological mechanisms and pathophysiological implications. Pharmacol Ther 98:299–323
Matsumoto RR (1989) GABA receptors: are cellular differences reflected in function? Brain Res Rev 14:203–225
Möhler H (1992) GABAergic synaptic transmission. Arzneim Forsch/Drug Res 42:211–214
Pan Y, Khalili P, Ripps H, Qian H (2005) Pharmacology of GABAC receptors: responses to agonists and antagonists distinguish A- and B-subtypes of homomeric ρ receptors expressed in Xenopus oocytes. Neurosci Lett 376:60–65
Qian H, Ripps H (2001) The GABAC receptors of retinal neurons. Prog Brain Res 131:295–308
Ragozzino D, Woodward RM, Murata Y, Eusebi F, Overman LE, Miledi R (1996) Design and in vitro pharmacology of a selective gamma-aminobutyric acidC receptor antagonist. Mol Pharmacol 50:1024–1030
Schlicker K, Boller M, Schmidt M (2004) GABAC receptor mediated inhibition of acutely isolated neurons of the rat dorsal lateral geniculate nucleus. Brain Res Bull 63:91–97
Urwyler S, Mosbacher J, Lingenhoehl K, Heid J, Hofstetter K, Froestl W, Bettler B, Kaupmann K (2001) Positive allosteric modulation of native and recombinant γ -amino butyric acidB receptors by 2,6-di-tert-butyl-4-(3-hydroxy-2,2-dimethyl-propyl)-phenol (CGP7930) and its aldehyde analog CGP13501. Mol Pharmacol 60:963–971
Wang P, Slaughter MM (2005) Effects of GABA receptor antagonists on retinal glycine receptors and on homomeric glycine receptor alpha subunits. J Neurophysiol 93:3120–3126
Yang XL (2004) Characterization of receptors for glutamate and GABA in retinal neurons. Prog Neurobiol 73:127–159
In Vitro Assay for GABAergic Compounds: [3H]-GABA Receptor Binding
Enna SJ, Snyder SH (1975) Properties of γ-Aminobutyric acid (GABA) receptor binding in rat brain synaptic membrane fractions. Brain Res 100:81–97
Enna SJ, Snyder SH (1977) Influence of ions, enzymes, and detergents on γ-Aminobutyric acid-receptor binding in synaptic membranes of rat brain. Mol Pharmacol 13:442–453
Enna SJ, Collins JF, Snyder SH (1977) Stereo specificity and structure-activity requirements of GABA receptor binding in rat brain. Brain Res 124:185–190
Knott C, Bowery NG (1991) Pharmacological characterization of GABAA and GABAB receptors in mammalian CNS by receptor binding assays. In: Greenstein B (ed) Neuroendocrine Research Methods, vol 2. Harwood Academic Publications, Chur, pp 699–722
Lüddens H, Korpi ER (1995) Biological function of GABAA/benzodiazepine receptor heterogeneity. J Psychiatry Res 29:77–94
Zukin SR, Young AB, Snyder SH (1974) Gamma-aminobutyric acid binding to receptor sites in the rat central nervous system. Proc Natl Acad Sci U S A 71:4802–4807
GABAA Receptor Binding
Alexander S, Peters J, Mathie A, MacKenzie G, Smith A (2001) TiPS nomenclature supplement 2001
Barnard EA (1998) Multiple subtypes of the GABAA receptors. Naunyn Schmiedebergs Arch Pharmacol 358(Suppl 2):R 570
Barnard EA (2000) The molecular architecture of GABAA receptors. In: Möhler H (ed) Handbook of experimental pharmacology, pharmacology of GABA and glycine neurotransmission, vol 150. Springer, Heidelberg, pp 79–100
Barnard EA, Langer SZ (1998) GABAA receptors. NCIUPHAR subcommittee on GABAA receptors. The IUPHAR compendium of receptor characterization and classification 1998
Barnard EA, Skolnick P, Olsen RW, Mohler H, Sieghart W, Biggio G, Braestrup C, Bateson AN, Langer SZ (1998) International Union of Pharmacology. XV. Subtypes of γ-aminobutyric acidA receptors: classification on the basis of subunit structure and receptor function. Pharmacol Rev 50:291–313
Beaumont K, Chilton WS, Yamamura HI, Enna SJ (1978) Muscimol binding in rat brain: association with synaptic GABA receptors. Brain Res 148:153–162
Boehm SL, Ponomarev I, Jennings AW, Withing PJ, Rosahl TW, Garrett EM, Blednow YA, Harris RA (2004) γ-Aminobutyric acid: a receptor subunit mutant mice: new perspectives on alcohol actions. Biochem Pharmacol 68:1581–1602
Bormann J (2000) The ‘ABC’ of GABA receptors. Trends Pharmacol Sci 21:16–19
Bormann J, Feigenspan A (1995) GABAC receptors. Trends Neurosci 18:515–519
Chambon JP, Feltz P, Heaulme M, Restle S, Schlichter R, Biziere K, Wermuth CG (1985) An arylaminopyridazine derivative of γ-Aminobutyric acid (GABA) is a selective and competitive antagonist of the GABAA receptor site. Proc Natl Acad Sci U S A 82:1832–1836
Cheng YC, Prusoff WH (1973) Relationship between the inhibition constant (K i) and the concentration of inhibitor which causes 50 per cent inhibition (I 50) of an enzymatic reaction. Biochem Pharmacol 22:3099–3108
Costa E (1998) From GABAA receptor diversity emerges a unified vision of GABAergic inhibition. Ann Rev Pharmacol Toxicol 38:321–350
Cromer BA, Morton CJ, Parker MW (2002) Anxiety over GABAA receptor structure relieved by AchBP. Trends Biochem Sci 27:180–287
Enna SJ, Möller H (1987) γ-aminobutyric acid (GABA) receptors and their association with benzodiazepine recognition sites. In: Meltzer HY (ed) Psychopharmacology: the third generation of progress. Raven Press, New York
Enna SJ, Snyder SH (1976) Influence of ions, enzymes, and detergents on γ-aminobutyric acid-receptor binding in synaptic membranes of rat brain. Mol Pharmacol 13:442–453
Gusti P, Ducic I, Puia G, Arban R, Walser A, Guidotti A, Costa E (1993) Imidazenil: a new partial positive allosteric modulator of γ-aminobutyric acid (GABA) action at GABAA receptors. J Pharmacol Exp Ther 266:1018–1028
Heaulme M, Chambon JP, Leyris R, Molimard JC, Wermuth CG, Biziere K (1986) Biochemical characterization of the interaction of three pyridazinyl-GABA derivatives with the GABAA receptor site. Brain Res 384:224–231
Heaulme M, Chambon JP, Leyris R, Wermuth CG, Biziere K (1987) Characterisation of the binding of [3H]SR 95531, a GABAA antagonist, to rat brain membranes. J Neurochem 48:1677–1686
Johnston GAR (1996) GABAC receptors: relatively simple transmitter-gated ion channels? Trends Pharmacol Sci 17:319–323
Kittler JT, Moss SJ (2003) Modulation of GABAA receptor activity by phosphorylation and receptor trafficking: implications for the efficacy of synaptic inhibition. Curr Opin Neurobiol 13:341–347
Kleingoor C, Ewert M, von Blankenfeld G, Seeburg PH, Kettenmann H (1991) Inverse but not full benzodiazepine agonists modulate recombinant α 6 β 2 γ 2 GABAA receptors in transfected human embryonic kidney cells. Neurosci Lett 130:169–172
Krogsgaard-Larsen P, Frølund B, Jørgensen FS, Schousboe A (1994) GABAA receptor agonists, partial agonists, and antagonists. Design and therapeutic prospects. J Med Chem 37:2489–2505
Krogsgaard-Larsen P, Frølund B, Liljefors T, Ebert B (2004) GABAA agonists and partial antagonists; THIP (Gaboxadol) as a non-opioid analgesic and a novel type of hypnotic. Biochem Pharmacol 68:1573–1580
Lambert JJ, Belelli D, Hill-Venning C, Peters JA (1995) Neurosteroids and GABAA receptor function. Trends Pharmacol Sci 16:295–303
Lambert JJ, Belelli D, Peden DR, Vardy AW, Peters JA (2003) Neurosteroid modulation of GABAA receptors. Prog Neurobiol 71:67–80
Lewin AH, de Costa BR, Rice KC, Solnick P (1989) meta- and para-Isothiocyanato-t-butylbicycloorthobenzoate: irreversible ligand of the γ-aminobutyric acid-regulated chloride ionophore. Mol Pharmacol 35:189–194
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265–275
Lüscher B, Keller CA (2004) Regulation of GABAA receptor trafficking, channel activity, and functional plasticity of inhibitory synapses. Pharmacol Ther 102:195–223
Macdonald RL, Gallagher MJ, Feng HJ, Kang J (2004) GABAA receptor epilepsy mutations. Biochem Pharmacol 68:1497–1506
Martini C, Rigacci T, Lucacchini A (1983) [3H]muscimol binding site on purified benzodiazepine receptor. J Neurochem 41:1183–1185
Mody I, Pearce RA (2004) Diversity of inhibitory neurotransmission through GABAA receptors. Trends Neurosci 27:569–575
Mohler H, Malherbe P, Draguhn A, Richards JG (1990) GABAA-receptors: structural requirements and sites of gene expression in mammalian brain. Neurochem Res 15:199–207
Rudolph U, Mohler H (2004) Analysis of GABAA receptor function and dissection of the pharmacology of benzodiazepines and general anesthetics through mouse genetics. Annu Rev Pharmacol Toxicol 44:475–498
Rudolph U, Crestani F, Möhler H (2001) GABAA receptor subtypes: dissecting their pharmacological functions. Trends Pharmacol Sci 22:188–194
Schwartz RD, Mindlin MC (1988) Inhibition of the GABA receptor-gated chloride ion channel in brain by noncompetitive inhibitors of the nicotinic receptor-gated cation channel. J Pharmacol Exp Ther 244:963–970
Sieghart W (2000) Unraveling the function of GABAA receptor subtypes. Trends Pharmacol Sci 21:411–416
Smith GB, Olsen RW (1995) Functional domains and GABAA receptors. Trends Pharmacol Sci 16:162–168
Snodgrass SR (1978) Use of 3H-muscimol for GABA receptor studies. Nature 273:392–394
Turner DM, Sapp DW, Olsen RW (1991) The benzodiazepine/alcohol antagonist Ro 15–4513: binding to a GABAA receptor subtype that is insensitive to diazepam. J Pharmacol Exp Ther 257:1236–1242
Vicini S (1991) Pharmacologic significance of the structural heterogeneity of the GABAA receptor-chloride ion channel complex. Neuropsychopharmacology 4:9–15
Williams M, Risley EA (1978) Characterization of the binding of [3H]muscimol, a potent γ-aminobutyric acid antagonist, to rat synaptosomal membranes using a filtration assay. J Neurochem 32:713–718
Zhang D, Pan Z-H, Awobuluyi M, Lipton SA (2001) Structure and function of GABAC receptors: a comparison of native versus recombinant vectors. Trends Pharmacol Sci 22:121–132
GABAB Receptor Binding
Bettler B, Kaupmann K, Mosbacher J, Gassmann M (2003) Molecular structure and physiological functions of GABAB receptors. Physiol Rev 84:835–867
Bittiger H, Bernasconi R, Froestl W, Hall R, Jaekel J, Klebs K, Krueger L, Mickel SJ, Mondadori C, Olpe HR, Pfannkuch F, Pozza M, Probst A, van Riezen H, Schmutz M, Schuetz H, Steinmann MW, Vassout A, Waldmeyer P, Bieck P, Farger G, Gleiter C, Schmidt EK, Marescuax C (1992) GABAb antagonists: potential new drugs. Pharmacol Commun 2:70–74
Bittiger H, Froestl W, Mickel SJ, Olpe HR (1993) GABAB receptor antagonists: from synthesis to therapeutic applications. Trends Pharmacol Sci 14:391–394
Bonanno G, Raiteri M (1992) Functional evidence for multiple γ-aminobutyric acidB receptor subtypes in the rat cerebral cortex. J Pharmacol Exp Ther 262:114–118
Bonanno G, Raiteri M (1993a) Multiple GABAB receptors. Trends Pharmacol Sci 14:259–261
Bonanno G, Raiteri M (1993b) γ-aminobutyric acid (GABA) autoreceptors in rat cerebral cortex and spinal cord represent pharmacologically distinct subtypes of the GABAB receptor. J Pharmacol Exp Ther 265:765–770
Bowery NG (1993) GABAB receptor pharmacology. Annu Rev Pharmacol Toxicol 33:109–147
Bowery NG, Enna SJ (2000) γ-Aminobutyric acidB receptors: first of functional metabotropic heterodimers. J Pharmacol Exp Ther 292:2–7
Bowery G, Hill DR, Hudson AL (1983) Characterization of GABAB receptor binding sites on rat whole brain synaptic membranes. Br J Pharmacol 78:191–206
Bowery NG, Hill DR, Hudson AL (1985) (3H)(−)baclofen: an improved ligand for GABAB sites. Neuropharmacology 24:207–210
Bowery NG, Bettler B, Froestl W, Gallagher JP, Marshall F, Raiteri M, Bonner TI, Enna SJ (2003) International Union of Pharmacology. XXXIII. Mammalian γ-aminobutyric acidB receptors: structure and function. Pharmacol Rev 54:247–264
Cheng YC, Prusoff WH (1973) Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (IC50) of an enzymatic reaction. Biochem Pharmacol 22:3099–3108
Drew CA, Johnston GAR, Weatherby RP (1984) Bicucculineinsensitive GABA receptors: studies on the binding of (−)-baclofen to rat cerebellar membranes. Neurosci Lett 52:317–321
Enna SJ, Möller H (1987) γ-aminobutyric acid (GABA) receptors and their association with benzodiazepine recognition sites. In: Meltzer HY (ed) Psychopharmacology: the third generation of progress. Raven Press, New York, pp 265–272
Froestl W, Mickel SJ, Schmutz M, Bittiger H (1996) Potent, orally active GABAB receptor antagonists. Pharmacol Commun 8:127–133
Hill DR, Bowery NG (1981) 3H-baclofen and 3H-GABA bind to bicuculline-insensitive GABAB sites in rat brain. Nature 290:149–152
Kato K, Goto M, Fukuda H (1983) Regulation by divalent cations of 3H-baclofen binding to GABAB sites in rat cerebellar membranes. Life Sci 32:879–887
Kaupmann K, Huggel K, Held J, Flor PJ, Bischoff S, Mickel SJ, McMaster G, Angst C, Bittiger H, Froesti W, Bettler B (1997) Expression cloning of GABAB receptors uncovers similarity to metabotropic receptors. Nature 386:239–246
Kaupmann K, Malitschek B, Schuler V, Heid J, Froestl J, Beck P, Mosbacher J, Bischoff S, Kulik A, Shigemoto R, Karschin AS, Bettler B (1998) GABAB-receptor subtypes assemble into functional heteromeric complexes. Nature 396:683–687
Kerr DIB, Ong J, Prager RH, Gynther BD, Curtis DR (1987) Phaclofen: a peripheral and central baclofen antagonist. Brain Res 405:150–154
Kerr DIB, Ong J, Johnston GAR, Abbenante J, Prager RH (1988) 2-Hydroxy-saclofen: am improved antagonist at central and peripheral GABAB receptors. Neurosci Lett 92:92–96
Kerr DIB, Ong J, Johnston GAR, Abbenante J, Prager RH (1989) Antagonism of GABAB receptors by saclofen and related sulphonic analogues of baclofen and GABA. Neurosci Lett 107:239–244
Lanza M, Fassio A, Gemignani A, Bonanno G, Raiteri M (1993) CGP 52432: a novel potent and selective GABAB autoreceptor antagonist in rat cerebral cortex. Eur J Pharmacol 237:191–195
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265–275
Olpe HR, Karlsson G, Pozza MF, Brugger F, Steinman M, van Riezen H, Fagg G, Hall RG, Froestl W, Bittiger H (1990) CGP 35348: a centrally active blocker of GABAB receptors. Eur J Pharmacol 187:27–38
Paredes RG, Ågmo A (1992) GABA and behavior: the role of receptor subtypes. Neurosci Biobehav Rev 16:145–170
Robinson TM, Cross AJ, Green AR, Toczek JM, Boar BR (1989) Effects of the putative antagonists phaclofen and δ-aminovaleric acid on GABAB receptor biochemistry. Br J Pharmacol 98:833–840
Scherer RA, Ferkany JW, Enna SJ (1988) Evidence for pharmacologically distinct subsets of GABAB receptors. Brain Res Bull 21:439–443
Shank RP, Baldy WJ, Mattucci LC, Vilani FJ Jr (1990) Ion and temperature effects on the biding of γ-aminobutyrate to its receptors and the high-affinity transport system. J Neurochem 54:2007–2015
Shoulson I, Odoroff C, Oakes D, Behr J, Goldblatt D, Caine E, Kennedy J, Miller C, Bamford K, Rubin A, Plumb S, Kurlan R (1989) A controlled clinical trial of baclofen as protective therapy in early Huntington’s disease. Ann Neurol 25:252–259
Wilkin GP, Hudson AL, Hill DR, Bowery NG (1981) Autoradiographic localisation of GABAB receptors in rat cerebellum. Nature 294:584–587
Benzodiazepine Receptor: [3H]-Flunitrazepam Binding Assay
Byrnes JJ, Greenblatt DJ, Miller LG (1992) Benzodiazepine receptor binding of nonbenzodiazepines in vivo: Alpidem, Zolpidem and Zopiclone. Brain Res Bull 29:905–908
Chang RSL, Snyder SH (1978) Benzodiazepine receptors: labelling in intact animals with [3H]-flunitrazepam. Eur J Pharmacol 48:213–218
Damm HW, Müller WE, Schläfer U, Wollert U (1978) [3H]Flunitrazepam: its advantages as a ligand for the identification of benzodiazepine receptors in rat brain membranes. Res Commun Chem Pathol Pharmacol 22:597–600
Davies MF, Onaivi ES, Chen SW, Maguire PA, Tsai NF, Loew GH (1994) Evidence for central benzodiazepine receptor heterogeneity from behavior tests. Pharmacol Biochem Behav 49:47–56
Gardner CR (1988) Pharmacological profiles in vivo of benzo-diazepine receptor ligands. Drug Dev Res 12:1–28
Griebel G, Perrault G, Letang V, Granger P, Avenet P, Schoemaker H, Sanger DJ (1999a) New evidence that the pharmacological effects of benzodiazepine receptor ligands can be associated with activities at different BZ (omega) receptor subtypes. Psychopharmacology (Berl) 146:205–213
Griebel G, Perrault G, Tan S, Schoemaker H, Sanger DJ (1999b) Comparison of the pharmacological properties of classical and novel BZ-omega receptor ligands. Behav Pharmacol 10:483–495
Hafely WE, Martin JR, Richard JG, Schoch P (1993) The multiplicity of actions of benzodiazepine receptor ligands. Can J Psychiatry 38(Suppl 4):S102–S108
Iversen LL (1983) Biochemical characterisation of benzodiazepine receptors. In: Trimble MR (ed) Benzodiazepines divided. Wiley, Chichester, pp 79–85
Jacqmin P, Wibo M, Lesne M (1986) Classification of benzodiazepine receptor agonists, inverse agonists and antagonists using bicuculline in an in vitro test. J Pharmacol (Paris) 17:139–145
Klepner CA, Lippa AS, Benson DI, Sano MC, Beer B (1979) Resolution in two biochemically and pharmacologically distinct benzodiazepine receptors. Pharmacol Biochem Behav 11:457–462
Langer SZ, Arbilla S (1988) Limitations of the benzodiazepine receptor nomenclature: a proposal for a pharmacological classification as omega receptor subtypes. Fundam Clin Pharmacol 2:159–170
Langer SZ, Arbilla S, Tan S, Lloyd KG, George P, Allen J, Wick AE (1990) Selectivity of omega-receptor subtypes as a strategy for the development of anxiolytic drugs. Pharmacopsychiatry 23:103–107
Lüddens H, Korpi ER, Seeburg PH (1995) GABAA/benzodiazepine receptor heterogeneity: neurophysiological implications. Neuropharmacology 34:245–254
Mennini T, Garattini A (1982) Benzodiazepine receptors: correlation with pharmacological responses in living animals. Life Sci 31:2025–2035
Möhler H, Okada T (1977a) Benzodiazepine receptor: demonstration in the central nervous system. Science 198:849–851
Möhler H, Okada T (1977b) Properties of 3H-diazepam binding to benzodiazepine receptors in rat cerebral cortex. Life Sci 20:2101–2110
Möhler H, Richards JG (1983) Benzodiazepine receptors in the central nervous system. In: Costa E (ed) The benzodiazepines: from molecular biology to clinical practice. Raven Press, New York, pp 93–116
Olsen RW (1981) GABA-benzodiazepine-barbiturate receptor interactions. J Neurochem 37:1–13
Schacht U, Baecker G (1982) Effects of clobazam in benzodiazepine-receptor binding assays. Drug Dev Res Suppl 1:83–93
Sieghart W (1989) Multiplicity of GABAA-benzodiazepine receptors. Trends Pharmacol Sci 10:407–410
Speth RC, Wastek GJ, Johnson PC, Yamamura HI (1978) Benzodiazepine binding in human brain: characterization using [3H]flunitrazepam. Life Sci 22:859–866
Speth RC, Wastek GJ, Yamamura HI (1979) Benzodiazepine receptors: temperature dependence of 3H-diazepam binding. Life Sci 24:351–358
Squires RF, Braestrup C (1977) Benzodiazepine receptors in rat brain. Nature 266:732–734
Supavilai P, Karobath M (1980) Heterogeneity of benzodiazepine receptors in rat cerebellum and hippocampus. Eur J Pharmacol 64:91–93
Sweetnam PM, Tallman JF (1985) Regional difference in brain benzodiazepine receptor carbohydrates. Mol Pharmacol 29:299–306
Takeuchi T, Tanaka S, Rechnitz GA (1992) Biotinylated 1012–S conjugate as a probe ligand for benzodiazepine receptors: characterization of receptor binding sites and receptor assay for benzodiazepine drugs. Anal Biochem 203:158–162
Tallman JF (1980) Interaction between GABA and benzodiazepines. Brain Res Bull 5:829–832
Serotonin Receptor Binding
Allen AR, Singh A, Zhuang ZP, Kung MP, Kung HF, Lucki I (1997) The 5-HT1A receptor antagonist p-MPPI blocks responses mediated by postsynaptic and presynaptic 5-HT1A receptors
Ansanay H, Sebben M, Bockaert J, Dumuis A (1996) Pharmacological comparisons between [3H]-GR113808 binding sites and functional 5-HT4 receptors in neurons. Eur J Pharmacol 298:165–174
Arranz B, Rosel P, San L, Sarro S, Navarro MA, Marcusson J (1998) Characterization of the 5-HT4 binding site in human brain. J Neural Transm 105:575–586
Bachy A, Héaulme M, Giudice A, Michaud JC, Lefevre IA, Souilhac J, Manara L, Emerit MB, Gozian H, Hamon M, Keane PE, Soubrié P, Le Fur G (1993) SR 57227A: a potent and selective agonist at central and peripheral 5-HT3 receptors in vitro and in vivo. Eur J Pharmacol 237:299–309
Barnes NM, Sharp T (1999) A review of central 5-HT receptors and their function. Neuropharmacology 38:1083–1152
Bockaert J, Fagni L, Dumuis A (1997) 5-HT4 receptors: an update. In: Baumgarten HG, Göthert M (eds) Handbook of experimental pharmacology. Serotoninergic neurons and 5-HT receptors in the CNS, vol 129. Springer, Berlin/Heidelberg, pp 439–474
Boess FG, Martin LL (1994) Molecular biology of 5-HT receptors. Neuropharmacology 33:275–317
Boess FG, Steward LJ, Steele JA, Liu D, Reid J, Glencorse TA, Martin IL (1997) Analysis of the ligand binding site of the 5-KT3 receptor using site direction mutagenesis: importance of glutamate 106. Neuropharmacology 36:637–647
Boess FG, Riemer C, Bos M, Bentley J, Bourson A, Sleight AJ (1998) The 5-hydroxytryptamine6 receptor-selective radioligand [3H]Ro 63–0563 labels 5-hydroxytryptamine receptor binding sites in rat and porcine striatum. Mol Pharmacol 54:577–583
Bonhaus DW, Bach C, DeSouza A, Salazar FH, Matsuoka DB, Zuppan P, Chan HW, Eglen RM (1995) The pharmacology and distribution of human 5-hydroxytryptamine2B (5-HT2B) receptor gene products: comparison with 5-HT2A and 5-HT2C receptors. Br J Pharmacol 115:622–628
Bourson A, Borroni E, Austin RH, Monsma FJ Jr, Sleight AJ (1995) Determination of the role of the 5-ht6 receptor in the rat brain: a study using antisense oligonucleotides. J Pharmacol Exp Ther 274:173–180
Branchek TA (1995) 5-HT4, 5-HT6, 5-HT7; molecular pharmacology of adenylate cyclase stimulating receptors. Neuroscience 7:375–382
Branchek TA, Blackburn TP (2000) 5-HT6 receptors as emerging targets for drug discovery. Annu Rev Pharmacol Toxicol 40:119–134
Branchek TA, Zgombick (1997) Molecular biology and potential role of 5-HT5, 5-HT6, and 5-HT7 receptors. In: Baumgarten HG, Göthert M (eds) Handbook of experimental pharmacology. Serotoninergic neurons and 5-HT receptors in the CNS, vol 129. Springer, Berlin/Heidelberg, pp 475–498
Brattelid T, Kvingedal AM, Krobert KA, Andressen KW, Bach T, Hystad ME, Kaumann AJ, Levy FO (2004) Cloning, pharmacological characterization and tissue distribution of an novel 5-HT4 receptor splice variant, 5-HT4i. Naunyn Schmiedebergs Arch Pharmacol 369:616–628
Briley M, Chopin P, Marien M, Moret C (1997) Functional neuropharmacology of compounds acting on 5-HT1B/1D receptors. In: Baumgarten HG, Göthert M (eds) Handbook of experimental pharmacology. Serotoninergic neurons and 5-HT receptors in the CNS, vol 129. Springer, Berlin/Heidelberg, pp 269–306
Bühlen M, Fink K, Böing C, Göthert M (1996) Evidence for presynaptic localization of inhibitory 5-HT1D β -like autoreceptors in the guinea-pig brain cortex. Naunyn Schmiedebergs Arch Pharmacol 353:281–289
Cappelli A, Donati A, Anzini M, Vomero S, de Benedetti PG, Menziani MC, Langer T (1996) Molecular structure and dynamics of some potent 5-HT3 receptor antagonists. Insight into the interaction with the receptor. Bioorg Med Chem 4:1255–1269
Carey JE, Wood MD, Blackburn TP, Browne MJ, Gale DG, Glen A, Flanigan TP, Hastwell C, Muir A, Robinson JH, Wilson S (1996) Pharmacological characterization of a recombinant human 5-HT2C receptor expressed in HEK293 cells. Pharmacol Commun 7:165–173
Chagraoui A, Potais P, Fillpox T, Mocaer E (2003) Agomelatine (S20088) antagonizes the penile erections induced by the stimulation of 5-HT2C receptors in Wistar rats. Psychopharmacology (Berl) 170:17–22
Chen K, Yang W, Grimsby J, Shih JC (1992) The human 5-HT2 receptor is encoded by a multiple intron-exon gene. Mol Brain Res 14:20–26
Clayton NM, Sargent R, Butler A, Gale J, Maxwell MP, Hunt AA, Barrett VJ, Cambridge D, Bountra C, Humphrey PP (1999) The pharmacological properties of the novel selective 5-HT3 receptor antagonist, alsosetron, and its effects on normal and perturbed small intestinal transit in the fasted rat. Neurogastroenterol Motil 11:207–217
Clitherow JW, Scopes DIC, Skingle M, Jordan CC, Feniuk W, Campbell IB, Carter MC, Collington EW, Connor HE, Higgins GA, Beattie D, Kelly HA, Mitchell WL, Oxford AW, Wadsworth AH, Tyers MB (1994) Evolution of a new series of [(N, N-dimethylamino)propyl]- and piperazinylbenzanilides as the first selective 5-HT1D antagonists. J Med Chem 37:2253–2257
Costal B, Naylor RJ (1997) Neuropharmacology of 5-HT3 receptor ligands. In: Baumgarten HG, Göthert M (eds) Handbook of experimental pharmacology. Serotoninergic neurons and 5-HT receptors in the CNS, vol 129. Springer, Berlin/Heidelberg, pp 409–438
Cushing DJ, Baez M, Kursar JD, Schenk K, Cohen ML (1994) Serotonin-induced contraction in canine coronary artery and saphenous vein: role of a 5-HT1D-like receptor. Life Sci 54:1671–1680
De la Vega L, Muñoz E, Calcado MA, Lieb K, Candelario-Jahil E, Gschaidmeier H, Färber L, Mueller W, Stratz T, Fiebich BL (2005) The 5-HT3 receptor antagonist tropisetron inhibits T cell activation by targeting the calcineurin pathway. Biochem Pharmacol 70:369–380
De Vries P, Heilgers JPC, Villalón CM, Saxena PR (1996) Blockade of porcine carotid vascular responses to sumatripan by GR127935, a selective 5-HT1D receptor antagonist. Br J Pharmacol 118:85–92
De Vries P, Apayadin S, Villalón CM, Heiligers JPC, Saxena PR (1997) Interactions of GR127935, a 5-HT1B/D receptor ligand, with functional 5-HT receptors. Naunyn Schmiedebergs Arch Pharmacol 355:423–430
de Vry J (1995) 5-HT1A receptor agonists: recent developments and controversial issues. Psychopharmacology (Berl) 121:1–26
de Vry J, Glaser T, Schuurman T, Schreiber R, Traber J (1991) 5-HT1A receptors in anxiety. In: Briley M, File SE (eds) New concepts in anxiety. McMillan Press, London, pp 94–129
Domenech T, Beleta J, Fernandez AG, Gristwood RW, Sanchez FC, Tolasa E, Palacios JM (1994) Identification and characterization of serotonin central 5-HT4 receptor binding sites in human brain: Comparison with other mammalian species. Mol Brain Res 21:176–180
Dumuis A, Gozian H, Sebben M, Ansanay H, Rizzi CA, Turconi M, Monferini E, Giraldo E, Schiantarelli P, Ladinky H (1992) Characterization of a novel 5-HT4 receptor antagonist of the azabicycloalkyl benzamidazolone class: DAU 6285. Naunyn Schmiedebergs Arch Pharmacol 345:264–269
Eglen RM (1967) 5-Hydroxytryptamine (5-HT)4 receptors and central nervous system function: an update. Prog Drug Res 49:9–24
Eglen RM, Hegde SS (1966) 5-Hydroxytryptamine (5-HT)4 receptors: physiology, pharmacology and therapeutic potential. Exp Opin Invest Drugs 5:373–388
Eglen RM, Wong EHF, Dumuis A, Bockaert J (1995) Central 5-HT4 receptors. Trends Pharmacol Sci 16:391–398
Endo T, Minami M, Kitamura N, Teramoto Y, Ogawa T, Nemoto M, Hamaue N, Hirafuji M, Yasuda E, Blower PR (1999) Effects of various 5-HT3 receptor antagonists, granisetron, ondansetron, ramosetron and azasetron on serotonin (5-HT) release from the ferret isolated ileum. Res Commun Med Pathol Pharmacol 104:145–155
Fink K, Zentner J, Göthert M (1995) Subclassification of presynaptic 5-HT autoreceptors in the human cerebral cortex as 5-HT1Dβ receptors. Naunyn Schmiedebergs Arch Pharmacol 352:451–454
Fitzpatrick LR, Lambert RM, Pendley CE, Martin GE, Bostwick JF, Gessner GW, Airey JE, Youssefyeh RD, Pendleton RG, Decktor DL (1990) RG 12915: a potent 5-hydroxytryptamine-3 antagonist that is an orally effective inhibitor of cytotoxic drug-induced emesis in the ferret and dog. J Pharmacol Exp Ther 254:450–455
Ford APDW, Clarke DW (1993) The 5-HT4 receptor. Med Res Rev 13:633–662
Foreman MM, Fuller RW, Rasmussen K, Nelson DL, Calligaro DO, Zhang L, Barrett JE, Booher RN, Paget CJ Jr, Flaugh ME (1994) Pharmacological characterization of LY293284: a 5-HT1A receptor agonist with high potency and selectivity. J Pharmacol Exp Ther 270:1270–1291
Gaster LM, Joiner GF, King FD, Wyman PA, Sutton JM, Bingham S, Ellis ES, Sanger GJ, Wardle KA (1995) N-[(1-Butyl-4-piperidinyl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-α]-indole-10-carboxamide hydrochloride: the first potent and selective 5-HT4 receptor antagonist amide with oral activity. J Med Chem 38:4760–4763
Gerald C, Adham N, Kao HT, Olsen MA, Laz TM, Schechter LE, Bard JA, Vaysse PJJ, Hartig PR, Branchek TA, Weinshank RL (1995) The 5-HT4 receptor: molecular cloning and pharmacological characterization of two splice variants. EMBO J 14:2806–2815
Gershon MD (2004) Review article: serotonin receptors and transporters – roles in normal and abnormal gastrointestinal motility. Aliment Pharmacol Ther 20(Suppl 7):3–14
Glennon RA, Dukat M (1997) 5-HT1 receptor ligands: update 1997. Serotonin ID Res Alert 2:351–372
Glennon RA, Dukat M, Westkaemper RB, Ismaiel AM, Izzarelli DG, Parker EM (1996) The binding of propranolol at 5-hydroxytryptamine1Dβ T355N mutant receptors may involve formation of two hydrogen bonds to asparagine. Mol Pharmacol 49:198–206
Gobbi M, Parotti L, Mennini T (1996) Are 5-hydroxytryptamine7 receptors involved in [3H]5-hydroxytryptamine binding to 5-hydroxytryptamine1nonA−nonB receptors in rat hypothalamus? Mol Pharmacol 49:556–559
Göthert M, Schlicker E (1997) Regulation of 5-HT release in the CNS by presynaptic 5-HT autoreceptors and by 5-HT heteroreceptors. In: Baumgarten HG, Göthert M (eds) Handbook of experimental pharmacology. Serotoninergic neurons and 5-HT receptors in the CNS, vol 129. Springer, Berlin/Heidelberg, pp 307–350
Grossman CJ, Kilpatrick GJ, Bunce KT (1993) Development of a radioligand binding assay for 5-HT4 receptors in guineapig and rat brain. Br J Pharmacol 109:618–624
Gustafson EL, Durkin MM, Bard JA, Zgombick J, Branchek TA (1996) A receptor autoradiographic and hybridization analysis of the distribution of the 5-HT7 receptor in rat brain. Br J Pharmacol 117:657–666
Hamon M (1997) The main features of central 5-HT1A receptor. In: Baumgarten HG, Göthert M (eds) Handbook of experimental pharmacology. Serotoninergic neurons and 5-HT receptors in the CNS, vol 129. Springer, Berlin/Heidelberg, pp 239–268
Hartig PR (1997) Molecular biology and transductional characteristics of 5-HT receptors. In: Baumgarten HG, Göthert M (eds) Handbook of experimental pharmacology. Serotoninergic neurons and 5-HT receptors in the CNS, vol 129. Springer, Berlin/Heidelberg, pp 175–212
Hartig PR, Hoyer D, Humphrey PPA, Martin GR (1996) Alignment of receptor nomenclature with the human genome: classification of 5-HT1B and 5-HT1D receptor subtypes. Trends Pharmacol Sci 17:103–105
Hedlund PB, Sutcliffe JG (2004) Functional, molecular and pharmacological advances in 5-HT7 receptor research. Trends Pharmacol Sci 25:481–486
Heidempergher F, Pillan A, Pinciroli V, Vaghi F, Arrigoni C, Bolis G, Caccia C, Dho L, McArthur R, Varsi M (1997) Phenylimidazolin-2-one derivatives as selective 5-HT3 receptor antagonists and refinement of the pharmacophore model for 5-HT3 receptor binding. J Med Chem 40:3369–3380
Hoyer D, Martin GR (1997) 5-HT receptor classification and nomenclature: towards a harmonization with the human genome. Neuropharmacology 36:419–428
Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, Saxena PR, Humphrey PP (1994) VII. International Union of Pharmacology classification of receptors for 5-Hydroxytryptamine (serotonin). Pharmacol Rev 46:157–203
Humphrey PPA, Hartig P, Hoyer D (1993) A proposed new nomenclature for 5-HT receptors. Trends Pharmacol Sci 14:233–236
Ishizuka J, Hsieh AC, Townsend CM, Thompson JC (1993) The effect of 5-HT3 receptor antagonist (ondansetron) on functioning human pancreatic carcinoids cells. Surg Oncol 2:221–225
Ito H, Hidaka K, Miyata K, Kamato T, Nishida A, Honda K (1992) Characterization of YM060, a potent and selective 5-hydroxytryptamine3 receptor antagonist, in rabbit nodose ganglion and N1E-115 neuroblastoma cells. J Pharmacol Exp Ther 263:1127–1132
Ito H, Akuzawa SA, Tsutsumi R, Kiso T, Kamato T, Nishida A, Yamano M, Miyata K (1995) Comparative study of the 5-HT3 receptor antagonists, YM060, YM114 (KAE-393) granisetron and ondansetron in rat vagus nerve and cerebral cortex. Neuropsychopharmacology 34:631–637
Jacobs BL, Fornal CA (1997) Physiology and pharmacology of brain serotoninergic neurons. In: Baumgarten HG, Göthert M (eds) Handbook of experimental pharmacology. Serotoninergic neurons and 5-HT receptors in the CNS, vol 129. Springer, Berlin/Heidelberg, pp 91–116
Johnson MP, Baez M, Kursar JD, Nelson DL (1995) Species differences in 5-HT2A receptors: cloned pig and monkey 5-HT2A receptors reveal conserved transmembrane homology to the human rather than rat sequence. Biochem Biophys Acta 1236:201–206
Karim F, Roerig SC, Saphier D (1996) Role of 5-hydroxytryptamine3 (5-HT3) antagonists in the prevention of emesis caused by anticancer therapy. Biochem Pharmacol 52:685–692
Katayama K, Morio Y, Haga K, Fukuda T (1995) Cisapride, a gastroprokinetic agent, binds to 5-HT4 receptors. Folia Pharmacol Jpn 105:461–468
Kaumann AJ (1994) Do human atrial 5-HT4 receptors mediate arrhythmias? Trends Pharmacol Sci 15:451–455
Kebabian JW, Neumeyer JL (1994) The handbook of receptor classification. Research Biochemicals International, Natick, pp 58–61
Kidd E, Bouchelet de Vendegies I, Levy JC, Harmon M, Gozian H (1992) The potent 5-HT3 receptor antagonist (R)-zacopride labels an additional high affinity site in the central nervous system. Eur J Pharmacol 211:133–136
Koulu M, Lapppalainen J, Hietala J, Sjoholm B (1990) Effects of chronic administration of ondansetron (GR38032F), a selective 5-HT3 receptor antagonist, on monoamine metabolism in mesolimbic and nigrostriatal dopaminergic neurons and on striatal D2 receptor binding. Psychopharmacology (Berl) 101:166–171
López-Rodíguez ML, Benhamú B, Viso A, Morcollo MJ, Murcia M, Orensanz L, Alfaro MJ, Martín MI (1999) Benzimidazole derivatives. Part 1: synthesis and structure-activity relationships of new benzimidazole-4-carboxamides and carboxylates as potent and selective 5-HT4 receptor antagonists. Bioorg Med Chem 7:2271–2281
Lovenberg TW, Baron BM, de Lecea L, Miller JD, Prosser RA, Rea MA, Foye PE, Racke M, Slone AL, Siegel BW, Danielson PE, Sutcliffe JG, Erlander MG (1993) A novel adenyl cyclase-activating serotonin receptor (5-HT7) implicated in the regulation of mammalian circadian rhythms. Neuron 11:449–458
Lucaites VL, Krushinski JH, Schaus JM, Audia JE, Nelson DE (2005) [3H]Y334370, a novel radioligand for the 5-HT1F receptor. II. Autoradiographic localization in rat, guinea pig, monkey and human brain. Naunyn Schmiedebergs Arch Pharmacol 371:178–184
Macor JE, Blank DH, Fox CB, Lebel LA, Newman ME, Post RJ, Ryan K, Schmidt AW, Schulz DW, Koe BK (1994) 5-[(3-Nitropyrid-2-yl)amino]indoles: novel serotonin antagonists with selectivity for the 5-HT1D receptor. Variation of the C3 substituent on the indole template leads to increased 5-HT1D receptor selectivity. J Med Chem 37:2509–2512
Macor JE, Gurley D, Lanthorn T, Loch J, Mack RA, Mullen G, Tran O, Wright N, Gordon JC (2001) The 5-HT3 antagonist tropisetron (ICS 205–930) is a potent and selective α 7 nicotinic receptor partial agonist. Bioorg Med Chem Lett 11:319–321
Malone HM, Peters JA, Lambert JJ (1991) Physiological and pharmacological properties of 5-HT3 receptors a patchclamp study. Neuropeptides 19(Suppl):S25–S30
Martin GR (1998) 5-Hydroxytryptamine receptors. NCIUPHAR subcommittee for 5-hydroxytryptamine (serotonin) receptors. In: Gridlestone D (ed) The IUPHAR compendium of receptor characterization and classification. IUPHAR Media, London, pp 167–184
Martin GR, Eglen RM (1998) 5-Hydroxytryptamine receptors. Trends Pharmacol Sci: Receptor Ion Channel Nomencl Suppl
Martin GR, Humphrey PPA (1994) Classification review. Receptors for 5-hydroxytryptamine: current perspectives on classification and nomenclature. Neuropharmacology 33:261–273
Miyata K, Yamano M, Kamato T, Akuzawa S (1995) Effect of serotonin (5-HT)3 – receptor antagonists, YM060, YM114 (KAE-393), ondansetron and granisetron on 5-HT4 receptors and gastric emptying in rodents. Jpn J Pharmacol 69:205–214
Modica M, Romeo G, Materia L, Russo F, Cagnotto A, Mennini T, Gáspár R, Falkay G, Fülöp F (2004) Synthesis and binding properties of several novel selective 5-HT3 receptor ligands. Bioorg Med Chem 12:3891–3901
Murphy DL, Wichems C, Li Q, Heils A (1999) Molecular manipulations as tools for enhancing our understanding of 5-HT neurotransmission. Trends Pharmacol Sci 20:246–252
Nelson DL (2004) 5-HT5 receptors. CNS Neurol Disord Drug Targets 3:53–58
Pauwels PJ (2000) Diverse signaling by 5-hydroxytryptamine (5-HT) receptors. Biochem Pharmacol 60:1743–1750
Peroutka SH (1993) 5-Hydroxytryptamine receptors. J Neurochem 60:408–418
Porsolt RD, Lenègre A, Caignard DH, Pfeiffer B, Mocaër E, Gardiola-Lemaître B (1992) Pharmacological profile of a new chroman derivative with 5-hydroxytryptamine1A agonist properties: S20499(+). Drug Dev Res 27:389–402
Price GW, Roberts C, Watson J, Burton M, Mulholland K, Middlemiss DN, Jones BJ (1996) Species differences in 5-HT autoreceptors. Behav Brain Res 73:79–82
Ramboz S, Oosting R, Amara DA, Kung HF, Blier P, Mendelson M, Mann JJ, Brunner D, Hen R (1998) Serotonin receptor 1A knockout: an animal model of anxiety-related disorder. Proc Natl Acad Sci U S A 95:14476–14481
Rival Y, Hoffmann R, Didier B, Rybaltchenko V, Bourguignon JJ, Wermuth CG (1998) 5-HT3 antagonists derived from aminopyridazine-type muscarinic M1 agonists. J Med Chem 41:311–317
Roberts C, Watson J, Burton M, Price GW, Jones BJ (1996) Functional characterization of the 5-HT terminal autoreceptor in the guinea-pig brain cortex. Br J Pharmacol 117:384–388
Roila F, Ballatori E, Tonato M, Favero D (1997) 5-HT3 Receptor antagonists: differences and similarities. Eur J Cancer 33:1364–1370
Rollema H, Clarke T, Sprouse JS, Schulz DW (1996) Combined administration of a 5-hydroxytryptamine (5-HT)1D antagonist and a 5-HT reuptake inhibitor synergistically increases 5-HT release in guinea pig hypothalamus in vivo. J Neurochem 67:2204–2207
Rosen T, Seeger TF, McLean S, Nagel AA, Ives JL, Guarino KJ, Bryce D, Furman J, Roth RW, Chalabi PM (1990) Synthesis, in vitro binding profile, and central nervous system penetrability of the highly potent 5-HT3 receptor antagonist [3H]-4-(2-methoxyphenly)-2[4(5)-methyl-5(4)-imidazolylmethyl]thiazole. J Med Chem 33:3020–3023
Roth BL, Hyde EG (1997) Pharmacology of 5-HT2 receptors. In: Baumgarten HG, Göthert M (eds) Handbook of experimental pharmacology. Serotoninergic neurons and 5-HT receptors in the CNS, vol 129. Springer, Berlin/Heidelberg, pp 367–394
Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ, Shen YX, Meltzer HY, Sibley DR (1994) Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 268:1403–1410
Rousselle JC, Massot O, Delepierre M, Zifa M, Rousseau B, Fillion G (1996) Isolation and characterization of an endogenous peptide from rat brain interacting specifically with the serotonergic 1B receptor subtypes. J Biol Chem 271:726–735
Routledge C, Bromidge SM, Moss SF, Price GW, Hirst W, Newman H, Riley G, Gager T, Staen J, Upton N, Clarke SE, Brown AM, Middlemiss DM (2000) Characterization of SB-271046, a potent, selective and orally active 5-HT6 receptor antagonist. Br J Pharmacol 130:1606–1612
Ruat M, Traiffort E, Arrang JM, Tradivel-Lacombe J, Diaz J, Leurs R, Schwartz CJ (1993) A novel rat serotonin (5-HT6) receptor: molecular cloning, localization and stimulation of cAMP accumulation. Biochem Biophys Res Commun 193:268–276
Sanger GJ, Nelson DR (1989) Selective and functional 5-hydroxytryptamine3 receptor antagonism by BRL 43694 (granisetron). Eur J Pharmacol 159:113–124
Saucler C, Albert PE (1997) Identification of an endogenous 5-hydroxytryptamine2A receptor in NIH-3 T3 cells: agonist-induced down-regulation involves decrease in receptor RNA and number. J Neurochem 68:1989–2011
Saxena PR (1994) Modern 5-HT receptor classification and 5-HT based drugs. Exp Opin Invest Drugs 3:513–523
Saxena PR, de Vries P, Villalón CM (1998) 5-HTa-like receptors: a time to bid goodbye. Trends Pharmacol Sci 19:311–316
Schiavi GB, Brunet S, Rizzi CA, Ladinsky H (1994) Identification of serotonin 5-HT4 recognition sites in the porcine caudate nucleus by radioligand binding. Neuropharmacology 33:543–549
Shen Y, Monsma FJ Jr, Metcalf MA, Jose PA, Hamblin MW, Sibley DR (1993) Molecular cloning and expression of a 5-hydroxytryptamine7 serotonin receptor subtype. J Biol Chem 268:18200–18204
Shi H, Chen K, Gallaher TK (1994) Structure and function of serotonin 5-HT2 receptors. NIDA Res Monogr Ser 146:284–297
Sills MA, Wolfe BB, Frazer A (1984) Determination of selective and nonselective compounds for the 5-HT1A and 5-HT1B receptor subtypes in rat frontal cortex. J Pharmacol Exp Ther 231:480–487
Silverstone PH, Greenshaw AJ (1996) 5-HT3 receptor antagonists. Expert Opin Ther Pat 6:471–481
Sleight AJ, Boess FG, Bourson A, Sibley DR, Monsma FJ (1995) 5-HT6 and 5-HT7 serotonin receptors: molecular biology and pharmacology. Neurotransmissions 11(3):1–5
Starke K, Göthert M, Kilbinger H (1989) Modulation of neurotransmitter release by presynaptic autoreceptors. Physiol Rev 69:864–989
Stowe RL, Barnes NM (1998) Selective labelling of receptor recognition sites in rat brain using [3H]5-carboxamidotryptamine. Neuropharmacology 37:1611–1619
Swain CJ, Baker K, Kneen C, Moseley J, Saunders J, Seward EM, Stevenson G, Beer M, Stanton J, Watling K (1991) Novel 5-HT3 antagonists: indole oxadiazoles. J Med Chem 34:140–151
Tricklebank MD (1996) The antipsychotic potential of subtypeselective 5-HT-receptor ligands based on interactions with mesolimbic dopamine systems. Behav Brain Res 73:15–17
Uphouse L (1997) Multiple serotonin receptors: too many, not enough, or just the right number? Neurosci Biobehav Rev 5:679–698
Valentin JP, Bonnafous R, John GW (1996) Influence of the endothelium and nitric oxide on the contractile response evoked by 5-HT1D receptor agonists in the rabbit isolated saphenous vein. Br J Pharmacol 119:35–42
Van Lommen G, de Bruyn M, Schroven M, Verschueren W, Jansses W, Verrelst J, Leysen J (1995) The discovery of a series of new non-indole 5-HT1D agonists. Bioorgan Med Chem Lett 5:2649–2654
Vanhoenacker P, Haegeman G, Leysen JE (2000) The 5-HT7 receptors: current knowledge and future prospects. Trends Pharmacol Sci 21:70–77
Villalón CM, Centurión D, Luján-Estrada M, Terrón JA, Sánchez-López A (1997) Mediation of 5-HT-induced external carotid vasodilatation in GR 127935-pretreated vagosympathectomized dogs by the putative 5-HT7 receptor. Br J Pharmacol 120:1319–1327
Waeber C, Pinkus LM, Palacios JM (1990) The (S) isomer of [3H]zacopride labels 5-HT3 receptors with high affinity in rat brain. Eur J Pharmacol 181:283–287
Wainscott DB, Krushinski JH, Audia JE, Schaus JM, Zgombick JM, Lucaites VL, Nelson DL (2005) 3H]Y334370, a novel radioligand for the 5-HT1F receptor. I. In vitro characterization of binding properties. Naunyn Schmiedebergs Arch Pharmacol 371:169–177
Wardle KA, Ellis ES, Baxter GS, Kennett GA, Gaster LM, Sanger GJ (1994) The effects of SB 204070, a highly potent and selective 5-HT4 receptor antagonist, on guinea-pig distal colon. Br J Pharmacol 112:789–794
Watts SW, Cohen ML (1999) Vascular 5-HT receptors: pharmacology and pathophysiology of 5-HT1B, 5-HT1D, 5-HT1F, 5-HT2B, and 5-HT7 receptors. Neurotransmissions 15:3–15
Wolf WA, Schutz LJ (1997) The serotonin 5-HT2C receptor is a prominent serotonin receptor in basal ganglia. Evidence from functional studies on serotonin-mediated phosphoinositide hydrolysis. J Neurochem 69:1449–1458
Wolff MC, Benvenga MJ, Calligaro DO, Fuller RW, Gidda JS, Hemrick-Luecke S, Lucot JB, Nelson DL, Overshiner CD, Leander JD (1997) Pharmacological profile of LY301317, a potent and selective 5-HT1A agonist. Drug Dev Res 40:17–34
Wooley ML, Marsden CA, Sleight AJ, Fone KCF (2003) Reversal of cholinergic-induced deficit in a rodent model of recognition memory by the selective 5-HT6 receptor antagonist, Ro 04–6790. Psychopharmacology (Berl) 170:358–367
Wooley ML, Marsden CA, Fone KCF (2004) 5-HT6 receptors. CNS Neurol Disord Drug Targets 3:59–79
Yan D, White MM (2005) Spatial orientation of the antagonist granisetron in the ligand-binding site of the 5-HT3 receptor. Mol Pharmacol 68:365–371
Serotonin (5-HT1A) Receptor: Binding of [3H]-8-Hydroxy-2-(di-n-Propylamino)-Tetralin ([3H]-DPAT)
Alper RH, Nelson DL (1998) Characterization of 5-HT1A receptor-mediated [35S]-GTPγS binding in rat hippocampal membranes. Eur J Pharmacol 343:303–312
Alper RH, Nelson DL (2000) Inactivation of 5-HT1A receptors in hippocampal and cortical homogenates. Eur J Pharmacol 390:67–73
Artais I, Romero G, Zazpe A, Monge A, Caldero JM, Roca J, Lasheras B, del Rio J (1995) The pharmacology of VA21B7: an atypical 5-HT3 receptor antagonist with anxiolytic-like properties in animal models. Psychopharmacology (Berl) 117:137–148
Bel N, Romero L, Celada P, De Mantigny C, Blier P, Artigas F (1994) Neurobiological basis for the potentiation of the antidepressant effect of 5-HT reuptake inhibitors by the 5-HT1A antagonist pindolol. In: Durkin T, Spampinato U, Cador M (eds) Monitoring molecules in neuroscience. Proceedings of the 6th international conference on in vivo methods, 17–20 September 1994. INSERM, Bordeaux, pp 209–210
Bjorvatn B, Neckelmann D, Ursin R (1992) The 5-HT1A antagonist (−)-alprenolol fails to modify sleep or zimeldineinduced sleep-waking effects in rats. Pharmacol Biochem Behav 42:49–56
Bradley PB (1991) Serotonin: receptors and subtypes. In: Idzikowski C, Cowen PJ (eds) Serotonin, sleep and mental disorder. Wrightson Biomedical Publishing, Petersfield, pp 9–22
Briley M, Chopin P, Moret C (1991) The role of serotonin in anxiety: behavioural approaches. In: Briley M, File SE (eds) New concepts in anxiety. McMillan Press, London, pp 56–73
Cao BJ, Rodgers RJ (1998) Comparative effects of novel 5-HT1A receptor ligands, LY293284, LY315712 and LY297996 on plus-maze anxiety in mice. Psychopharmacology (Berl) 139:185–194
Cowen PJ (1991) Serotonin receptor subtypes: implications for psychopharmacology. Br J Psychiatry 159(Suppl 12):7–14
Deakin JFW (1991) Serotonin subtypes and affective disorders. In: Idzikowski C, Cowen PJ (eds) Serotonin, sleep and mental disorder. Wrightson Biomedical Publishing, Petersfield, pp 161–178
Deans C, Leathley M, Goudie A (1989) In vivo interactions of NAN-190, a putative selective 5-HT1A receptor antagonist with ipsapirone. Pharmacol Biochem Behav 34:927–929
Dourish CT, Hutson PH, Curzon G (1986) Putative anxiolytics 8-OH-DPAT, buspirone and TVX Q 7821 are agonists at 5-HT1A autoreceptors in the raphe nucleus. TIPS 7:212–214
Dreshfield LJ, Wong DT, Perry KW, Engelman EA (1996) Enhancement of fluoxetine-dependent increase of extracellular serotonin (5-HT) levels by (−)-pindolol, an antagonist at 5-HT1A receptors. Neurochem Res 21:557–562
Dugovic C, Leysen JE, Wauquier A (1991) Serotonin and sleep in the rat: the role of 5-HT2 receptors. In: Idzikowski C, Cowen PJ (eds) Serotonin, sleep and mental disorder. Wrightson Biomedical Publishing, Petersfield, pp 77–88
Elmendorf JS, Chen D, Pessin JE (1998) Guanosine 5′-O-(3-thiotriphosphate) (GPTγS) stimulation of GLUT4 translocation is tyrosine kinase-dependent. J Biol Chem 273:13289–13296
Fabre V, Boni C, Mocaer E, Lesourd M, Hamon M, Laporte AM (1997) [3H]Alnespirone: a novel specific radioligand for 5-HT1A receptors in the rat brain. Eur J Pharmacol 337:297–308
Fletcher A, Pike VW, Cliffe IA (1995) Visualization and characterization of 5-HT receptors and transporters in vivo and in man. Semin Neurosci 7:421–431
Fletcher A, Forster EA, Bill DJ, Brown G, Cliffe IA, Hartley JE, Jones DE, McLenachen A, Stanhope KJ, Critchley DJP, Childs KJ, Middlefell VC, Lanfumey L, Corradetti R, Laporte AM, Gozian H, Hamon M, Dourish CT (1996) Electrophysiological, biochemical, neurohormonal and behavioural studies with WAY-100635, a potent, selective and silent 5-HT1A receptor antagonist. Behav Brain Res 73:337–353
Fozard JR (1984) MDL 72222: a potent and highly selective antagonist at neuronal 5-hydroxytryptamine receptors. Naunyn Schmiedebergs Arch Pharmacol 326:36–44
Frazer A, Maayani S, Wolfe BB (1990) Subtypes of receptors for serotonin. Annu Rev Pharmacol Toxicol 30:307–348
Fuller RW (1990) Serotonin receptors and neuroendocrine responses. Neuropsychopharmacology 3:495–502
Gilbert AM, Stack GP, Nilakantan R, Kodah J, Tran M, Scerni R, Shi X, Smith DL, Andree TH (2004) Modulation of selective serotonin uptake inhibitor and 5-HT1A antagonist activity in 8-aza-bicyclo [3.2.1]octane derivatives of 2,3-dihydro-1,4-benzodioxane. Bioorg Med Chem Lett 14:515–518
Glennon RA (1991) Serotonin receptors and site-selective agents. J Physiol Pharmacol 42:49–60
Göthert M (1990) Presynaptic serotonin receptors in the central nervous system. Ann N Y Acad Sci 604:102–112
Gozlan H, El Mestikawy S, Pichat L, Glowinsky J, Hamon M (1983) Identification of presynaptic serotonin autoreceptors using a new ligand: 3H-PAT. Nature 305:140–142
Gozlan H, Thibault S, Laporte AM, Lima L, Hamon M (1995) The selective 5-HT1A antagonist radioligand [3H]WAY-100635 labels both G-protein-coupled and free 5-HT1A receptors in rat brain membranes. Eur J Pharmacol Mol Pharmacol Sect 288:173–186
Grahame-Smith DG (1991) The neuropharmacology of 5-HT in anxiety. In: Briley M, File SE (eds) New concepts in anxiety. McMillan Press, London, pp 46–55
Grasby PM, Sharp T, Allen T, Grahame-Smith DG (1992) The putative 5-HT1A antagonist BMY 7378 blocks 8-OHDPAT-induced changes in local cerebral glucose utilization in the conscious rat. Neuropharmacology 31:547–551
Griebel G (1996) Variability in the effects of 5-HT-related compounds in experimental models of anxiety: evidence for multiple mechanisms of 5-HT in anxiety or never ending story? Pol J Pharmacol 48:129–136
Griebel G, Misslin R, Pawlowski M, Lemaître BG, Guillaumet G, Bizot-Espiard J (1992) Anxiolytic-like effects of a selective 5-HT1A agonist, S20244, and its enantiomers in mice. Neuroreport 3:84–86
Hall MD, El Mestikawy S, Emerit MB, Pichat L, Hamon M, Gozlan H (1985) [3H]-8-Hydroxy-2-(di-n-propylamino)-tetralin binding to pre- and postsynaptic 5-hydroxytryptamine sites in various regions of rat brain. J Neurochem 44:1685–1696
Handley SL (1991) Serotonin in animal models of anxiety: the importance of stimulus and response. In: Idzikowski C, Cowen PJ (eds) Serotonin, sleep and mental disorder. Wrightson Biomedical Publishing, Petersfield, pp 89–115
Handley SL, McBlane JM (1993) 5-HT drugs in animal models of anxiety. Psychopharmacology (Berl) 112:13–20
Harder JA, Ridley RM (2000) The 5-HT1A antagonist, WAY 100 635, alleviates cognitive impairments induced by dizocilpine (MK-801) in monkeys. Neuropharmacology 39:547–552
Hascoet M, Bourin M, Todd KG, Couetoux du Tertre A (1994) Anti-conflict effect of 5-HT1A receptor agonists in rats: a new model for evaluating anxiolytic-like activity. J Psychopharmacol 8:227–237
Heuring RE, Peroutka SJ (1987) Characterization of a novel 3H-5-hydroxytryptamine binding site subtype in bovine brain membranes. J Neurosci 7:894–903
Hughes ZA, Starr KR, Langmead CJ, Hill M, Bartoszyk GD, Hagan JJ, Middlemiss DN, Dawson LA (2005) Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone. Eur J Pharmacol 510:49–57
Hume SP, Ashworth S, Opacka-Juffry J, Ahier RG, Lammertsma AA, Pike VW, Cliffe IA, Fletcher A, White AC (1995) Evaluation of [O-methyl-3H]WAY-100635 as an in vivo radioligand for 5-HT1A receptors in rat brain. Eur J Pharmacol 271:515–523
Iversen SD (1984) 5-HT and anxiety. Neuropharmacology 23:1553–1560
Jenck F, Bos M, Wichmann J, Stadler H, Martin JR, Moreau JL (1998) The role of 5-HT2C receptors in affective disorders. Expert Opin Invest Drugs 7:1587–1599
Jerning E, Svantesson GT, Mohell N (1998) Receptor binding characteristics of [3H]NAD-299, a new selective HT1A receptor antagonist. Eur J Pharmacol 360:219–225
Johansson L, Sohn D, Thorberg SO, Jackson DM, Kelder D, Larsson LG, Renyi L, Ross SB, Wallsten C, Erikson H, Hu PS, Jerning E, Mohell N, Westlind-Danielsson A (1997) The pharmacological characterization of a novel selective 5-hydroxytryptamine1A receptor antagonist, NAD 299. J Pharmacol Exp Ther 283:216–225
Jolas T, Haj-Damane S, Lanfumey L, Fattaccini CM, Kidd EJ, Adrien J, Gozian H, Guardiola-Lemaitre B, Hamon M (2004) (−)Tertatolol is a potent antagonist at pre- and postsynaptic serotonin 5-HT1A receptors in the rat brain. Naunyn Schmiedebergs Arch Pharmacol 347:453–463
Kennett GA, Bright F, Trail B, Blackburn TB, Sanger GJ (1997) Anxiolytic-like actions of the selective 5-HT4 receptor antagonists SB204070A and SB207266A in rats. Neuropharmacology 36:707–712
Khawaja X (1995) Quantitative autoradiographic characterization of the binding of [3H]WAY-100635, a selective 5-HT1A receptor antagonist. Brain Res 673:217–225
Khawaja X, Ennis C, Minchin MCW (1997) Pharmacological characterization of recombinant human 5-hydroxytryptamine1A receptors using a novel antagonist ligand [3H]WAY-100635. Life Sci 60:653–665
Kleven MS, Assié MB, Koek W (1997) Pharmacological characterization of in vivo properties of putative mixed 5-HT1A agonist/5-HT2A/2C antagonist anxiolytics. II. Drug discrimination and behavioral observation studies in rats. J Pharmacol Exp Ther 282:747–759
Kung HF, Kung MP, Clarke W, Maayani S, Zhuang ZP (1994a) A potential 5-HT1A receptor antagonist: p-MPPI. Life Sci 55:1459–1462
Kung MP, Zhuang ZP, Frederick D, Kung HF (1994b) In vivo binding of [123I]4-(2′-Methoxyphenyl)-1-[2′-(N-2″pyridinyl)-p-iodobenzamido]-ethyl-piperazine, p-MPPI, to 5-HT1A receptors in rat brain. Synapse 18:359–366
Kung MP, Frederick D, Mu M, Zhuang ZP, Kung HF (1995) 4-(2′-Methoxyphenyl)-1-[2′-(n-2″-pyridinyl)-p-iodobenzamido]-ethyl-piperazine ([125I]p-MPPI) as a new selective radioligand on serotonin-1A sites in rat brain: in vitro binding and autoradiographic studies. J Pharmacol Exp Ther 272:429–437
Kung MP, Mu M, Zhuang ZP, Kung HF (1996) NCS-MPP (4-(2′-methoxy-phenyl)-1-[2′ -(N-2″-pyridinyl)-p-isothiocyanobenz amido]-ethyl-piperazine): a high affinity and irreversible 5-HT1A receptor ligand. Life Sci 58:179–186
Laporte AM, Lima L, Gozlan H, Hamon M (1994) Selective in vivo labelling of brain HT1A receptors by [3H]WAY-100635 in the mouse. Eur J Pharmacol 271:505–514
Larkman PM, Rainnie DG, Kelly JS (1991) Serotonin receptor electrophysiology and the role of potassium channels in neuronal excitability. In: Idzikowski C, Cowen PJ (eds) Serotonin, sleep and mental disorder. Wrightson Biomedical Publishing, Petersfield, pp 41–64
Lee CH, Oh JI, Park HD, Kim HJ, Park TK, Kim JS, Hong CY, Lee SJ, Ahn KH, Kim YZ (1999) Pharmacological characterization of LB50016, N-(4-amino)butyl-3-phenylpyrrolidine derivative, as a new 5-HT1A receptor agonist. Arch Pharm Res 22:157–164
Mattson RJ, Catt JD, Sloan CP, Gao Q, Carter RB, Gentile A, Mahle CD, Matos FF, McGovern R, Vander Maelen CP, Yocca FD (2003) Development of a presynaptic 5-HT1A antagonist. Bioorg Med Chem Lett 13:285–288
Meert TF, Awouters F (1991) Serotonin 5-HT2 antagonists: a preclinical evaluation of possible therapeutic effects. In: Idzikowski C, Cowen PJ (eds) Serotonin, sleep and mental disorder. Wrightson Biomedical Publishing, Petersfield, pp 65–76
Middlemiss DN, Fozard JR (1983) 8-Hydroxy-2-(di-n-propylamino)-tetralin discriminates between subtypes of the 5-HT1 recognition site. Eur J Pharmacol 90:151–153
Millan MJ, Brocco M, Gobert A, Schreiber R, Dekeyne A (1999) S-16924 [(fi)-2-1-2-(2,3-dihydro-benzo[1,4]dioxin5-yloxy)-ethy[l]-pyrrolidin-3yl-1-(4-fluorophenyl) ethanone], a novel, potential antipsychotic with marked serotonin1A agonist properties: III Anxiolytic actions in comparison with clozapine and haloperidol. J Pharmacol Exp Ther 288:1002–1014
Millan MJ, Gobert A, Lejeune F, Newman-Tancredi A, Rivet JM, Auclair A, Peglion JL (2001) S33005, a novel ligand of both serotonin and norepinephrine transporters: I Receptor binding, electrophysiological, and neurochemical profile in comparison with reboxetine, citalopraa, and clomipramine. J Pharmacol Exp Ther 298:565–580
Misslin R, Griebel G, Saffroy-Spittler M, Vogel E (1990) Anxiolytic and sedative effects of 5-HT1A ligands, 8-OH-DPAT and MDL 73005EF, in mice. Neuroreport 1:267–270
Neckelmann D, Bjørkum AA, Bjorvatn B, Ursin R (1996) Sleep and EEG power spectrum of the 5-HT1A receptor antagonist NAN-190 alone and in combination with citalopram. Behav Brain Res 75:159–168
New JS (1990) The discovery and development of buspirone: a new approach to the treatment of anxiety. Med Res Rev 10:283–326
Newman ME, Lerer B, Shapira B (1992) 5-HT-1A receptor-mediated effects of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 17:1–19
Newman-Tancredi A, Verrièle L, Chaput C, Millan MJ (1998a) Labelling of recombinant human and native rat serotonin HT1A receptors by a novel, selective radioligand, [3H]S 15535: definition of its binding profile using agonists, antagonists and inverse agonists. Naunyn Schmiedebergs Arch Pharmacol 357:205–217
Newman-Tancredi A, Chaput C, Touzart M, Verrièle L, Millan MJ (1998b) Parallel evaluation of 5-HT1A receptor localization and functionality: autoradiographic studies with [35S]-GTPγS and the novel, selective radioligand [3H]S 15535. In: Martin GR, Eglen RM, Hoyer D, Hamblin MW, Yocca F (eds) Advances in serotonin research. Molecular biology, signal transduction, and therapeutics. Annals of the New York Academy of Sciences, vol 861. New York Academy of Sciences, New York, pp 263–264
Pazos A, Hoyer D, Palacios JM (1984) The binding of serotonergic ligands to the porcine choroid plexus: characterization of a new type of serotonin recognition site. Eur J Pharmacol 106:539–546
Pedigo NW, Yammamura HI, Nelson DL (1981) Discrimination of multiple [3H]5-hydroxytryptamine binding sites by the neuroleptic spiperone in rat brain. J Neurochem 36:220–226
Peroutka SJ (1985) Selective interaction of novel anxiolytics with 5-hydroxytryptamine1A receptors. Biol Psychiatry 20:971–979
Peroutka SJ (1986) Pharmacological differentiation and characterization of 5-HT1A, 5-HT1B and 5-HT1C binding sites in rat frontal cortex. J Neurochem 47:529–540
Peroutka SJ (1988) 5-Hydroxytryptamine receptor subtypes: molecular, biochemical and physiological characterization. Trends Neurosci 11:496–500
Pike VW, Halldin C, McCarron JA, Lundkvist C, Hirani E, Olsson H, Hume SP, Karlsson P, Osman S, Swahn CG, Hall H, Wikstrom H, Mensonidas M, Poole KG, Farde L (1998) [Carbonyl11 C]-Desmethyl-WAY 100635 (DWAY) is a potent and selective radioligand for central 5-HT1A receptors in vitro and in vivo. Eur J Nucl Med 25:338–346
Raymond JR, El Mestikawy S, Fargin A (1992) The 5-HT1A receptor: from molecular characteristics to clinical correlates. In: Brann MR (ed) Molecular biology of G-Protein-coupled receptors. Birkhäuser, Böston/Basel/Berlin, pp 113–141
Roca J, Artaiz I, del Rio J (1995) 5-HT3 receptor antagonists in development of anxiolytics. Expert Opin Invest Drugs 4:333–342
Rydelek-Fitzgerald L, Tietler M, Fletcher PW, Ismaiel AM, Glennon RA (1990) NAN-190: agonist and antagonist interactions with brain 5-HT1A receptors. Brain Res 532:191–196
Sanell J, Halldin C, Hall H, Thorberg SO, Werner T, Sohn D, Sedvall G, Farde L (1999) Radiosynthesis and autoradiographic evaluation of [11C]NAD-299, a radioligand for visualisation of the 5-HT1A receptor. Nucl Med Biol 26:159–164
Saxena PR, Lawang A (1985) A comparison of cardiovascular and smooth muscle effects of 5-hydroxytryptamine and 5-carboxamidotryptamine, a selective agonist of 5-HT1 receptors. Arch Int Pharmacodyn 277:235–252
Schlegel JR, Peroutka SJ (1986) Nucleotide interactions with 5-HT1A binding sites directly labeled by [3H]-8-hydroxy-2(di-n-propylamino)tetralin ([3H]-8-OH-DPAT). Biochem Pharmacol 35:1943–1949
Seifritz E, Stahl SM, Gillin JC (1997) Human sleep EEG following the 5-HT1A antagonist pindolol: possible disinhibition of raphe neuron activity. Brain Res 759:84–91
Sharp T, Backus LI, Hjorth S, Bramwell SR, Grahame-Smith DG (1990) Further investigation of the in vivo pharmacological properties of the putative 5-HT1A antagonist BMY 7378. Eur J Pharmacol 176:331–340
Smart CM, Biello SM (2001) WAY-100635, a specific 5-HT1A antagonist, can increase the responsiveness of the mammalian circadian pacemaker to photic stimuli. Neurosci Lett 305:33–36
Standaert M, Bandyopadhyay G, Galloway L, Ono Y, Mukai H, Farese R (1998) Comparative effects of GPTy S and insulin of rho, phosphatidylinositol 3-kinase, and protein kinase N in rat adipocytes. J Biol Chem 273:7470–7477
Stanhope KJ, Dourish CT (1996) Effects of 5-HT1A receptor agonists, partial agonists and a silent antagonists on the performance of the conditioned emotional response test in the rat. Psychopharmacology (Berl) 128:293–303
Sundaram H, Turner JD, Strang PG (1995) Characterization of recombinant serotonin 5-HT1A receptors expressed in Chinese hamster ovary cells: the agonist [3H]lisuride labels free receptor and receptor coupled to G protein. J Neurochem 65:1909–1916
Traber J, Glaser T (1987) 5-HT1A receptor-related anxiolytics. TIPS 8:432–437
Trillat AC, Malagié I, Allainmat MM, Anmela MC, Jacquot C, Langlois M, Gardier AM (1998) Effects of WAY 100635 and (−)-5-Me-8-OH-DPAT, a novel 5-HT1A receptor antagonist on 8-OH-DPAT responses. Eur J Pharmacol 147:41–49
Verge D, Daval G, Marcinkiewicz M, Patey A, El Mestikawy H, Gozlan Hamon M (1986) Quantitative autoradiography of multiple 5-HT1 receptor subtypes in the brain of control of 5,7-dihydroxytryptamine-treated rats. J Neurosci 6:3474–3482
Yocca FD, Hyslop DK, Smith DW, Maayani S (1987) BMY 7378, a buspirone analog with high affinity, selectivity and low intrinsic activity at the 5-HT1A receptor in rat and guinea pig hippocampal membranes. Eur J Pharmacol 137:293–294
Serotonin (5-HT1B) Receptors in Brain: Binding of [3H]5-Hydroxytryptamine ([3H]5-HT)
Boulenguez P, Chauveau J, Segu L, Morel A, Lanoir J, Delaage M (1992) Biochemical and pharmacological characterization of serotonin-O-carboxymethylglycyl[125I]iodotyrosinamide, a new radioligand probe for 5-HT1B and 5-HT1D binding sites. J Neurochem 58:951–959
Domenech T, Beleta J, Palacios JM (1997) Characterization of human serotonin 1D and 1B receptors using [3H]-GR125743, a novel radiolabelled serotonin 5-HT1D/1B receptor antagonist. Naunyn Schmiedebergs Arch Pharmacol 356:328–334
Hartig PR, Branchek TA, Weinshank RL (1992) A subfamily of 5-HT1D receptor genes. Trends Pharmacol Sci 13:152–159
Hoyer D, Engel G, Kalkman HO (1985) Molecular pharmacology of 5-HT1 and 5-HT2 recognition sites in rat and pig brain membranes: radioligand binding studies with [3H]5-HT, [3H]8OH-DPAT, (−)I[125I]iodocyanopindolol, [3H]mesulergine and [3H]ketanserin. Eur J Pharmacol 118:13–23
Hoyer D, Schoeffter P, Waeber C, Palacios JM (1990) Serotonin 5-HT1D receptors. Ann N Y Acad Sci 600:168–181
Humphrey PPA, Feniuk W, Marriott AS, Tanner RJN, Jackson MR, Tucker ML (1991) Preclinical studies on the antimigraine drug, Sumatriptan. Eur Neurol 31:282–290
Jenck F, Moreau JL, Mutel V, Martin JR, Haefely WE (1993) Evidence for a role of 5-HT1C receptors in the antiserotoninergic properties of some antidepressant drugs. Eur J Pharmacol 231:223–229
Jenck F, Moreau JL, Mutel V, Martin JR (1994) Brain 5-HT1C receptors and antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 18:563–574
Koe BK, Lebel LA, Fox CB, Macor JE (1992) Characterization of [3H]CP-96,501 as a selective radioligand for the serotonin 5-HT1B receptor: binding studies in rat brain membranes. J Neurochem 58:1268–1276
Lebel LA, Koe BK (1992) Binding studies with the 5-HT1B receptor agonist [3H]CP-96,501 in brain tissues. Drug Dev Res 27:253–264
Mahle CD, Nowak HP, Mattson RJ, Hurt SD, Yocca FD (1991) [3H]-carboxamidotryptamine labels multiple high affinity 5-HT1D-like sites in guinea pig brain. Eur J Pharmacol 205:323–324
Massot O, Rousselle JC, Grimaldi B, Cloët-Tayarani I, Fillion MP, Plantefol M, Bonnin A, Prudhomme N, Fillion G (1998) Molecular, cellular and physiological characteristics of 5-HT-moduline, a novel endogenous modulator of 5-HT1B receptor subtype. In: Martin GR, Eglen RM, Hoyer D, Hamblin MW, Yocca F (eds) Advances in serotonin research Molecular biology, signal transduction, and therapeutics. Annals of the New York Academy of Sciences, vol 861. New York Academy of Sciences, New York, pp 174–182
Middlemiss DN (1984) Stereoselective blockade at [3H]5-HT binding sites and at the 5-HT autoreceptor by propranolol. Eur J Pharmacol 101:289–293
Middlemiss DN, Fozard JR (1983) 8-Hydroxy-2-(di-n-propylamino)-tetralin discriminates between subtypes of the 5-HT1 recognition site. Eur J Pharmacol 90:151–153
Nowak HP, Mahle CD, Yocca FD (1993) [3H]-carboxamidotryptamine labels 5-HT1D binding sites in bovine substantia nigra. Br J Pharmacol 109:1206–1211
Palacios JM, Waeber C, Bruinvels AT, Hoyer D (1992) Direct visualisation of serotonin1D receptors in the human brain using a new iodinated ligand. Mol Brain Res 346:175–179
Pedigo NW, Yammamura HI, Nelson DL (1981) Discrimination of multiple [3H]5-hydroxytryptamine binding sites by the neuroleptic spiperone in rat brain. J Neurochem 36:220–226
Peroutka SJ (1986) Pharmacological differentiation and characterization of 5-HT1A, 5-HT1B and 5-HT1C binding sites in rat frontal cortex. J Neurochem 47:529–540
Peroutka SJ (1988) 5-Hydroxytryptamine receptor subtypes: molecular, biochemical and physiological characterization. Trends Neurosci 11:496–500
Peroutka S, Snyder SH (1979) Multiple serotonin receptors: differential binding of [3H]5-hydroxytryptamine, [3H]lysergic acid diethylamide and [3H]spiroperidol. Mol Pharmacol 16:687–699
Price GW, Burton MJ, Collin LJ, Duckworth M, Gaster L, Göthert M, Jones BJ, Roberts C, Watson JM, Middlemiss DN (1997) SB-216641 and BL-15572 compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors. Naunyn Schmiedebergs Arch Pharmacol 356:312–320
Schlicker E, Werner U, Hamon M, Gozlan H, Nickel B, Szelenyi I, Göthert M (1992) Anpirtoline, a novel highly potent 5-HT1B receptor agonist with antinociceptive/antidepressant-like actions in rodents. Br J Pharmacol 105:732–738
Segu L, Chauveau J, Boulenguez P, Morel A, Lanoir J, Delaage M (1991) Synthesis and pharmacological study of radioiodinated serotonin derivative specific for 5-HT1B and 5-HT1D binding sites in the central nervous system. C R Acad Sci (Paris) 312:655–661
Selkirk JV, Scott C, Ho M, Burton MJ, Watson J, Gaster LM, Collin L, Jones BJ, Middlemiss DN, Price GW (1998) SB-224289 – a novel selective (human) 5-HT1B receptor antagonist with negative intrinsic activity. Br J Pharmacol 125:202–208
5-HT3 Receptor in Rat Entorhinal Cortex Membranes: Binding of [3H]GR 65630
Azukawa S, Miyata K, Fukutomi H (1995) Characterization of [3H]YM060, a potent and selective 5-HT3 receptor radioligand, in the cerebral cortex of rats. Eur J Pharmacol 281:37–42
Barnes NM, Costall B, Naylor RJ (1988) [3H]Zacopride: ligand for the identification of 5-HT3 recognition sites. J Pharm Pharmacol 40:548–551
Barnes JM, Barnes NM, Champaneria S, Costall B (1990) Characterization and autoradiographic localization of 5-HT3 receptor recognition sites identified with [3H]-(S)-zacopride in the forebrain of the rat. Neuropharmacology 29:1037–1045
Barnes JM, Barnes NM, Costall B, Jagger SM, Naylor RJ, Robertson DW, Roe SY (1992) Agonist interactions with 5-HT3 receptor recognition sites in the rat entorhinal cortex labelled by structurally diverse radioligands. Br J Pharmacol 105:500–504
Bonhaus DW, Loury DN, Jakeman LB, To Z, deSouza A, Eglen RM, Wong EHF (1993) [3H]BIMU-1, a 5-hydroxytryptamine3 receptor ligand in NG 108 cells, selectively labels sigma-2 binding sites in guinea pig hippocampus. J Pharmacol Exp Ther 267:961–970
Bönisch H, Barann M, Graupner J, Göthert M (1993) Characterization of 5-HT3 receptors of N1E-115 mouse neuroblastoma cells by the use of the influx of the organic cation [14C]-guanidinium. Br J Pharmacol 108:436–442
Butler A, Hill JM, Ireland SJ, Jordan CD, Tyres MB (1988) Pharmacological properties of GR38032F, a novel antagonist at 5-HT3 receptors. Br J Pharmacol 94:397–412
Costall B, Naylor RJ, Tyers MB (1988) Recent advances in the neuropharmacology of 5-HT3 agonists and antagonists. Rev Neurosci 2:41–65
Costall B, Naylor RT, Tyers MB (1990) The psychopharmacology of 5-HT3 receptors. Pharmacol Ther 47:181–202
Davies PA, Pistis M, Hanna MC, Peters JA, Lambert JJ, Hales TG, Kirkness EF (1999) The 5-HT3B subunit is a major determinant of serotonin receptor function. Nature 397:359–363
Dunn RW, Carlezon WA Jr, Corbett R (1991) Preclinical anxiolytic versus antipsychotic profiles of the 5-HT3 antagonists ondansetron, zacopride, 3α-tropanyl-1H-indole-3-carboxylic ester, and 1αH, 3αH, 5αH-tropan-3-yl-3,5-dihydrochlorobenzoate. Drug Dev Res 23:289–300
Emerit MB, Riad M, Fattacini CM, Hamon M (1993) Characteristics of [14C]guanidium accumulation in NG 108–15 cells exposed to serotonin 5-HT3 receptor ligands and substance P. J Neurochem 60:2059–2067
Gehlert DR, Schober DA, Gackenheimer SL, Mais DE, Ladouceur G, Robertson DW (1993) Synthesis and evaluation of [125I]-(S)-iodozacopride, a high affinity radioligand for 5-HT3 receptors. Neurochem Int 23:373–383
Hewlett WA, Fridman S, Trivedi BL, Schmidt DE, de Paulis T, Ebert MH (1998) Characterization of desamino5-[125I]iodo-3-methoxy-zacopride, ([125I]MIZAK) binding to 5-HT3 receptors in the rat brain. Prog Neuro Psychopharmacol Biol Psychol 22:397–410
Hewlett WA, Trivedi BL, Zhang ZJ, de Paulis T, Schmidt DE, Lovinger DM, Sib Ansari M, Ebert MH (1999) Characterization of (S)-des-4-amino-3-[125I]iodozacopride ([125I]DAIZAC), a selective high affinity ligand for 5-hydroxytryptamine3 receptors. J Pharmacol Exp Ther 288:221–231
Hovius R, Schmid EL, Tairi AP, Blasey H, Bernard AR, Lundstrom K, Vogel H (1999) Fluorescence techniques for fundamental and applied studies of membrane protein receptors: the serotonin 5-HT3 receptor. J Recept Signal Transduct 19:533–545
Hoyer D (1990) Serotonin 5-HT3, 5-HT4 and 5-HT-M receptors. Neuropsychopharmacology 3:371–383
Hoyer D, Neijt HC (1988) Identification of serotonin 5-HT3 recognition sites in membranes of N1E-115 neuroblastoma cells by radioligand binding. Mol Pharmacol 33:303–309
Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, Saxena PR, Humphrey PP (1994) VII. International Union of Pharmacology classification of receptors for 5-Hydroxytryptamine (serotonin). Pharmacol Rev 46:157–203
Jansen FP, Wu TS, Voss HP, Steinbusch HWM, Vollinga RC, Rademaker B, Bast A, Timmerman H (1994) Characterization of the binding of the first selective radiolabelled histamine H3 receptor antagonist, [125I]iodophenpropit. Br J Pharmacol 113:355–362
Kilpatrick GJ, Jones BJ, Tyers MB (1987) Identification and distribution of 5-HT3 receptors in rat brain using radioligand binding. Nature 330:746–748
Kilpatrick GJ, Jones BJ, Tyers MB (1989) Binding of the 5-HT3 ligand, [3H]-GR 65630, to rat area postrema, vagus nerve and the brains of several species. Eur J Pharmacol 159:157–164
Kilpatrick GJ, Bunce KT, Tyer MB (1990) 5-HT3 Receptors. Med Res Rev 10:441–475
Kilpatrick GJ, Butler A, Hagan RM, Jones BJ, Tyers MB (1990) [3H]GR67330, a very high affinity ligand for 5-HT3 receptors. Naunyn Schmiedebergs Arch Pharmacol 342:22–30
Kooyman AR, Zwart R, Vanderheijden PML, van Hooft JA, Vijverberg HPM (1994) Interaction between enatiomers of mianserin and ORG3770 at 5-HT3 receptors in cultured mouse neuroblastoma cells. Neuropharmacology 33:501–507
Leurs R, Vollinga RC, Timmerman H (1995) The medicinal chemistry and therapeutic potentials of ligands of the histamine H3 receptor. Prog Drug Res 45:107–165
Leurs R, Blandina P, Tedford C, Timmerman H (1998) Therapeutic potentials of histamine H3 receptor agonists and antagonists. Trends Pharmacol Sci 19:177–183
Ligneau X, Garbag M, Vizueta ML, Diaz J, Purand K, Stark H, Schunack W, Schwartz JC (1994) [125I]Iodoproxyfan, a new antagonist to label and visualize cerebral histamine H3 receptors. J Pharmacol Exp Ther 271:452–459
Martin GR, Humphrey PPA (1994) Classification review. Receptors for 5-hydroxytryptamine: current perspectives on classification and nomenclature. Neuropharmacology 33:261–273
Mason NS, Hewlett WA, Ebert MH, Schmidt DE, de Paulis T (1996) Labeling of (S)-Des-4-amino-3-[125I]iodozacopride (DAIZAC), a high affinity radioligand for the 5-HT3 receptor. J Label Compd Radiopharm 38:955–961
Miller K, Weisberg E, Fletcher PW, Teitler M (1992) Membrane bound and solubilized 5-HT3 receptors: improved radioligand binding assays using bovine area postrema or rat cortex and the radioligands [3H]-GR 65630, [3H]-BRL43694, and [3H]-Ly278584. Synapse 11:58–66
Peroutka SJ (1988) 5-Hydroxytryptamine receptor subtypes: molecular, biochemical and physiological characterization. Trends Neurosci 11:496–500
Peroutka SJ (1991) Serotonin receptor subtypes and neuropsychiatric diseases: focus on 5-HT1D and 5-HT3 receptor agents. Pharmacol Rev 43:579–586
Perry DC (1990) Autoradiography of [3H]quipazine in rat brain. Eur J Pharmacol 187:75–85
Pinkus LM, Sarbin NS, Barefoot DS, Gordon JC (1989) Association of [3H]zacopride with 5-HT3 binding sites. Eur J Pharmacol 168:355–362
Reiser G, Hamprecht B (1989) Substance P and serotonin act synergistically to activate a cation permeability in a neuronal cell line. Brain Res 479:40–48
Robertson DW, Bloomquist W, Cohen ML, Reid LR, Schenk K, Wong DT (1990) Synthesis and biochemical evaluation of tritium-labeled 1-methyl-N-[8-methyl-8azabicyclo[3.2.1]oct-3-yl)-1H-indazole-3-carboxamide, a useful radioligand for 5-HT3 receptors. J Med Chem 33:3176–3181
Saxena PR (1994) Modern 5-HT receptor classification and 5-HT based drugs. Exp Opin Invest Drugs 3:513–523
Stark H, Schlicker E, Schunack W (1996) Development of histamine H3 receptor antagonists. Drugs Fut 21:507–520
Steward LJ, Ge J, Bentley KR, Barber PC, Hope FG, Lambert FJ, Peters JA, Blackburn TP, Barnes NM (1995) Evidence that the atypical 5-HT3 receptor ligand, [3H]-BRL46470, labels additional 5-HT3 binding sites compared to [3H]-granisetron. Br J Pharmacol 116:1781–1788
Tairi AP, Hovius R, Pick H, Blasey H, Bernard A, Surprenant A, Lundstrom K, Vogel H (1998) Ligand binding to the serotonin 5-HT3 receptor studied with a novel fluorescent ligand. Biochemistry 37:15850–15864
Thompson AJ, Price KL, Reeves DC, Chan SL, Chau PI, Lummis SCR (2005) Locating an antagonist in the 5-HT3 receptor binding site using modeling and radioligand binding. J Biol Chem 280:20476–20482
Watling KJ (1989) 5-HT3 receptor agonists and antagonists. Neurotransmissions 3:1–4
Watling KJ, Aspley S, Swain CJ, Saunders J (1988) [3H]Quaternised ICS 205–930 labels 5-HT3 receptor binding sites in rat brain. Eur J Pharmacol 149:397–398
Histamine H3 Receptor Binding in Brain
Arrang JM, Garbarg M, Schwartz JC (1985) Autoregulation of histamine release in brain by presynaptic H3-receptors. Neuroscience 15:533–562
Arrang JM, Garbarg M, Lancelot JC, Lecomte JM, Pollard H, Robba M, Schunack W, Schwartz JC (1987) Highly potent and selective ligands for histamine H3-receptors. Nature 327:117–123
Arrang JM, Roy J, Morgat JL, Schunack W, Schwartz JC (1990) Histamine H3-receptor binding sites in rat brain membranes: modulation by guanine nucleotides and divalent cations. Eur J Pharmacol 188:219–227
Haaksma EEJ, Leurs R, Timmerman H (1990) Histamine receptors: subclasses and specific ligands. Pharmacol Ther 47:73–104
Hew KWS, Hodgkinson CR, Hill SJ (1990) Characterization of histamine H3-receptors in guinea-pig ileum with H3-selective ligands. Br J Pharmacol 101:621–624
Hill SJ (1990) Distribution, properties, and functional characteristics of three classes of histamine receptor. Pharmacol Rev 42:45–83
Hill SJ (1992) Histamine receptor agonists and antagonists. Neurotransmissions 8(1):1–5
Hill SJ, Ganellin CR, Timmerman H, Schwartz JC, Shankley NP, Young JM, Schunack W, Levi R, Haas HL (1997) International Union of Pharmacology. XIII. Classification of histamine receptors. Pharmacol Rev 49:253–278
Jansen FP, Rademaker B, Bast A, Timmerman H (1992) The first radiolabeled histamine H3 receptor antagonist, [125I]iodophenpropit: saturable and reversible binding to rat cortex membranes. Eur J Pharmacol 217:203–205
Korte A, Myers J, Shih NY, Egan RW, Clark MA (1990) Characterization and tissue distribution of H3 histamine receptors in guinea pigs by Nα-methylhistamine. Biochem Biophys Res Commun 168:979–986
Leurs R, van der Goot H, Timmerman H (1991) Histaminergic agonists and antagonists. Recent developments. Adv Drug Res 20:217–304
Leurs R, Blandina P, Tedford C, Timmerman H (1998) Therapeutic potential of histamine H3 receptor agonists and antagonists. Trends Pharmacol Sci 19:177–183
Leurs R, Bakker RA, Timmerman H, de Esch IJP (2005) The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat Rev Drug Discov 4:107–120
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265–275
Passani MB, Lin JS, Hanccck A, Crochet S, Blandina P (2004) The histamine H3 receptor as a novel therapeutic target for cognitive and sleep disorders. Trends Pharmacol Sci 25:618–625
Schlicker E, Betz R, Göthert M (1988) Histamine H3-receptormediated inhibition of serotonin release in the rat brain cortex. Naunyn Schmiedebergs Arch Pharmacol 337:588–590
Timmerman H (1990) Histamine H3 ligands: just pharmacological tools or potential therapeutic agents? J Med Chem 33:4–11
Van der Goot H, Schepers MJP, Sterk GJ, Timmerman H (1992) Isothiourea analogues of histamine as potent agonists or antagonists of the histamine H3-receptor. Eur J Med Chem 27:511–517
Van der Werf JF, Timmerman H (1989) The histamine H3 receptor: a general presynaptic regulatory system? Trends Pharmacol Sci 10:159–162
West RE Jr, Zweig A, Shih NY, Siegel MI, Egan RW, Clark MA (1990) Identification of two H3-histamine receptor subtypes. Mol Pharmacol 38:610–613
Pentylenetetrazole (Metrazol) Induced Convulsions
Bastian JW, Krause WE, Ridlon SA, Ercoli N (1959) CNS drug specificity as determined by the mouse intravenous pentylenetetrazole technique. J Pharmacol Exp Ther 127:75–80
Domino EF (1964) Centrally acting skeletal muscle relaxants. In: Laurence DR, Bacharach AL (eds) Evaluation of drug activities: pharmacometrics. Academic, London/New York, pp 313–324
Lippa AS, PristiHa A, Nash BA, Greenblatt EN (1979) Preclinical neuropsychopharmacological testing procedures for anxiolytic drugs. In: Fielding S, Lal H (eds) Anxiolytics. Futura Publishing, New York, pp 41–81
Löscher W, Hönack D, Fassbender CP, Nolting B (1991) The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. III. Pentylentetrazole seizure models. Epilepsy Res 8:171–189
Starzl TE, Niemer WT, Dell M, Forgrave PR (1953) Cortical and subcortical electrical activity in experimental seizures induced by Metrazol. J Neuropathol Exp Neurol 12:262–276
Strychnine-Induced Convulsions
Bigler ED (1977) Comparison of effects of bicuculline, strychnine, and picrotoxin with those of pentylenetetrazol on photically evoked after discharges. Epilepsia 18:465–470
Costa E, Guidotti A, Mao CC (1975) New concepts in the mechanism of action of benzodiazepines. Life Sci 17:167–186
Lambert DM, Poupaert JH, Maloteaux JM, Dumont P (1994) Anticonvulsant activities of N-benzyloxycarbonylglycine after parenteral administration. Neuroreport 5:777–780
McAllister KH (1992) N-Methyl-d-aspartate receptor antagonists and channel blockers have different effects upon a spinal seizure model in mice. Eur J Pharmacol 211:105–108
Picrotoxin-Induced Convulsions
Buckett WR (1981) Intravenous bicuculline test in mice: characterisation with Gabaergic drugs. J Pharmacol Methods 5:35–41
Costa E, Guidotti A, Mao CC, Suria A (1975) New concepts in the mechanism of action of benzodiazepines. Life Sci 17:167–186
Enna SJ, Möller H (1987) γ-aminobutyric acid (GABA) receptors and their association with benzodiazepine recognition sites. In: Meltzer HY (ed) Psychopharmacology: the third generation of progress. Raven Press, New York, pp 265–272
Usunoff G, Atsev E, Tchavdarov D (1969) On the mechanisms of picrotoxin epileptic seizure (macro- and microelectrode investigations). Electroencephalogr Clin Neurophysiol 27:444
Isoniazid-Induced Convulsions
Costa E, Guidotti A, Mao CC (1975) Evidence for involvement of GABA in the action of benzodiazepines: studies on rat cerebellum. In: Costa E, Greengard P (eds) Mechanisms of action of benzodiazepines. Advances in biochemical psychopharmacology, vol 14. Raven Press, New York, pp 113–151
Yohimbine-Induced Convulsions
Dunn RW, Corbett R (1992) Yohimbine-induced convulsions involve NMDA and GABAergic transmission. Neuropharmacology 31:389–395
Dunn R, Fielding S (1987) Yohimbine-induced seizures in mice: a model predictive of potential anxiolytic and GABAmimetic agents. Drug Dev Res 10:177–188
Dunn RW, Corbett R, Martin LL, Payack JF, Laws-Ricker L, Wilmot CA, Rush DK, Cornfeldt ML, Fielding S (1990) Preclinical anxiolytic profiles of 7189 and 8319, novel noncompetitive NMDA antagonists. In: Current and future trends in anticonvulsant, anxiety, and stroke therapy. Wiley-Liss, pp 495–512
Litchfield J, Wilcoxon F (1949) A simplified method of evaluating dose effect experiments. J Pharmacol Exp Ther 96:99–113
Foot-Shock-Induced Aggression
Blanchard RJ, Blanchard DC (1977) Aggressive behavior in the rat. Behav Biol 21:197–224
Brady JV, Nauta WJH (1953) Subcortical mechanisms in emotional behavior: affective changes following septal forebrain lesions in the albino rat. J Comp Physiol Psychol 46:339–346
Chen G, Bohner B, Bratten AC (1963) The influence of certain central depressants on fighting behavior of mice. Arch Int Pharmacodyn 142:30–34
Heise GA, Boff E (1961) Taming action of chlordiazepoxide. Fed Proc 20:393–397
Hotchkiss AK, Ostby JS, Vandenbergh JG, Gray LE Jr (2003) An environmental antiandrogen, vinclozolin, alters the organization of play behavior. Physiol Behav 79:151–156
Irwin S, Kinohi R, Van Sloten M, Workman MP (1971) Drug effects on distress-evoked behavior in mice: methodology and drug class comparisons. Psychopharmacologia (Berl) 20:172–185
Kruk MR, van der Poel AM, de Vos-Frerichs TP (1979) The induction of aggressive behaviour by electrical stimulation in the hypothalamus of male rats. Behaviour 70:292–322
Mos J, Olivier B (1991) Concepts in animal models for pathological aggressive behaviour in humans. In: Olivier B, Mos J, Slangen JL (eds) Animal models in psychopharmacology, Advances in pharmacological sciences. Birkhäuser Verlag, Basel, pp 297–316
Pellis SM (2002) Sex differences in play fighting revisited: traditional and nontraditional mechanisms of sexual differentiation in rats. Arch Sex Behav 31:17–26
Pellis SM, McKenna M (1995) What do rats find rewarding in play fighting? – an analysis using drug-induced non-playful partners. Behav Brain Res 68:65–73
Pellis SM, Pellis VC (1998) Play fighting in comparative perspective: a schema for neurobehavioral analyses. Neurosci Behav Rev 23:87–101
Pellis SM, Field EF, Smith LK, Pellis VC (1997) Multiple differences in the play fighting of male and female rats. Implications for the causes and functions pf play. Neurosci Biobehav Rev 21:105–120
Randall LO, Heise GA, Schalleck W, Bagdon RE, Banziger R, Boris A, Moe A, Abrams WB (1961) Pharmacological and clinical studies on Valium(T.M.). A new psychotherapeutic agent of the benzodiazepine class. Curr Ther Res 9:405–425
Rudzik AD, Hester JB, Tang AH, Straw RN, Friis W (1973) Triazolobenzazepines, a new class of central nervous system-depressant compounds. In: Garattini S, Mussini E, Randall LO (eds) The benzodiazepines. Raven Press, New York, pp 285–297
Schneider M, Koch M (2005) Deficient social and play behavior in juvenile and adult rats after neonatal cortical lesion: effects of chronic pubertal cannabinoid treatment. Neuropsychopharmacology 30:944–957
Siviy SM, Line BS, Darcy EA (1995) Effects of MK-8o1 on rough-and-tumble play in juvenile rats. Physiol Behav 57:843–847
Tedeschi RE, Tedeschi DH, Mucha A, Cook L, Mattis PA, Fellows EJ (1959) Effects of various centrally acting drugs on fighting behavior of mice. J Pharmacol Exp Ther 125:28–34
Tedeschi DH, Fowler PJ, Miller RB, Macko E (1969) Pharmacological analysis of footshock-induced fighting behaviour. In: Garattini S, Sigg EB (eds) Aggressive behaviour. Excerpta Medica Foundation, Amsterdam, pp 245–252
Ulrich R, Symannek B (1969) Pain as a stimulus for aggression. In: Garattini S, Sigg EB (eds) Aggressive behaviour. Excerpta Medica Foundation, Amsterdam, pp 59–69
Isolation-Induced Aggression
Anrade ML, Benton D, Brain PF, Ramirez JM, Walmsley SV (1988) A reexamination of the hypoglycemia-aggression hypothesis in laboratory mice. Int J Neurosci 41:179–186
Caharperntier J (1969) Analysis and measurement of aggressive behaviour in mice. In: Garattini S, Sigg EB (eds) Aggressive behaviour. Excerpta Medica Foundation, Amsterdam, pp 86–100
Davbanzo JP (1969) Observations related to drug-induced alterations in aggressive behaviour. In: Garattini S, Sigg EB (eds) Aggressive behaviour. Excerpta Medica Foundation, Amsterdam, pp 263–272
Francès H (1988) New animal model of social behavioral deficit: reversal by drugs. Pharmacol Biochem Behav 29:467–470
Francès H, Monier C (1991) Tolerance to the behavioural effect of serotonergic (5-HT1B) agonists in the isolation induced social behavioural deficit test. Neuropharmacology 30:623–627
Francès H, Khidichian F, Monier C (1990) Increase in the isolation-induced social behavioural deficit by agonists at 5-HT1A receptors. Neuropharmacology 29:103–107
Guidotti A, Dong E, Matsumoto K, Pinna G, Rasmusson AM, Costa E (2001) The socially-isolated mouse: a model to study the putative role of allopregnenolone and 5α-dihydroxy progesterone in psychiatric disorders. Brain Res Rev 37:110–115
Hoffmeister F, Wuttke W (1969) On the actions of psychotropic drugs on the attack- and aggressive-defensive behaviour of mice and cats. In: Garattini S, Sigg EB (eds) Aggressive behaviour. Excerpta Medica Foundation, Amsterdam, pp 273–280
Krsiak M (1974) Behavioral changes and aggressivity evoked by drugs in mice. Res Commun Chem Pathol Pharmacol 7:237–257
Krsiak M (1975) Timid singly-house mice: their value in prediction of psychotropic activity of drugs. Br J Pharmacol 55:141–150
Krsiak M (1979) Effects of drugs on behaviour of aggressive mice. Br J Pharmacol 65:525–533
Krsiak M, Janku I (1969) The development of aggressive behaviour in mice by isolation. In: Garattini S, Sigg EB (eds) Aggressive behaviour. Excerpta Medica Foundation, Amsterdam, pp 101–105
Lagerspetz KMJ (1969) Aggression and aggressiveness in laboratory mice. In: Garattini S, Sigg EB (eds) Aggressive behaviour. Excerpta Medica Foundation, Amsterdam, pp 77–85
Le Douarec JC, Broussy L (1969) Dissociation of the aggressive behaviour in mice produced by certain drugs. In: Garattini S, Sigg EB (eds) Aggressive behaviour. Excerpta Medica Foundation, Amsterdam, pp 281–295
McMillen BA, Scott SM, Williams HL, Sanghera MK (1987) Effects of gespirone, an aryl-piperazine anxiolytic drug, on aggressive behavior and brain monoaminergic neurotransmission. Naunyn Schmiedebergs Arch Pharmacol 335:454–464
McMillen BA, Wooten MH, King SW, Scott SM, Williams HL (1992) Interaction between subchronic administration of alprazolam and aryl-piperazine anxiolytic drugs in aggressive mice. Biog Amines 9:131–140
Oliver B, Mos J (1992) Rodent models of aggressive behavior and serotonergic drugs. Prog Neuro Psychopharm Biol Psychiatry 16:847–870
Olivier B, van Dalen D (1982) Social behaviour in rats and mice: an ethologically based model for differentiating psychoactive drugs. Aggress Behav 8:163–168
Sánchez C, Arnt J, Moltzen EK (1996) The antiaggressive potency of (−)-penbutolol involves both 5-HT1A and 5-HT1B receptors and β-adrenoceptors. Eur J Pharmacol 297:1–8
Scriabine A, Blake M (1962) Evaluation of centrally acting drugs in mice with fighting behavior induced by isolation. Psychopharmacologia 3:224–226
Valzelli L (1967) Drugs and aggressiveness. In: Garratini S, Shore PA (eds) Advances in pharmacology, vol 5. Academic, New York, pp 79–108
Valzelli L (1969) Aggressive behaviour induced by isolation. In: Garattini S, Sigg EB (eds) Aggressive behaviour. Excerpta Medica Foundation, Amsterdam, pp 70–76
White SM, Kucharik RF, Moyer JA (1991) Effects of serotoninergic agents on isolation-induced aggression. Pharmacol Biochem Behav 39:729–736
Yen CY, Stanger RL, Millman N (1959) Ataractic suppression of isolation-induced aggressive behavior. Arch Int Pharmacodyn 123:179–185
Resident-Intruder Aggression Test
Brain PF, Howell PA, Benton D, Jones SE (1979) Studies on responses by “residents” rats housed in different ways to intruders of differing endocrine status. J Endocrinol 81:135–136
Flannelly K, Lore R (1975) Dominace-subordinance in cohabitating pairs of adult rats: effects on aggressive behavior. Aggress Behav 1:331–340
Mos J, Olivier B, Poth M, van Aken H (1992) The effects of intraventricular administration of eltoprazine, 1-(3-trifluoromethylphenyl)piperazine hydrochloride and 8-hydroxy-2-(di-n-propylamino)tetralin on resident intruder aggression in the rat. Eur J Pharmacol 212:295–298
Muehlenkamp F, Lucion A, Vogel WH (1995) Effects of selective serotonergic agonists on aggressive behavior in rats. Pharmacol Biochem Behav 50:671–674
Sijbesma H, Schipper J, de Kloet ER, Mos J, van Aken H, Olivier B (1991) Postsynaptic 5-HT1 receptors and offensive aggression in rats: a combined behavioural and autoradiographic study with eltoprazine. Pharmacol Biochem Behav 38:447–458
Water Competition Test
Baenninger LP (1970) Social dominance orders in the rat: “Spontaneous” food and water competition. J Comp Physiol Psychol 71:202–209
Muehlenkamp F, Lucion A, Vogel WH (1995) Effects of selective serotonergic agonists on aggressive behavior in rats. Pharmacol Biochem Behav 50:671–674
Syme GJ (1974) Competitive orders a measures of social dominance. Anim Behav 22:931–940
Maternal Aggression in Rats
Kruk MR, Zethof T (1987) Postpartum aggression in rats does not influence threshold currents for EBS-induced aggression. Brain Res 404:263–266
Mos J, Olivier B, Van Oorschot R (1984) Different test situations for measuring offensive aggression in male rats do not result in the same wound pattern. Physiol Behav 32:453–456
Mos J, Olivier B, Lammers JHCM, van der Poel AM, Kruk MR, Zethof T (1987a) Postpartum aggression in rats does not influence threshold currents for EBS-induced aggression. Brain Res 404:263–266
Mos J, Olivier B, van Oorschot R (1987b) Maternal aggression towards different sized male opponents: effect of chlordiazepoxide treatment of the mothers and d-amphetamine treatment of the intruders. Pharmacol Biochem Behav 26:577–584
Mos J, Olivier B, van Oorschot R, van Aken H, Zethof T (1989) Experimental and ethological aspect of maternal aggression in rats: five years of observations. In: Blanchard RJ, Brain PF, Blanchard DC, Parmigiani S (eds) Ethoexperimental approaches to the study of behavior. Kluwer Academic Publication, Dordrecht/Boston/London, pp 385–398
Mos J, Olivier B, van Oorschot R (1990) Behavioural and neuropharmacological aspects of maternal aggression in rodents. Aggress Behav 16:145–163
Olivier B (1981) Selective antiaggressive properties of DU27725: ethological analysis of intermale and territorial aggression in the male rat. Pharmacol Biochem Behav 14(Suppl 1):61–77
Olivier B, Mos J (1986) A female aggression paradigm for use in psychopharmacology: maternal agonistic behavior in rats. In: Brain PF, Ramirez JM (eds) Cross-disciplinary studies on aggression. University of Seville Press, Seville, pp 73–111
Olivier B, Mos J (1992) Rodent models of aggressive behavior and serotonergic drugs. Prog Neuro Psychopharm Biol Psychiatry 16:847–870
Olivier B, Mos J, van Oorschot R (1985) Maternal aggression in rats: effects of chlordiazepoxide and fluprazine. Psychopharmacology (Berl) 86:68–76
Olivier B, Rasmussen D, Raghoebar M, Mos J (1990) Ethopharmacology: a creative approach to identification and characterization of novel psychotropics. Drug Metabol Drug Interact 8:11–29
Olivier B, Mos J, van Oorschot R, Hen R (1995) Serotonin receptors and animal models of aggressive behavior. Pharmacopsychiatry 28(Suppl):80–90
Palanza P, Rodgers RJ, Ferrari PF, Parmigiani S (1996) Effects of chlordiazepoxide on maternal aggression in mice depend on experience of resident and sex of intruder. Pharmacol Biochem Behav 54:175–182
Rage Reaction in Cats
Glusman M (1974) The hypothalamic ‘savage’ syndrome. Res Publ Assoc Res Nerv Ment Dis 52:52–92
Malick JB (1970) Effects of selected drugs on stimulus-bound emotional behaviour elicited by hypothalamic stimulation in the cat. Arch Int Pharmacodyn Ther 186:137–141
Murasaki M, Hara T, Oguchi T, Inami M, Ikeda Y (1976) Action of enpiprazole on emotional behaviour induced by hypothalamic stimulation in rats and cats. Psychopharmacologia 49:271–274
Pieri L (1983) Preclinical pharmacology of midazolam. Br J Clin Pharmacol 16:17S–27S
Siegel A, Schubert K (1995) Neurotransmitters regulating feline aggression. Rev Neurosci 6:47–61
Siegel A, Shaikh MB (1997) The neural bases of aggression and rage in the cat. Aggress Violent Behav 1:241–271
Siegel A, Schubert K, Shaikh MB (1997) Neurotransmitters regulating defensive rage behavior in the cat. Neurosci Biobehav Rev 21:733–742
Siegel A, Schubert KL, Shaikh MB (1998) Neurotransmitters regulating defensive rage behavior in the cat. Neurosci Biobehav Rev 21:733–742
Siegel A, Roeling TAP, Gregg TR, Kruk MR (1999) Neuropharmacology of brain-stimulation-evoked aggression. Neurosci Biobehav Rev 23:359–389
Anti-Anxiety Test (Light–dark Model)
Barnes NM, Costall B, Domeney AM, Gerrard PA, Kelly ME, Krähling H, Naylor RJ, Tomkins DM, Williams TJ (1991) The effects of umespirone as a potential anxiolytic and antipsychotic agent. Pharmacol Biochem Behav 40:89–96
Barnes NM, Cheng CHK, Costall B, Ge J, Kelly ME, Naylor RJ (1992a) Profiles of R(+)/S(−)-Zacopride and anxiolytic agents in a mouse model. Eur J Pharmacol 218:91–100
Barnes NM, Costal B, Ge J, Kelly ME, Naylor RJ (1992b) The interaction of R(+)-and S(−)-zacopride with PCPA to modify rodent aversive behavior. Eur J Pharmacol 218:15–25
Blumstein LK, Crawley JN (1983) Further characterisation of a simple, automated exploratory model for the anxiolytic effects of benzodiazepines. Pharmacol Biochem Behav 18:37–40
Broekkamp CLE, Berendsen HHG, Jenk F, van Delft AML (1989) Animal models for anxiety and response to serotonergic drugs. Psychopathology 22(Suppl 1):2–12
Costall B, Hendrie CA, Kelly ME, Naylor RJ (1987) Actions of sulpiride and tiapride in a simple model of anxiety in mice. Neuropharmacology 26:195–200
Costall B, Kelley ME, Naylor RJ, Onaivi ES (1988) Actions of buspirone in a putative model of anxiety in the mouse. J Pharm Pharmacol 40:494–500
Costall B, Jones BJ, Kelly ME, Naylor RJ, Tomkins DM (1989) Exploration of mice in a black and white test box: validation as a model of anxiety. Pharmacol Biochem Behav 32:777–785
Crawley JN (1981) Neuropharmacologic specificity of a simple animal model for the behavioral actions of benzodiazepines. Pharmacol Biochem Behav 15:695–699
Crawley J, Goodwin KK (1980) Preliminary report of a simple animal behavior model for the anxiolytic effects of benzodiazepines. Pharmacol Biochem Behav 13:167–170
Griebel G (1995) 5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: more than 30 years research. Pharmacol Ther 65:319–395
Hascoët M, Bourin M (1998) A new approach to the light/dark test procedure in mice. Pharmacol Biochem Behav 60:645–653
Kauppila T, Tanila H, Carlson S, Taira T (1991) Effects of atipamezole, a novel α2-adrenoreceptor antagonist, in open-field, plus-maze, two compartment exploratory, and forced swimming tests in rats. Eur J Pharmacol 205:177–182
Kilfoil T, Michel A, Montgomery D, Whithing RL (1989) Effects of anxiolytic and anxiogenic drugs on exploratory activity in a simple model of anxiety in mice. Neuropharmacology 28:901–905
Manser CE, Elliott H, Morriss TH, Broom DM (1996) The use of a novel operant test to determine the strength of preference for flooring in laboratory rats. Lab Anim 30:1–6
Sanchez C (1995) Serotonergic mechanisms involved in the exploratory behaviour of mice in a fully automated two compartment black and white test box. Pharmacol Toxicol 77:71–78
Schipper J, Tulp MTM, Berkelmans B, Mos J, Van der Heijden JAM, Olivier B (1991) Preclinical pharmacology of Flesinoxan: a potential anxiolytic and antidepressant drug. Hum Psychopharmacol 6:53–61
Treit D (1985) Animal models for the study of anti-anxiety agents: a review. Neurosci Biobehav Rev 9:203–222
Anticipatory Anxiety in Mice
Borsini F, Lecci A, Volterra G, Meli A (1989) A model to measure anticipatory anxiety in mice? Psychopharmacology (Berl) 98:207–211
Lecci A, Borsini F, Mancinelli A, D’Aranno V, Stasi MA, Volterra G, Meli A (1990a) Effects of serotoninergic drugs on stress-induced hyperthermia (SIH) in mice. J Neural Transm 82:219–230
Lecci A, Borsini F, Volterra G, Meli A (1990b) Pharmacological validation of a novel animal model of anticipatory anxiety in mice. Psychopharmacology (Berl) 101:255–261
Tulp M, Olivier B, Schipper J, van der Pel G, Mos J, van der Heyden J (1991) Serotonin reuptake blockers: is there preclinical evidence for their efficacy in obsessive-compulsive disorder? Hum Psychopharmacol 6:S63–S71
Van der Heyden JASM, Zethof TKK, Olivier B (1997) Stress-induced hyperthermia in singly housed mice. Physiol Behav 62:463–470
Zelthof TJJ, van der Heyden JAM, Olivier B (1991) A new animal model for anticipatory anxiety? In: Olivier B, Mos J, Slangen JL (eds) Animal models in psychopharmacology, Advances in pharmacological sciences. Birkhäuser Verlag, Basel, pp 65–68
Zelthof TJJ, van der Heyden JAM, Tolboom JTBM, Olivier B (1995) Stress-induced hyperthermia as a putative anxiety model. Eur J Pharmacol 294:125–135
Social Interaction in Rats
Angelis L, File SE (1979) Acute and chronic effects of three benzodiazepines in the social interaction test in mice. Psychopharmacology (Berl) 64:127–129
Barnes NM, Costall B, Domeney AM, Gerrard PA, Kelly ME, Krähling H, Naylor RJ, Tomkins DM, Williams TJ (1991) The effects of umespirone as a potential anxiolytic and antipsychotic agent. Pharmacol Biochem Behav 40:89–96
Blackburn TP, Baxter GS, Kennett GA, King FD, Piper DC, Sanger GJ, Thomas DR, Upton N, Wood MD (1993) BRL 46470A: a highly potent, selective and long acting 5-HT3 receptor antagonist with anxiolytic-like properties. Psychopharmacology (Berl) 110:257–264
Carlsson M, Carlsson A (1990) Interactions between glutaminergic and monoaminergic systems within the basal ganglia: implications for schizophrenia and Parkinson’s disease. Trends Neural Sci 13:272–276
Corbett R, Dunn RW (1991) Effects of HA-966 on conflict, social interaction, and plus maze behaviors. Drug Dev Res 24:201–205
Corbett R, Fielding S, Cornfeldt M, Dunn RW (1991) GABAmimetic agents display anxiolytic-like effects in the social interaction and elevated plus maze procedures. Psychopharmacology 104:312–316
Corbett R, Hartman H, Kerman LL, Woods AT, Strupczewski JT, Helsley GC, Conway PC, Dunn RW (1993) Effects of atypical antipsychotic agents on social behavior in rodents. Pharmacol Biochem Behav 45:9–17
Corbett R, Camacho F, Woods AT, Kerman LL, Fishkin RJ, Brooks K, Dunn RW (1995) Antipsychotic agents antagonize non-competitive N-methyl-d-aspartate antagonist-induced behaviors. Psychopharmacology (Berl) 120:67–74
Costall B, Naylor RJ (1992) Anxiolytic potential of 5-HT3 receptor antagonists. Pharmacol Toxicol 70:157–162
Costall B, Naylor RJ (1995) Behavioural interactions between 5-hydroxytryptophan, neuroleptic agents and 5-HT receptor antagonists in modifying rodent response to adverse situations. Br J Pharmacol 116:2989–2999
Costall B, Kelly ME, Onaivi ES, Naylor RJ (1990) The effect of ketotifen in rodent models of anxiety and on the behavioural consequences of withdrawing from treatment with drugs of abuse. Naunyn Schmiedebergs Arch Pharmacol 341:547–551
Costall B, Domeney AM, Hughes J, Kelly ME, Naylor RJ, Woodruff GN (1991) Anxiolytic effects of CCKB antagonists. Neuropeptides 19(Suppl):65–73
Dunn RW, Corbett R, Martin LL, Payack JF, Laws-Ricker L, Wilmot CA, Rush DK, Cornfeldt ML, Fielding S (1990) Preclinical anxiolytic profiles of 7189 and 8319, novel noncompetitive NMDA antagonists. In: Current and future trends in anticonvulsant, anxiety, and stroke therapy. WileyLiss, pp 495–512
File SE (1980) The use of social interactions as a method for detecting anxiolytic activity of chlordiazepoxide-like drugs. J Neurosci Methods 1:219–238
File SE, Hyde RJ (1979) A test of anxiety that distinguishes between the actions of benzodiazepines and those of other minor tranquilizers and stimulants. Pharmacol Biochem Behav 11:65–69
File SE, Johnston AL (1989) Lack of effects of 5-HT3 receptor antagonists in the social interaction and elevated plus-maze tests in the rat. Psychopharmacology (Berl) 99:248–251
Gardner C, Guy A (1984) A social interaction model of anxiety sensitive to acutely administered benzodiazepines. Drug Dev Res 4:207–216
Gheusi G, Bluthe RM, Goodall G, Dantzer R (1994) Ethological study of the effects of tetrahydroaminoacridine (THA) on social recognition in rats. Psychopharmacology (Berl) 114:644–650
Hughes J, Boden P, Costall B, Domeney A, Kelly E, Horwell DC, Hunter JC, Pinnock RD, Woodruff GN (1990) Development of a class of selective cholecystokinin type B receptor antagonists having a potent anxiolytic activity. Proc Natl Acad Sci U S A 87:6728–6732
Kennett GA (1992) 5-HT1C Receptors antagonists have anxiolytic-like actions in the rat social interaction model. Psychopharmacology (Berl) 107:379–384
Kennett GA, Whitton P, Shah K, Curzon G (1989) Anxiogeniclike effects of mCPP and TFMPP in animal models are opposed by 5-HT1C receptor antagonists. Eur J Pharmacol 164:445–454
Kennett GA, Wood MD, Glen A, Grewal S, Forbes I, Gadre A, Blackburn TP (1994) In vivo properties of SB 200646A, a 5-HT2C/2B receptor antagonist. Br J Pharmacol 111:797–802
Kennett GA, Bailey F, Piper DC, Blackburn TP (1995) Effect of SB 200646A, a 5-HT2C/5-HT2B receptor antagonist, in two conflict models of anxiety. Psychopharmacology (Berl) 118:178–182
Kennett GA, Bright F, Trail B, Baxter GS, Blackburn TP (1996a) Effects of the 5-HT2B receptor antagonist, BW 723C86, on three rat models of anxiety. Br J Pharmacol 117:1443–1448
Kennett GA, Wood MD, Bright F, Cilia J, Piper DC, Gager T, Thomas D, Baxter GS, Forbes IT, Ham P, Blackburn TP (1996b) In vitro and in vivo profile of SE 206553, a potent 5-HT2C/5-HT2B receptor antagonist with anxiolyticlike properties. Br J Pharmacol 117:427–434
Kennett GA, Wood MD, Bright F, Trail B, Riley G, Holland V, Avenell KY, Stean TT, Upton N, Bromidge S, Forbes IT, Brown AM, Middlemiss DN, Blackburn TP (1997a) SE 242084, a selective and brain penetrant 5-HT2C receptor antagonist. Neuropharmacology 36:609–620
Kennett GA, Bright F, Trail B, Blackburn TP, Sanger GJ (1997b) Anxiolytic-like actions of the 5-HT4 receptor antagonists SB 204070A and SB 207266A in rats. Neuropharmacology 36:707–712
Sams-Dodd F (1995) Automation of the social interaction test by a video-tracking system: behavioural effects of repeated phencyclidine treatment. J Neurosci Methods 59:157–167
Sams-Dodd F (1997) Effect of novel antipsychotic drugs on phencyclidine-induced stereotyped behaviour and social isolation in the rat social interaction test. Behav Pharmacol 8:196–215
Singh L, Field MJ, Hughes J, Menzies R, Oles RJ, Vass CA, Woodruff GN (1991) The behavioural properties of CI-998, a selective cholecystokininB receptor antagonist. Br J Pharmacol 104:239–245
Szewczak MR, Cornfeldt ML, Dunn RW, Wilker JC, Geyer HM, Glamkowski EJ, Chiang Y, Fielding S (1987) Pharmacological evaluation of HP 370, a potential atypical antipsychotic agent. 1. In vivo profile. Drug Dev Res 11:157–168
Treit D (1985) Animal models for the study of anti-anxiety agents: a review. Neurosci Biobehav Rev 9:203–222
Volke V, Soosaar A, Koks S, Bourin M, Mannisto PT, Vasar E (1997) 7-Nitroindazole, a nitric oxide synthase inhibitor, has anxiolytic-like properties in exploratory models of anxiety. Psychopharmacology (Berl) 131:399–405
Winslow JT, Camacho F (1995) Cholinergic modulation of a decrement in social investigation following repeated contacts between mice. Psychopharmacology (Berl) 121:164–172
Wongwitdecha N, Marsden CA (1996) Social isolation increases aggressive behaviour and alters the effects of diazepam in the rat social interaction test. Behav Brain Res 75:27–32
Woodall KL, Domeney AM, Kelly ME (1996) Selective effects of 8-OH-DPAT on social competition in the rat. Pharmacol Biochem Behav 54:169–173
Elevated Plus Maze Test
Brakebusch C, Seidenbecher CI, Asztely F, Rauch U, Matthies H, Meyer H, Krug M, Böckers TM, Zhou X, Kreutz MR, Montag D, Gundelfinger ED, Fässler R (2002) Brevican-deficient mice display impaired hippocampal CA1 long-term potentiation but show no obvious deficits in learning and memory. Mol Cell Biol 22:7417–7427
Brett RR, Pratt JA (1990) Chronic handling modifies the anxiolytic effect of diazepam in the elevated plus-maze. Eur J Pharmacol 178:135–138
Corbett R, Fielding St, Cornfeldt M, Dunn RW (1991) GABAmimetic agents display anxiolytic-like effects in the social interaction and elevated plus maze procedures. Psychopharmacology 104:312–316
Cryan JF, Kelly PH, Chaperon F, Gentsch C, Mombereau C, Lingenhoehl K, Froestl W, Bettler B, Kaupmann K, Spooren PJM (2004) Behavioral characterization of the novel GABAB receptor positive modulator GS39783 (N, N′-dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine): anxiolytic-like activity without side effects associated with baclofen or benzodiazepines. J Pharmacol Exp Ther 310:952–963
Danks AM, Oestreicher AB, Spruijt Gispen WH, Isaakson RL (1991) Behavioral and anatomical consequences of unilateral fornix lesions and the administration of nimodipine. Brain Res 557:308–312
Di Cicco D, Antal S, Ammassari-Teule M (1991) Prenatal exposure to gamma/neutron irradiation: sensorimotor alterations and paradoxical effects on learning. Teratology 43:61–70
Dunn RW, Carlezon WA, Corbett R (1991) Preclinical anxiolytic versus antipsychotic profiles of the 5-HT3 antagonists ondansetron, zacopride, 3α-tropanyl-1H-indole-3carboxylic acid ester, and 1αH, 3α, 5αH-Tropan-3-yl-3,5- dichlorobenzoate. Drug Dev Res 23:289–300
File SE, Mabbutt PS, Hitchcott PH (1990) Characterisation of the phenomenon of “one-trial tolerance” to the anxiolytic effect of chlordiazepoxide in the elevated plus-maze. Psychopharmacology (Berl) 102:98–101
Handley SL, McBlane JW (1993) An assessment of the elevated X-maze for studying anxiety and anxiety-modulating drugs. J Pharmacol Toxicol Methods 29:129–138
Harro J, Pöld M, Vasar E (1990) Anxiogenic-like action of caerulein, a CCK-8 receptor agonist, in the mouse: influence of acute and subchronic diazepam treatment. Naunyn Schmiedebergs Arch Pharmacol 341:62–67
Ho YJ, Eichemdorff J, Schwarting RKW (2002) Individual response profiles of male Wistar rats in animal models for anxiety and depression. Behav Brain Res 136:1–12
Jardim MC, Nogueira RL, Graeff FG, Nunes-de-Souza RL (1999) Evaluation of the elevated T-maze as an animal model of anxiety in the mouse. Brain Res Bull 48:407–411
Karl T, Hoffmann T, Pabst R, von Hörsten S (2003) Behavioral effects of neuropeptide γ in F344 rat substrains with reduced dipeptidyl-peptidase IV activity. Pharmacol Biochem Behav 75:869–879
Kauppila T, Tanila H, Carlson S, Taira T (1991) Effects of atipamezole, a novel α2-adrenoreceptor antagonist, in open field, plus-maze, two compartment exploratory, and forced swimming tests in rats. Eur J Pharmacol 205:177–182
Keck ME, Welt T, Wigger A, Renner U, Engelmann M, Holsboer F, Landgraf R (2001) The anxiolytic effect of CRH1 receptor antagonist R121919 depends on innate emotionality in rats. Eur J Neurosci 13:373–380
Korsgaard MPG, Hartz BP, Brown WD, Ahring PK, Strøbœk D, Mirza NR (2005) Anxiolytic effects of Maxipost (BMS-204352) and Retigabine via activation of neuronal Kv7 channels. J Pharmacol Exp Ther 314:282–292
Korte SM, De Boer SF (2003) A robust animal model of state anxiety: fear-potentiated behaviour in the elevated plusmaze. Eur J Pharmacol 463:163–175
Landgraf R, Wigger A, Holsboer A, Neumann ID (1999) Hyperactive hypothalamo-pituitary-adrenocortical (HPA) axis in rats bred for high anxiety-related behavior. Neuroendocrinology 11:405–407
Lapin IP (1995) Only controls: effect of handling, sham injection, and intraperitoneal injection of saline on behavior of mice in an elevated plus-maze. J Pharmacol Toxicol Methods 34:73–77
Liebisch G, Montkowski A, Holsboer F, Landgraf R (1998) Behavioral profiles of two Wistar rat lines selectively bred for high or low anxiety-related behavior. Behav Brain Res 94:301–310
Montag-Sallaz M, Montag D (2003) Severe cognitive and motor coordination deficits in Tenascin-R-deficient mice. Genes Brain Behav 2:20–31
Montgomery KC (1958) The relation between fear induced by novel stimulation and exploratory behaviour. J Comp Physiol Psychol 48:254–260
Munn NL (1950) The role of sensory processes in maze behavior. In: Handbook of psychological research in the rat. Houghton Mifflin, Boston, pp 181–225
Pellow S (1986) Anxiolytic and anxiogenic drug effects in a novel test of anxiety: are exploratory models of anxiety in rodents valid? Methods Find Exp Clin Pharmacol 8:557–565
Pellow S, File SE (1986) Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in the rat. Pharmacol Biochem Behav 25:525–529
Pellow S, Chopin P, File SE, Briley M (1985) Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 14:149–167
Pokk P, Liljequist S, Zharkovsky A (1996) Ro 15–4513 potentiates, instead of antagonizes, ethanol-induced sleep in mice exposed to small platform stress. Eur J Pharmacol 317:15–20
Schwarzberg H, Kalbacher H, Hoffmann W (1999) Differential behavioral effects of TFF peptides: injections of synthetic TFF3 into the rat amygdala. Pharmacol Biochem Behav 62:173–178
Shepherd JK, Grewal SS, Fletcher A, Bill DJ, Dourish CT (1994) Behavioral and pharmacologic characterization of the elevated “zero-maze” as an animal model of anxiety. Psychopharmacology (Berl) 116:56–65
Silva RH, Frussa-Filho R (2000) The plus-maze discriminative avoidance task: a new model to study memory-anxiety interactions. Effects of chlordiazepoxide and caffeine. J Neurosci Methods 102:117–125
Silverman P (1978) Approach to a conditioned stimulus: mazes. In: Animal behaviour in the laboratory. Chapman and Hall, London, pp 110–119
Toubas PL, Abla KA, Cao W, Logan LG, Seale TW (1990) Latency to enter a mirrored chamber: a novel behavioral assay for anxiolytic agents. Pharmacol Biochem Behav 35:121–126
Water Maze Test
Bane A, Rojas D, Indermaur K, Bennett T, Avery D (1996) Adverse effects of dextromorphan on the spatial learning of rats in the Morris water maze. Eur J Pharmacol 302:7–12
Connor DJ, Langlais PJ, Thal LJ (1991) Behavioral impairments after lesions in the nucleus basalis by ibotenic acid and quisqualic acid. Brain Res 555:84–90
McNaughton N, Morris RGM (1987) Chlordiazepoxide, an anxiolytic benzodiazepine, impairs place navigation in rats. Behav Brain Res 24:39–46
Morris RGM (1981) Spatial localization does not require the presence of local cues. Learn Motiv 12:239–260
Morris R (1984) Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 11:47–60
Morris RGM, Anderson E, Lynch GS, Baudry M (1986) Selective impairment of learning and blockade of long-term potentiation by an N-methyl-d-aspartate receptor antagonist, AP5. Nature 319:774–776
Rowan MJ, Culle WK, Moulton B (1990) Buspirone impairment of performance of passive avoidance and spatial learning tasks in the rat. Psychopharmacology (Berl) 100:393–398
Schmitt U, Hiemke C (2002) Tiagabine, a γ-amino-butyric acid transport inhibitor impairs spatial learning in the Morris water maze. Behav Brain Res 133:391–394
Van der Staay FJ (2000) Effects of the size of the Morris water tank on spatial discrimination learning in the CFW1 mouse. Physiol Behav 68:599–602
Winter B, Bert B, Fink H, Dirnagl U, Endres M (2004) Dysexecutive syndrome after mild cerebral ischemia? Mice learn normally but have deficits in strategic switching. Stroke 35:191–195
Staircase Test
Emmanouil D, Quock RM (1990) Effects of benzodiazepine antagonist, inverse agonist and antagonist drugs in mouse staircase test. Psychopharmacology (Berl) 102:95–97
Houri D (1985) Staircase test of central nervous system drugs. Pharmacometrics 30:467–479
Keane PE, Simiand J, Morre M, Biziere K (1988) Tetrazepam: a benzodiazepine which dissociates sedation from other benzodiazepine activities. I. Psychopharmacological profile in rodents. J Pharmacol Expert Ther 245:692–698
Porsolt RD, Lenègre A, Avril I, Doumont G (1988) Antagonism by exifone, a new cognitive enhancing agent, of the amnesias induced by four benzodiazepines in mice. Psychopharmacology (Berl) 95:291–297
Simiand J, Keane PE, Morre M (1984) The staircase test in mice: a simple and efficient procedure for primary screening of anxiolytic agents. Psychopharmacology (Berl) 84:48–53
Simiand J, Keane PE, Barnouin MC, Keane M, Soubrié P, Le Fur G (1993) Neurospychopharmacological profile in rodents of SR 57746A, a new, potent 5-HT1A receptor agonist. Fundam Clin Pharmacol 7:413–427
Steru L, Thierry B, Chermat R, Millet B, Simon P, Porsolt RD (1987) Comparing benzodiazepines using the staircase test in mice. Psychopharmacology (Berl) 92:106–109
Thiébot MH, Soubrié P, Simon P, Boissier JR (1973) Dissociation de deux composantes du comportement chez le Rat sous l’effet de psychotropes. Application à l’etude des anxiolytiques. Psychopharmacologia 31:77–90
Cork Gnawing Test in the Rat
Pollard GT, Howard JL (1991) Cork gnawing in the rat as a screening method for buspirone-like anxiolytics. Drug Dev Res 22:179–187
Pollard GT, Nanry KP, Howard JL (1992) Effects of tandospirone in three behavioral tests for anxiolytics. Eur J Pharmacol 221:297–305
Distress Vocalization in Rat Pups
Gardner CR (1985) Distress vocalisation in rat pups: a simple screening method for anxiolytic drugs. J Pharmacol Methods 14:181–187
Griebel G, Simiand J, Steinberg R, Jung M, Gully D, Roger P, Geslin M, Scatton B, Maffrand JP, Soubrié P (2002) 4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S5)2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)1,3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophinreleasing factor1 receptor antagonist. II. Characterization in rodent models of stress-related disorders. J Pharmacol Exp Ther 301:332–345
Insel TR, Winslow JT (1991) Rat pup ultrasonic vocalizations: an ethologically relevant behaviour response to anxiolytics. In: Olivier B, Mos J, Slangen JL (eds) Animal models in psychopharmacology, Advances in pharmacological sciences. Birkhäuser Verlag, Basel, pp 15–36
Kehne JH, Coverdale S, McCloskey TC, Hoffman DC, Cassella JV (2000) Effect of the CRF1 receptor antagonist, CP 154,526, in the separation-induced vocalization anxiolytic test in rat pups. Neuropharmacology 39:1357–1367
Lister RG (1990) Ethologically-based animal models of anxiety disorders. Pharmacol Ther 46:321–340
Molewijk HE, Hartog K, van der Poel AM, Mos J, Olivier B (1996) Reduction of guinea pig pup isolation calls by anxiolytic and antidepressant drugs. Psychopharmacology (Berl) 128:31–38
Rupniak NMJ, Carlson EC, Harrison T, Oates B, Seward E, Owen S, de Felipe C, Hunt S, Wheeldon A (2000) Pharmacological blockade of substance P (NK1) receptors attenuates neonatal vocalization in guinea-pigs and mice. Neuropharmacology 39:1413–1421
Schipper J, Tulp MTM, Berkelmans B, Mos J, Van der Heijden JAM, Olivier B (1991) Preclinical pharmacology of flesinoxan: a potential anxiolytic and antidepressant drug. Hum Psychopharmacol 6:53–61
Siemiatkowski M, Maciejak P, Sienkiewicz-Jarosz H, Czlonkowska AI, Szyndler J, Gryczymńska A, Plazńik A (2001) Opposite effects of olanzapine and haloperidol in rat ultrasonic vocalization test. Pol J Pharmacol 53:669–673
Steinberg R, Alonso R, Rouquier L, Desvignes C, Michaud JC, Cudennec A, Jung M, Simiand J, Griebel G, Emonds-Alt X, Le Fur G, Soubrie P (2002) SSR240600 [(R)-2-(1-[2-[4-[2-[3,5-bis(trifluoromethyl)phenyl]acetyl]-2-(3,4-dichlorophenyl)-2-morpholinyl]ethyl]-4-piperidinyl)2-methyl-propanamide], a centrally active nonpeptide antagonist of the tachykinin neurokinin 1 receptor: II. Neurochemical and behavioral characterization. J Pharmacol Exp Ther 303(3):1180–1188
Tulp M, Olivier B, Schipper J, van der Poel G, Mos J, van der Heyden J (1991) Serotonin reuptake blockers: Is there preclinical evidence for their efficacy in obsessive-compulsive disorder? Hum Psychopharmacol 6:S63–S71
van der Poel AM, Molewijk E, Mos J, Olivier B (1991) Is clonidine anxiogenic in rat pups? In: Olivier B, Mos J, Slangen JL (eds) Animal models in psychopharmacology, Advances in pharmacological sciences. Birkhäuser Verlag, Basel, pp 107–116
Schedule Induced Polydipsia in Rats
Bös M, Jenck F, Martin JR, Moreau JL, Sleight AJ, Wichmann J, Widmer U (1997) Novel agonists of 5-HT2C receptors. Synthesis and biological evaluation of substituted 2-(indol-1-yl)-1-methylethylamines and 2-(indeno[1,2-b]pyrrol-1-yl)1-methylethylamines. Improved therapeutics for obsessive compulsive disorder. J Med Chem 40:2762–2769
Didriksen M, Olsen GM, Christensen AV (1993) Effect of clozapine upon schedule-induced polydipsia (SIP) resembles neither the actions of dopamine D1 nor D2 receptor blockade. Psychopharmacology (Berl) 113:28–34
Falk JL (1971) The nature and determinants of adjunctive behavior. Physiol Behav 6:577–588
Martin JR, Bös M, Jenck F, Moreau JL, Mutel V, Sleight AJ, Wichmann J, Andrews SJ, Berendsen HHG, Broekkamp CLE, Ruigt GSF, Köhler C, van Delft AML (1998) 5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential. J Pharmacol Exp Ther 286:913–924
Pellon R, Blackman DE (1992) Effects of drugs on the temporal distribution of schedule-induced polydipsia in rats. Pharmacol Biochem Behav 43:689–695
Pitman RK (1989) Animal models of compulsive behavior. Biol Psychiatry 26:189–198
Woods A, Smith C, Szewczak M, Dunn RW, Cornfeldt M, Corbett R (1993) Selective re-uptake inhibitors decrease schedule-induced polydipsia in rats: a potential model for obsessive compulsive disorder. Psychopharmacology (Berl) 112:195–198
Woods-Kettelberger AT, Smith CP, Corbett R, Szewczak MR, Roehr JE, Bores GM, Klein JT, Kongsamut S (1996) Besipirdine (HP 749) reduces schedule-induced polydipsia in rats. Brain Res Bull 41:125–130
Yadin E, Friedman E, Bridger WH (1991) Spontaneous alternation behavior: an animal model for obsessive-compulsive disorder? Pharmacol Biochem Behav 40:311–315
Four Plate Test in Mice
Aron C, Simon P, Larousse C, Boissier JR (1971) Evaluation of a rapid technique for detecting minor tranquilizers. Neuropharmacology 10:459–469
Boissier JR, Simon P, Aron C (1968) A new method for rapid screening of minor tranquilizers in mice. Eur J Pharmacol 4:145–151
Hascoe M, Bourin M, du Tertre C (1997) Influence of prior experience on mice behavior using the four-plate test. Pharmacol Biochem Behav 58:1131–1138
Lenègre A, Chermat R, Avril I, Stéru L, Porsolt RD (1988) Specificity of Piracetam’s anti-amnesic activity in three models of amnesia in the mouse. Pharmacol Biochem Behav 29:625–629
Simon P (1970) Les Anxiolytiques. Possibilités d’étude chez l’animal. Actual Pharmacol 23:47–78
Stephens DN, Schneider HH, Kehr W, Andrews JS, Rettig KJ, Turski L, Schmiechen R, Turner JD, Jensen LH, Petersen EN, Honore T, Bondo Jansen J (1990) Abecarnil, a metabolically stable, anxioselective β-carboline acting at benzodiazepine receptors. J Pharmacol Expert Ther 253:334–343
Foot-shock-Induced Freezing Behavior in Rats
Conti LH, Maciver CR, Ferkany JW, Abreu ME (1990) Footshock-induced freezing behavior in rats as a model for assessing anxiolytics. Psychopharmacology (Berl) 102:492–497
De Vry J, Benz U, Traber J (1993) Shock-induced ultrasonic vocalization in young adult rats: a model for testing putative anti-anxiety drugs. Eur J Pharmacol 249:331–339
Kaltwasser MT (1990) Startle-inducing stimuli evoke ultrasonic vocalization in the rat. Physiol Behav 48:13–17
Miczek KA, Tornatzky W, Vivian J (1991) Ethology and neuropharmacology: rodent ultrasounds. In: Oliver B, Mos J, Sangar J (eds) Animal Models in Psychopharmacology. Birkhäuser Verlag, Basel, pp 409–427
Nielsen CK, Sánchez C (1995) Effect of chronic diazepam treatment on footshock-induced ultrasonic vocalization in adult male rats. Pharmacol Toxicol 77:177–181
Schreiber R, Melon C, De Vry J (1998) The role of 5-HT receptor subtypes in the anxiolytic effects of selective serotonin reuptake inhibitors in the rat ultrasonic vocalization test. Psychopharmacology 135:383–391
Tonoue T, Ashida A, Makino H, Hata H (1986) Inhibition of shock-elicited ultrasonic vocalization by opioid peptides in the rat: a psychotropic effect. Psychoneuroendocrinology 11:177–184
Experimental Anxiety in Mice
Ogawa N, Kuwahara K (1966) Psychophysiology of emotion: communication of emotion. Jpn J Psychosom Med 6:352–357
Ogawa N, Hara C, Ishikawa M (1990) Characteristic of sociopsychological stress induced by the communication box method in mice and rats. In: Manninen O (ed) Environmental stress. ACES Publishing, Tampele, pp 417–427
Ogawa N, Hara C, Takaki S (1993) Anxiolytic activity of SC-48274 compared with those of buspirone and diazepam in experimental anxiety models. Jpn J Pharmacol 61:115–121
mCPP-Induced Anxiety in Rats
Aulakh CS, Mazzola-Pomietto P, Murphy DL (1995) Longterm antidepressant treatments alter 5-HT2A and 5-HT2C receptor mediated hyperthermia in Fawn-Hooded rats. Eur J Pharmacol 282:65–70
Beckett SRG, Aspley S, Graham M, Marsden CA (1996) Pharmacological manipulation of ultrasound induced defense behaviour in the rat. Psychopharmacology 127:384–390
Bilkei-Gorzo A, Gyertyan I, Szabados T (1996) mCPP-induced anxiety – a potential new method for screening anxiolytic drugs. Neurobiology 4:253–255
Bilkei-Gorzo A, Gyertyan I, Levay G (1998) mCPP-induced anxiety in the light–dark box in rats – a new method for screening anxiolytic activity. Psychopharmacology (Berl) 136:291–298
Curzon G, Gibson EL, Kennedy AJ, Kennett GA, Sarna GS, Whitton P (1991) Anxiogenic and other effects of mCPP, a 5-HT1C agonist. In: Briley M, File SE (eds) New concepts in anxiety. McMillan Press, London, pp 154–167
Czyrak A, Skuza G, Rogóz Z, Frankiewicz T, Maij J (1994) Pharmacological action of zotepine and other antipsychotics on central 5-hydroxytryptamine receptor subtypes. Arzneim Forsch/Drug Res 44:113–118
Dryden S, Wang Q, Frankish HM, Williams G (1996) Differential effects of the 5-HT1B/2C receptor agonist mCPP and the 5-HT1A agonist flexinoxan on neuropeptide Y in the rat: evidence that NPY may mediate serotonin’s effects on food intake. Peptides 17:943–949
Gibson EL, Barnfield AMC, Curzon G (1996) Dissociation of effects of chronic diazepam treatment and withdrawal on hippocampal dialysate 5-HT and mCPP-induced anxiety in rats. Behav Pharmacol 7:185–193
Griebel G, Misslin R, Pawloaski M, Vogel E (1991) m-Chlorophenylpiperazine enhances neophobic and anxious behaviour in mice. NeuroReport 2:627–629
Kennett GA, Whitton P, Shah K, Curzon G (1989) Anxiogeniclike effects of mCPP and TFMPP in animal models are opposed by 5-HT1C receptor antagonists. Eur J Pharmacol 164:445–454
Kennett GA, Wood MD, Bright F, Cilia J, Piper DC, Gager T, Thomas D, Baxter GS, Forbes LT, Ham P, Blackburn TP (1996) In vitro and in vivo profile of SB 206553, a potent 5-HT2C/5-HT2B receptor antagonist with anxiolyticlike properties. Br J Pharmacol 117:427–434
Kennett GA, Wood MD, Bright F, Trail B, Riley G, Holland V, Avenell KY, Stean T, Upton N, Bromidge S, Forbes IT, Brown AM, Middlemiss DN, Blackburn TP (1997a) SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist. Neuropharmacol 36:609–620
Kennett GA, Ainsworth K, Trail B, Blackburn TP (1997b) BW 723C86, a 5-HT2B receptor agonist, causes hyperphagia and reduced grooming in rats. Neuropharmacol 36:233–239
Meert TF, Melis W, Aerts N, Clinke G (1997) Antagonism of meta-chlorphenylpiperazine-induced inhibition of exploratory activity in an emergence procedure, the open field test, in rats. Behav Pharmacol 8:353–363
Robertson DW, Blooquist W, Wong DT, Cohen ML (1992) MCPP but not TFMPP is an antagonist at cardiac 5-HT3 receptors. Life Sci 50:599–605
Rocha B, di Scala G, Jenk F, Moreau JL, Sandner G (1993) Conditioned place aversion induced by 5-HT1C receptor antagonists. Behav Pharmacol 4:101–106
Samanin R, Mennini T, Ferraris A, Bendotti C, Borsini F, Garattini S (1979) m-Chlorophenylpiperazine: a central serotonin agonist causing powerful anorexia in rats. Naunyn Schmiedebergs Arch Pharmacol 308:159–163
Wallis CJ, Lal H (1998) A discriminative stimulus produced by 1-(3-chlorophenyl)-piperazine (mCPP) as a putative animal model of anxiety. Progr Neuropsychopharmacol Biol Psychiatry 22:547–565
Yamada J, Sugimoto Y, Yoshikawa T, Horisaka K (1996) Effects of adrenomedullation and adrenalectomy on the 5-HT2 receptor agonists DOI- and mCPP-induced hypophagia in rats. Neurosci Lett 209:113–116
Acoustic Startle Response in Rats
Acri JB, Grunberg NE, Morse DA (1991) Effects of nicotine on the acoustic startle reflex amplitude in rats. Psychopharmacology (Berl) 104:244–248
Astrachan DI, Davis M (1981) Spinal modulation of the acoustic startle response: the role of norepinephrine, serotonin and dopamine. Brain Res 206:223–228
Cadet JL, Kuyatt B, Fahn S, De Souza EB (1987) Differential changes in 125I-LSD-labeled 5-HT-2 serotonin receptors in discrete regions of brain in the rat model of persistent dyskinesias induced by iminodipropionitrile (IDPN): evidence from autoradiographic studies. Brain Res 437:383–386
Davis M (1980) Neurochemical modulation of sensory-motor reactivity: acoustic and tactile startle reflexes. Neurosci Biobehav Rev 4:241–263
Davis M (1982) Agonist-induced changes in behavior as a measure of functional changes in receptor sensitivity following chronic antidepressant treatment. Science 18:137–147
Davis M (1986) Pharmacological and anatomical analysis of fear conditioning using the fear-potentiated startle paradigm. Behav Neurosci 100:814–824
Davis M (1992) The role of the amygdala in fear-potentiated startle: implications for animal models of anxiety. Trends Pharmacol Sci 13:35–41
Davis M, Astrachan DI, Kass E (1980) Excitatory and inhibitory effects of serotonin on sensomotoric reactivity measured with acoustic startle. Science 209:521–523
Hijzen TH, Woudenberg F, Slangen JL (1990) The long-term effects of diazepam and pentylenetetrazol on the potentiated startle response. Pharmacol Biochem Behav 36:35–38
Hijzen TH, Houtzager SWJ, Joordens RJE, Olivier B, Slangen JL (1995) Predictive validity of the potentiated startle response as a behavioral model for anxiolytic drugs. Psychopharmacol 118:150–154
Keith VA, Mansbach RS, Geyer MA (1991) Failure of haloperidol to block the effects of phencyclidine and dizocilpine on prepulse inhibition of startle. Biol Psychiatry 30:557–566
Mansbach RS, Markou A, Patrick GA (1994) Lack of altered startle response in rats following termination of self-administered or noncontingently infused cocaine. Pharmacol Biochem Behav 48:453–458
Rigdon GC, Viik K (1991) Prepulse inhibition as a screening test for potential antipsychotics. Drug Dev Res 23:91–99
Schulz DW, Mansbach RS, Sprouse J, Braselton JP, Collins J, Corman M, Dunaikis A, Faraci S, Schmidt AW, Seeger T, Seymour P, Tingley FD III, Winston EN, Chen YL, Heym J (1996) CP-154–526: a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors. Proc Natl Acad Sci U S A 93:10477–10482
Taylor MK, Ison JR, Schwarzkopf SB (1995) Effects of single and repeated exposure to apomorphine on the acoustic startle reflex and its inhibition by a visual prepulse. Psychopharmacology (Berl) 120:117–127
Vale AL, Green S (1996) Effects of chlordiazepoxide, nicotine and d-amphetamine in the rat potentiated startle model of anxiety. Behav Pharmacol 7:138–143
Varty GB, Higgins GA (1994) Differences between three rat strains in sensitivity to prepulse inhibition of an acoustic startle response: influence of apomorphine and phencyclidine pre-treatment. J Psychopharmacol 8:148–156
Vivian JA, Farrell WJ, Sapperstein SB, Miczek KA (1994) Diazepam withdrawal: effects of diazepam and gespirone on acoustic startle-induced 22 kHz ultrasonic vocalizations. Psychopharmacology (Berl) 114:101–108
Walker DL, Davis M (1997) Anxiogenic effects of high illumination levels assessed with the acoustic startle response in rats. Biol Psychiatry 42:461–471
Weiss GT, Davis M (1976) Automated system for acquisition and reduction of startle response data. Pharmacol Biochem Behav 4:713–720
Yilmazer-Hanke DN, Faber-Zuschratter H, Linke R, Schwegler H (2002) Contribution of amygdala neurons containing peptides and calcium-binding proteins to fear-potentiated startle and exploration-related anxiety in inbred Roman high- and low-avoidance rats. Eur J Neurosci 15:1206–1218
Young BJ, Helmstetter FJ, Rabchenuk SA, Leaton RN (1991) Effects of systemic and intra-amygdaloid diazepam on long-term habituation of acoustic startle in rats. Pharmacol Biochem Behav 39:903–909
Zajaczkowski W, Górka Z (1993) The effects of single and repeated administration of MAO inhibitors on acoustic startle response in rats. Pol J Pharmacol 45:157–166
Unconditioned Conflict Procedure (Vogel Test)
La Marca S, Dunn RW (1994) The α2 antagonists idazoxan and rauwolscine but not yohimbine or piperoxan are anxiolytic in the Vogel lick-shock paradigm following intravenous administration. Life Sci 54:179–184
Langen B, Egerland U, Bernöster K, Dost R, Unverferth K, Rundfeldt C (2005) Characterization in rats of the anxiolytic potential of ELB139 [1-(4-chlorphenyl)-4-piperidin-1-yl-1,5-dihydro-imidazol-2-on], a new agonist at the benzodiazepine binding site of the GABAA receptor. J Pharmacol Exp Ther 314:717–724
Mathiasen L, Mirza NR (2005) A comparison of chlordiazepoxide, bretazenil, L838,417 and zolpidem in a validated mouse Vogel conflict test. Psychopharmacology (Berl) 182:475–484
Miklya I, Knoll J (1988) A new sensitive method which unlike the VOGEL test detects the anxiolytic effect of tofisopam. Pol J Pharmacol Pharm 40:561–572
Patel J, Malick JB (1982) Pharmacological properties of tracazolate: a new non-benzodiazepine anxiolytic agent. Eur J Pharmacol 78:323
Patel JB, Martin C, Malick JB (1983) Differential antagonism of the anticonflict effects of typical and atypical anxiolytics. Eur J Pharmacol 86:295–298
Przegalinski E, Chojnacka-Wojcik E, Filip M (1992) Stimulation of 5-HT1A receptors is responsible for the anticonflict effect of ipsapirone in rats. J Pharm Pharmacol 44:780–782
Sanger DJ, Joly D, Zivkovic B (1985) Behavioral effects of nonbenzodiazepine anxiolytic drugs: a comparison of CGS 9896 and zopiclone with chlordiazepoxide. J Pharm Exp Ther 232:831–837
Uyeno ET, Davies MF, Pryor GT, Loew GH (1990) Selective effect on punished versus unpunished responding in a conflict test as the criterion for anxiogenic activity. Life Sci 47:1375–1382
Vogel JR, Beer B, Clody DE (1971) A simple and reliable conflict procedure for testing anti-anxiety agents. Psychopharmacologia (Berl) 21:1–7
Novelty-Suppressed Feeding
Bodnoff SR, Suranyi-Cadotte B, Aitken DH, Quirion R, Meaney MJ (1988) The effects of chronic antidepressant treatment in an animal model of anxiety. Psychopharmacology (Berl) 95:298–302
Bodnoff SR, Suranyi-Cadotte B, Quirion R, Meaney MJ (1989) A comparison of the effects of diazepam versus typical and atypical anti-depressant drugs in an animal model of anxiety. Psychopharmacology (Berl) 97:277–279
Borsini F, Brambilla A, Cesana R, Donetti A (1993) The effect of DAU 6215, a novel 5-HT-5 antagonist, in animal models of anxiety. Pharmacol Res 27:151–164
Cooper SJ, Crummy YMT (1978) Enhanced choice of familiar food in a food preference test after chlordiazepoxide administration. Psychopharmacology (Berl) 59:51–56
Fletcher PJ, Davies M (1990) Effects of 8-OH-DPAT, buspirone and ICS 205–930 on feeding in a novel environment: comparison with chlordiazepoxide and FG 7142. Psychopharmacology (Berl) 102:301–308
Porschel BPH (1971) A simple and specific screen for benzodiazepine-like drugs. Psychopharmacologia 19:193–198
Shephard RA, Broadhurst PL (1982) Hyponeophagia and arousal in rats: effects of diazepam, 5-methoxy-N, N-dimethyltryptamine, d-amphetamine and food deprivation. Psychopharmacology (Berl) 78:368–378
Soubrie P, Kulkarni S, Simon P, Boissier JR (1975) Effets des anxiolytiques sur la prise de norriture de rats et de souris places en situation nouvelle ou familière. Psychopharmacologia 45:203–210
Shock Probe Conflict Procedure
Meert TF, Colpaert FC (1986) The shock probe conflict procedure. A new assay responsive to benzodiazepines, barbiturates and related compounds. Psychopharmacol 88:445–450
Ultrasound Induced Defensive Behavior in Rats
Beckett SRG, Marsden CA (1995) Computer analysis and quantification of periaqueductal grey-induced defence behavior. J Neurosci Methods 58:157–161
Beckett SRG, Aspley S, Graham M, Marsden CA (1996) Pharmacological manipulation of ultrasound induced defence behaviour in the rat. Psychopharmacology 127:384–390
Molewijk HE, van der Poel AM, van der Heyden JAM, Olivier B (1995) Conditioned ultrasonic distress vocalization in adult male rats as a behavioural paradigm for screening antipanic drugs. Psychopharmacology (Berl) 117:32–40
Anxiety/Defense Test Battery in Rats
Blanchard RJ, Blanchard DC (1989) Antipredator defensive behaviors in a visible burrow system. J Comp Physiol 103:70–82
Blanchard RJ, Blanchard DC, Flannely KJ, Hori K (1986a) Ethanol changes patterns of defensive behaviour in wild rats. Physiol Behav 38:645–650
Blanchard RJ, Flannely HJ, Blanchard DC (1986b) Defensive behaviours of laboratory and wild Rattus norvegicus. J Comp Physiol 100:101–107
Blanchard DC, Hori K, Rodgers RJ, Hendrie CA, Blanchard RJ (1989) Differential effects of benzodiazepines and 5-HT1A agonists on defensive patterns of wild rattus. In: Bean, Cools, Archer (eds) Behavioural pharmacology of 5-HAT. Erlbaum, Hillsdale, pp 145–147
Blanchard DC, Blanchard RJ, Tom P, Rodgers RJ (1990) Diazepam changes risk assessment in an anxiety/defense test battery. Psychopharmacology (Berl) 101:511–518
Blanchard DC, Shepherd JK, Rodgers RJ, Blanchard RJ (1992) Evidence for differential effects of 8-OH-DPAT on male and female rats in the anxiety/defense test battery. Psychopharmacology (Berl) 106:531–539
Farook JM, Zhu YZ, Wang H, Moochhala S, Lee L, Wong PT (2001) Strain differences in freezing behavior of PVG hooded and Sprague Dawley rats: differential cortical expression of cholecystokinin2 receptors. Neuroreport 12:2717–2720
Farook JM, Wang Q, Moochhala SM, Zhu ZY, Lee L, Wong PTH (2004a) Distinct regions of periaqueductal gray (PAG) are involved in freezing behavior in hooded PVG rats in the cat-freezing test apparatus. Neurosci Lett 354:139–142
Farook JM, McLachlan CS, Zhu YZ, Lee L, Moochhala SM, Wong PTH (2004b) The CCK2 agonist BC264 reverses freezing behavior habituation in PVG hooded rats on repeated exposures to a cat. Neurosci Lett 355:205–208
Griebel G, Sanger DJ, Perrault G (1997) Genetic differences in the mouse defense battery. Aggress Behav 23:19–31
Griebel G, Curet O, Perrault G, Sanger DJ (1998a) Behavioral effects of phenelzine in an experimental model for screening anxiolytic and anti-panic drugs. Neuropharmacol 37:927–935
Griebel G, Perrault G, Sanger DJ (1998b) Characterization of the behavioral profile of the non-peptide CRF receptor antagonist CP-154,526 in anxiety models of rodents. Comparison with diazepam and buspirone. Psychopharmacology (Berl) 138:55–66
Griebel G, Moindrot N, Aliaga C, Simiand J, Soubrié P (2001) Characterization of neurokinin-2 and neurotensin receptor antagonists in the mouse defense test battery. Neurosci Biobehav Rev 25:619–626
Griebel G, Simiand J, Steinberg R, Jung M, Gully D, Roger P, Geslin M, Scatton B, Maffrand JP, Soubrié P (2002) 4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S5)2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)1,3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophinreleasing factor1 receptor antagonist. II. Characterization in rodent models of stress-related disorders. J Pharmacol Exp Ther 301:332–345
Wang H, Zhu YZ, Wong PTH, Farook JM, Teo AL, Lee LKH, Moochhala S (2003) cDNA microarray analysis of gene expression in anxious PVG and SD rats after cat-freezing test. Exp Brain Res 149:413–421
Repetitive Transcranial Magnetic Stimulation
Barker AT, Jalinous R, Freeston IL (1985) Non-invasive stimulation of the human motor cortex. Lancet 1:1106–1107
Ben-Shachar D, Gazawi H, Riboyad-Levin J, Klein E (1999) Chronic repetitive transcranial magnetic stimulation alters β-adrenergic and 5-HT2 receptor characteristics in rat brain. Brain Res 816:78–83
Fleischmann A, Prolov K, Abarbanel J, Belmaker RH (1995) The effect of transcranial magnetic stimulation of rat brain on behavioral models of depression. Brain Res 699:130–132
Hausmann A, Weis C, Marksteiner J, Humpel C (2000) Chronic repetitive transcranial magnetic stimulation enhances c-fos in the parietal cortex and hippocampus. Brain Res Mol Brain Res 76:355–362
Hedges DW, Massari C, Salyer DL, Lund TD, Hellewell JL, Johnson AC, Lephart ED (2003) Duration of transcranial magnetic stimulation effects on the neuroendocrine stress response and coping behavior of adult male rats. Prog Neuropsychopharm Biol Psychiatry 27:633–638
Hedges DW, Higginbotham BJ, Salyer DL, Lund TD (2005) Transcranial magnetic stimulation effects on one-trail learning and response to anxiogenic stimuli in adult male rats. J ECT 21:25–30
Isogawa K, Fujiki M, Akiyoshi J, Tsutsumi T, Horinouchi Y, Kodama K, Nagayama H (2003) Anxiety induced by repetitive transcranial magnetic stimulation is suppressed by chronic treatment of paroxtine in rats. Pharmacopsychiatry 36:7–11
Isogawa K, Fujiki M, Akiyoshi J, Tsutsumi T, Kodama K, Matsushita H, Tanaka Y, Kobayashi H (2005) Anxiolytic suppression of repetitive transcranial magnetic stimulation-induced anxiety in the rats. Progr Neuropsychopharm Biol Psychiatry 29:664–668
Ji RR, Schlaepfer TE, Aizenman CD, Epstein CM, Qiu D, Huang JC, Rupp F (1998) Repetitive transcranial magnetic stimulation activates specific regions in rat brain. Proc Natl Acad Sci U S A 95:15635–15640
Kanno M, Matsumoto M, Togashi H, Yoshioka M, Mano Y (2003) Effects of repetitive transcranial magnetic stimulation on behavior and neurochemical changes in rats during an elevated plus-maze test. J Neurol Sci 211:5–14
Keck ME, Engelmann M, Müller MB, Henniger MSH, Hermann B, Rupprecht R, Neumann ID, Toschi N, Landgraf R, Post A (2000) Repetitive transcranial magnetic stimulation induces active coping strategies and attenuates the neuroendocrine stress response in rats. J Psych Res 14:265–276
Keck ME, Welt T, Post A, Müller MB, Toschi N, Wigger A, Landgraf R, Holsboer F, Engelmann M (2001) Neuroendocrine and behavioral effects of repetitive transcranial magnetic stimulation in a psychopathological animal model are suggestive of antidepressant-like effects. Neuropsychopharmacology 24:337–349
Luft AR, Kaelin-Lang A, Hauser TK, Cohen LG, Thakor NV, Hanley DF (2001) Transcranial magnetic stimulation in the rat. Exp Brain Res 140:112–121
Sachdev PS, McBride R, Loo C, Mitchell PM, Malhi GS, Crooker V (2002) Effect of different frequencies of transcranial magnetic stimulation (TMS) on the forced swim model of depression in rats. Biol Psychiatry 51:474–479
Tsutsumi T, Fujiki M, Akiyoshi J, Horinouchi Y, Isogawa K, Hori S, Nagayama H (2002) Effect of repetitive transcranial magnetic stimulation on forced swimming test. Progr Neuropsychopharm Biol Psychiatry 26:107–111
Weissman JD, Epstein CM, Davey KR (1992) Magnetic brain stimulation and brain size: relevance to animal studies. Electroencephalogr Clin Neurophysiol 85:215–219
Zyss T, Górka Z, Kowalska M, Vetulani J (1997) Preliminary comparison of behavioral and biochemical effects of chronic transcranial magnetic stimulation and electroconvulsive shock in the rat. Biol Psychiatry 42:920–924
Marmoset Human Threat Test
Barnes NM, Costall B, Domeney AM, Gerrard PA, Kelly ME, Krahling H, Naylor RJ, Tomkins DM, Williams TJ (1991) The effects of umespirone as a potential anxiolytic and antipsychotic agent. Pharmacol Biochem Behav 40:89–96
Barros M, Boere V, Huston JP, Tomaz C (2000) Measuring fear and anxiety in the marmoset (Callithrix penicillata) with a novel predator confrontation model: effects of diazepam. Behav Brain Res 108:205–211
Borsini F, Brambilla A, Cesana R, Donetti A (1993) The effect of DAU 6215, a novel 5HAT-3 antagonist in animal models of anxiety. Pharmacol Res 27:151–164
Cilia J, Piper DC (1997) Marmoset conspecific confrontation: an ethologically-based model of anxiety. Pharmacol Biochem Behav 58:85–91
Costall B, Domeney AM, Naylor RJ, Tyers MB (1987) Effects of the 5-HT3 receptor antagonist, GR38032F, on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain. Br J Pharmacol 92:881–894
Costall B, Domeney AM, Gerrard PA, Kelley ME, Naylor RJ (1988) Zacopride: anxiolytic profile in rodent and primate models of anxiety. J Pharm Pharmacol 40:302–305
Costall B, Domeney AM, Farre AJ, Kelly ME, Martinez L, Naylor RJ (1992) Profile of action of a novel 5-hydroxytryptamine1A receptor ligand E-4424 to inhibit aversive behavior in the mouse, rat and marmoset. J Pharmacol Exp Ther 262:90–98
Jones BJ, Costall B, Domeney AM, Kelly ME, Naylor RJ, Oakley NR, Tyers MB (1988) The potential anxiolytic activity of GR38032F, a 5-HT3 receptor antagonist. Br J Pharmacol 93:985–993
Stevenson MF, Poole TB (1976) An ethogram of the common marmoset (Callithrix jacchus): general behavioural repertoire. Anim Behav 24:428–451
Psychosocial Stress in Tree Shrews
Czéh B, Pudovkina O, van der Hart MGC, Simon M, Heilbronner U, Michaelis T, Watanabe T, Frahm J, Fuchs E (2005) Examining SLV-323, a novel NK1 receptor antagonist, in a chronic stress model for depression. Psychopharmacology (Berl) 180:548–557
Fischer HD, Heinzeller T, Raab A (1985) Gonadal response to psychosocial stress in male tree shrews (Tupaia belangeri): morphometry of testis, epididymis and prostate. Andrologia 17:262–275
Fuchs E (2005) Social stress in tree shrews as an animal model of depression: an example of an behavioral model of a CNS disorder. CNS Spectr 10:182–190
Fuchs E, Flügge G (2002) Social stress in tree shrews. Effects on physiology, brain function, and behavior of subordinate individuals. Pharmacol Biochem Behav 73:247–258
Fuchs E, Jöhren O, Flügge G (1993) Psychosocial conflict in the tree shrew: effects on sympathoadrenal activity and blood pressure. Psychoneuroendocrinology 18:557–565
Fuchs E, Kramer M, Hermes B, Netter P, Hiemke C (1996) Psychological stress in tree shrews: clomipramine counteracts behavioral and endocrine changes. Pharmacol Biochem Behav 54:219–228
Lucassen PJ, Fuchs E, Czeh B (2004) Antidepressant treatment with tianeptine reduces apoptosis in the hippocampal dentate gyrus and temporal cortex. Biol Psychiatry 55:789–796
Shively CA, Register TC, Friedman PD, Morgan TM, Thompson J, Lanier T (2005) Social stress-associated depression in adult female cynomolgus monkeys (Macaca fascicularis). Biol Psychiatry 69:67–84
Aversive Brain Stimulation
Aguiar MS, Brandão ML (1994) Conditioned place aversion produced by microinjection of substance P into the periaqueductal gray of rats. Behav Pharmacol 5:369–373
Aguiar MS, Brandão ML (1996) Effects of microinjections of the neuropeptide substance P in the dorsal periaqueductal gray on the behavior of rats in the plus-maze test. Physiol Behav 60:1183–1186
Audi EA, de Aguiar JC, Graeff FG (1988) Mediation by serotonin of the antiaversive effect of zimelidine and propranolol injected into the dorsal midbrain central grey. J Psychopharmacol 2:26–32
Audi EA, de Oliveira RMW, Graeff FG (1991) Microinjection of propranolol into the dorsal periaqueductal gray causes an anxiolytic effect in the elevated plus-maze antagonized by ritanserin. Psychopharmacology (Berl) 105:553–557
Beckett S, Marsden CA (1997) The effect of central and systemic injection of the 5-HT1A receptor agonist 8-OHDPAT and the 5-HT1A antagonist WAY100635 on periaqueductal grey-induced defensive behaviour. J Psychopharmacol 11:35–40
Bovier P, Broekkamp CLE, Lloyd KG (1982) Enhancing GABAergic transmission reverses the aversive state in rats induced by electrical stimulation of the periaqueductal grey region. Brain Res 248:313–320
Brandão ML (1993) Involvement of opioid mechanisms in the dorsal periaqueductal gray in drug abuse. Rev Neurosci 4:397–405
Brandão ML, Lopez-Garcia JA, Roberts HMT (1991) Electrophysiological evidence for the involvement of 5-HT2 receptors in the antiaversive action of 5-HT in the dorsal periaqueductal grey. In: Olivier B, Mos J, Slangen JL (eds) Animal models in psychopharmacology, Advances in pharmacological sciences. Birkhäuser Verlag, Basel, pp 75–79
Broekkamp CL, Dortmans C, Berendsen HHG, Jenk F (1991) Pharmacology of fear, induced by periaqueductal gray stimulation in the rat. In: Olivier B, Mos J, Slangen JL (eds) Animal models in psychopharmacology, Advances in pharmacological sciences. Birkhäuser Verlag, Basel, pp 69–74
Clarke A, File SA (1982) Effects of ACTH, benzodiazepines and 5-HT antagonists on escape from periaqueductal grey stimulation in the rat. Progr Neuro-Psychopharmacol Biol Psychiat 6:27–35
De Araujo JE, Huston JP, Brandão ML (1998) Aversive effects of the C-fragment of substance P in the dorsal periaqueductal gray matter. Exp Brain Res 123:84–89
Graeff FG (1991) Neurotransmitters in the dorsal periaqueductal grey and animal models of panic anxiety. In: Briley M, File SE (eds) New concepts in anxiety. McMillan Press, London, pp 288–312
Graeff FG, Brandão ML, Audi EA, Schütz MTB (1986) Modulation of the brain aversive system by GABAergic and serotoninergic mechanisms. Behav Brain Res 21:65–72
Graeff FG, Audi EA, Almeida SS, Graeff EO, Hunziker MHL (1990) Behavioral effects of 5-HT receptor ligands in the aversive brain stimulation, elevated plus-maze and learned helplessness tests. Neurosci Biobehav Rev 14:501–506
Graeff FG, Silveira MCL, Nogueira RL, Audi EA, Oliveira RMW (1993) Role of the amygdala and periaqueductal gray in anxiety and panic. Behav Brain Res 58:123–131
Graeff FG, Viana MB, Mora PO (1997) Dual role of 5-HT in defense and anxiety. Neurosci Biobehav Rev 21:791–799
Jenck F, Broekkamp CLE, von Delft AML (1989) Effects of serotonin receptor antagonists on PAG stimulation induced aversion: different contribution of 5-HT1, 5-HT2 and 5-HT3 receptors. Psychopharmacology (Berl) 97:489–495
Jenck F, Moreau JL, Martin JR (1995) Dorsal periaqueductal gray-induced aversion as a simulation of panic anxiety: elements of face and predictive validity. Psychiatry Res 57:181–191
Jenck F, Martin JR, Moreau JL (1996) Behavioral effects of CCKB receptor ligands in a validated simulation of panic anxiety in rats. Eur Neuropsychopharmacol 6:291–298
Jenck F, Moreau JL, Berendsen HHG, Boes M, Broekkamp CLE, Martin JR, Wichmann J, von Delft AML (1998) Antiaversive effects of 5-HT2c receptor agonists and fluoxetine in a model of panic-like anxiety. Eur Neuropsychopharmacol 8:161–168
Jenck F, Martin JR, Moreau JL (1999) The 5-HT1A receptor agonist flesinoxan increases aversion in a model of panic-like anxiety in rats. J Psychopharmacol 13:166–170
Melo LL, Brandão ML (1995) Involvement of 5-HT1A and 5-HT2 receptors of the inferior colliculus in aversive states induced by exposure of rats to the elevated plus-maze test. Behav Pharmacol 6:413–417
Motta V, Penha K, Brandão ML (1995) Effects of microinjections of m and k receptor agonists into the dorsal periaqueductal gray of rats submitted to the plus maze test. Psychopharmacology (Berl) 120:470–474
Nogueira RL, Graeff FG (1991) 5-HT mediation of the antiaversive effect of isomoltane injected into the dorsal periaqueductal grey. Behav Pharmacol 2:73–77
Nogueira RL, Graeff FG (1995) Role of 5-HT receptor subtypes in the modulation of dorsal periaqueductal gray generated aversion. Pharmacol Biochem Behav 52:1–6
Paxinos G, Watson C (1982) The rat brain in stereotaxic coordinates. Academic, New York
Schenberg LC, Bittencourt AS, Sudré ECM, Vargas LC (2001) Modeling panic attacks. Neurosci Biobehav Rev 25:647–659
Schütz MTB, de Aguiar JC, Graeff FG (1985) Anti-aversive role of serotonin in dorsal periaqueductal grey matter. Psychopharmacology (Berl) 85:340–345
Sidman Avoidance Paradigm
Balfour DJK (1990) A comparison of the effects of nicotine and (+)-amphetamine on rat behavior in an unsignalled Sidman avoidance schedule. J Pharm Pharmacol 42:257–260
Duffield PH, Jamieson DD, Duffield AM (1989) Effect of aqueous and lipid-soluble extracts of Kava on the conditioned avoidance in rats. Arch Int Pharmacodyn 301:81–90
Galizio M, Journey JW, Royal SA, Welker JA (1990) Variable-interval schedules of time-out from avoidance: effects of anxiolytic and antipsychotic drugs in rats. Pharmacol Biochem Behav 37:235–238
Heise GA, Boff E (1962) Continuous avoidance as a base-line for measuring behavioral effects of drugs. Psychopharmacologia 3:264–282
Patel JB, Migler B (1982) A sensitive and selective monkey conflict test. Pharmacol Biochem Behav 17:645–649
Shekar A, Hingtgen JN, DiMicco JA (1987) Selective enhancement of shock avoidance responding elicited by GABA blockade in the posterior hypothalamus of rats. Brain Res 420:118–128
Sidman M (1953a) Avoidance conditioning with brief shock and no enteroceptive warning signal. Science 118:157–158
Sidman M (1953b) Two temporal parameters of the maintenance of avoidance behavior by the white rat. J Comp Physiol Psychol 46:253–261
Szewczak MR, Corbett R, Rush DK, Wilmot CA, Conway PG, Strupczewski JT, Cornfeldt M (1995) The pharmacological profile of iloperidone, a novel atypical antipsychotic agent. J Pharmacol Exp Ther 274:1404–1413
Wadenberg ML, Young KA, Trompler RA, Zavodny RA, Richter TJ, Hicks OB (1998) A novel computer-controlled conditioned avoidance apparatus for rats. J Pharmacol Toxicol Methods 38:211–215
Geller Conflict Paradigm
Barrett JE (1991) Animal behavior models in the analysis and understanding of anxiolytic drugs acting on serotonin receptors. In: Olivier B, Mos J, Slangen JL (eds) Animal models in psychopharmacology, Advances in pharmacological sciences. Birkhäuser Verlag, Basel, pp 37–52
Barrett JE, Gleeson S, Nader MA, Hoffmann SM (1989) Anticonflict effects of the 5-HT1A compound flesinoxan. J Psychopharmacol 3:64–69
Barrett JE, Gamble EH, Zhang L, Guardiola-Lemaître B (1994) Anticonflict and discriminative stimulus effect in the pigeon of a new methoxy-chroman 5-HT1A agonist, (+)S 20244 and its enantiomers (+)S 20499 and (−)S 20500. Psychopharmacol 116:73–78
Beaufour CC, Ballon N, le Bihan C, Hamon M, Thiébot MH (1999) Effects of chronic antidepressants in an operant conflict procedure of anxiety in the rat. Pharmacol Biochem Behav 62:591–599
Bignami G (1988) Pharmacology and anxiety: inadequacies of current experimental approaches and working models. Pharmacol Biochem Behav 29:771–774
Broersen LM, Woudenberg F, Slangen JL (1991) The lack of tolerance to the anxiolytic effects of benzodiazepines in the Geller/Seifter conflict test. In: Olivier B, Mos J, Slangen JL (eds) Animal models in psychopharmacology, Advances in pharmacological sciences. Birkhäuser Verlag, Basel, pp 97–101
Chipkin RE, Iorio LC, Coffin VL, McQuade RD, Berger JG, Barnett A (1988) Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity. J Pharmacol Exper Ther 247:1093–1102
Commissaris RL, Fontana DJ (1991) A potential animal model for the study of antipanic treatments. In: Olivier B, Mos J, Slangen JL (eds) Animal models in psychopharmacology, Advances in pharmacological sciences. Birkhäuser Verlag, Basel, pp 53–59
Cook L, Davidson AB (1973) Effects of behaviorally active drugs in a conflict-punishment procedure in rats. In: Garattini S, Mussini E, Randall LO (eds) The benzodiazepines. Raven Press, New York, pp 327–345
Cook L, Sepinwall J (1975) Behavioral analysis of the effects and mechanisms of action of benzodiazepines. In: Costa E, Greengard P (eds) Mechanisms of action of benzodiazepines. Raven Press, New York, pp 1–28
Davidson AB, Cook L (1969) Effects of combined treatment with trifluoperazine-HCl and amobarbital on punished behavior in rats. Psychopharmacologia (Berl) 15:159–168
Ervin GN, Cooper BR (1988) Use of conditioned taste aversion as a conflict model: effects of anxiolytic drugs. J Pharmacol Exp Ther 245:137–146
Ervin GN, Soroko FS, Cooper BR (1987) Buspirone antagonizes the expression of conditioned taste aversion in rats. Drug Dev Res 11:87–95
Geller I, Seifter J (1960) The effects of meprobamate, barbiturates, d-amphetamine and promazine on experimentally induced conflict in the rat. Psychopharmacologia 1:482–492
Geller I, Kulak JT, Seifter J (1962) The effects of chlordiazepoxide and chlorpromazine on a punishment discrimination. Psychopharmacologia 3:374–385
Gleeson S, Ahlers ST, Mansbach RS, Foust JM, Barrett JE (1989) Behavioral studies with anxiolytic drugs: VI. Effects on punished responding of drugs interacting with serotonin receptor subtypes. J Pharmacol Exp Ther 250:809–817
Hanson HM, Stone CA (1964) Animal techniques for evaluating antianxiety drugs. In: Nodine JN, Siegler PE (eds) Animal and clinical pharmacologic techniques in drug evaluation. Year Book Medical Publication, Chicago, pp 317–324
Howard JL, Pollard GT (1990) Effects of buspirone in the Geller-Seifter conflict test with incremental shock. Drug Dev Res 19:37–49
Iorio LC, Barnett A, Billard W, Gold EH (1986) Benzodiazepines: structure-activity relationships between D1 receptor blockade and selected pharmacological effects. In: Breese GR, Creese I (eds) Neurobiology of central D1 dopamine receptors. Plenum Press, New York, pp 1–14
Iversen S (1983) Animal models of anxiety. In: Trimble RM (ed) Benzodiazepines divided. Wiley, Chichester, pp 87–99
Keane PE, Siminand J, Morre M, Biziere K (1988) Tetrazepam: a benzodiazepine which dissociates sedation from other benzodiazepine activities. I. Psychopharmacological profile in rodents. J Pharmacol Exper Ther 245:692–698
Koene P, Vossen JMH (1991) Drug effects on speed of conflict resolution in the Skinnerbox. In: Olivier B, Mos J, Slangen JL (eds) Animal models in psychopharmacology, Advances in pharmacological sciences. Birkhäuser Verlag, Basel, pp 53–59
Mc Millan DE (1973) Drugs and punished responding. I: ratedependent effects under multiple schedules. J Exp Anal Behav 19:133–145
Morse WH (1964) Effect of amobarbital and chlorpromazine on punished behavior in the pigeon. Psychopharmacologia 6:286–294
Mos J, van Hest A, van Drimmelen M, Herremans AHJ, Olivier B (1997) The putative 5-HT1A receptor antagonist DU125530 blocks the discriminative stimulus of the5-HT1A receptor agonist flesinoxan in pigeons. Eur J Pharmacol 325:145–153
Patel JB, Migler B (1982) A sensitive and selective monkey conflict test. Pharmacol Biochem Behav 17:645–649
Pollard GT, Nanry KP, Howard JL (1992) Effects of tandospirone in three behavioral tests for anxiolytics. Eur J Pharmacol 221:297–305
Prado de Carvalho L, Venault P, Potier MC, Dodd RH, Brown CL, Chapoutier G, Rossier RH (1986) 3-(Methoxycarbonyl)-amino-β-carboline, a selective antagonist of the sedative effects of benzodiazepines. Eur J Pharmacol 129:232–233
Schipper J, Tulp MTM, Berkelmans B, Mos J, Van der Heijden JAM, Olivier B (1991) Preclinical pharmacology of Flesinoxan: a potential anxiolytic and antidepressant drug. Hum Psychopharmacol 6:53–61
Silverman P (1978) Operant conditioning. In: Animal behaviour in the laboratory. Chapman and Hall, London, pp 141–178
Simiand J, Keane PE, Barnouin MC, Keane M, Soubrié P, Le Fur G (1993) Neurospychopharmacological profile in rodents of SR 57746A, a new, potent 5-HT1A receptor agonist. Fundam Clin Pharmacol 7:413–427
Slangen JL (1991) Drug discrimination and animal models. In: Olivier B, Mos J, Slangen JL (eds) Animal models in psychopharmacology, Advances in pharmacological sciences. Birkhäuser Verlag, Basel, pp 359–373
Thiébot MH, Dangoumau L, Richard G, Puech AJ (1991) Safety signal withdrawal: a behavioral paradigm sensitive to both “anxiolytic” and “anxiogenic” drugs under identical experimental conditions. Psychopharmacology (Berl) 103:415–424
van Heest A, Slangen JL, Olivier B (1991) Is the conditioned taste aversion procedure a useful tool in the drug discrimination research? In: Olivier B, Mos J, Slangen JL (eds) Animal models in psychopharmacology, Advances in pharmacological sciences. Birkhäuser Verlag, Basel, pp 399–405
Wuttke W, Kelleher RT (1970) Effects of some benzodiazepines on punished and unpunished behavior in the pigeon. J Pharmacol Exper Ther 172:397–405
Progressive Ratio Procedure
Barr AM, Phillips AG (1999) Withdrawal following exposure to d-amphetamine decreases responding for a sucrose solution as measured by a progressive ratio schedule of reinforcement. Psychopharmacology (Berl) 141:99–106
Bourland JA, French ED (1995) Effects of remoxipride, an atypical antipsychotic, on cocaine self-administration in the rat using fixed -and progressive-ratio schedules of reinforcement. Drug Alcohol Depend 40:111–114
Drews E, Schneider M, Koch M (2005) Effects of the cannabinoid agonist win 55,212–2 on operant behavior and locomotor activity in rats. Pharmacol Biochem Behav 80:145–150
Duvauchelle CL, Sapoznik T, Kornetsky C (1998) The synergistic effects of combining cocaine and heroin (“Speedball”) using a progressive-ratio schedule of drug reinforcement. Pharmacol Biochem Behav 61:297–302
Ferguson SA, Paule MG (1996) Effects of chlorpromazine and diazepam on time estimation behavior and motivation of rats. Pharmacol Biochem Behav 53:115–122
Grottnick AJ, Fletcher PJ, Higgins GA (2000) Studies to investigate the role of 5-HT2C1 receptors on cocaineand food-maintained behavior. J Pharmacol Exp Ther 295:1183–1191
Kozinowski AP, Johnson KM, Deschaux O, Bandyopadhyay BD, Araldi GL, Carmona G, Munzar P, Smith MP, Balster RL, Beardsley PM, Tella SR (2003) Mixed cocaine agonist/antagonist properties of (+).methyl-4β-(4-chlorophenyl)-1-methylpiperidine-3α-carboxylate, a piperidine-based analog of cocaine. J Pharmacol Exp Ther 305:143–150
McGregor A, Lacosta S, Roberts DC (1993) l-tryptophan decreases the breaking point under a progressive ratio schedule of intravenous cocaine reinforcement in the rat. Pharmacol Biochem Behav 44:651–655
Mobini S, Chiang TJ, Ho MY, Bradshaw CM, Szabadi E (2000) Comparison of the effects of clopazine, haloperidol, chlorpromazine and d-amphetamine on performance of a timeconstrained progressive ratio schedule and on locomotor behavior in the rat. Psychopharmacology (Berl) 152:47–54
Poncelet M, Chermat R, Soubrie P, Simon P (1983) The progressive ration schedule as a model for studying the psychomotor stimulant activity of drugs in the rat. Psychopharmacology (Berl) 80:184–189
Pulvirenti L, Balducci C, Koob GF (1997) Dextromorphan reduces intravenous cocaine self-administration in the rat. Eur J Pharmacol 321:279–281
Pulvirenti L, Balducci C, Pierci M, Koob GF (1998) Characterization of the effects of the partial dopamine agonist Terguride on cocaine self-administration in the rat. J Pharmacol Exp Ther 286:1231–1238
Reilly S (1999) Reinforcement value of gustatory stimuli determined by progressive ratio performance. Pharmacol Biochem Behav 63:301–311
Richardson NR, Roberts DC (1991) Fluoxetine pretreatment reduces breaking points on a progressive ratio schedule reinforced by intravenous cocaine self-administration in the rat. Life Sci 49:833–840
Schneider M, Koch M (2002) The cannabinoid agonist WIN 55–212–2 reduces sensorimotor gating and recognition memory in rats. Behav Pharmacol 13:29–37
Schneider M, Koch M (2003) Chronic pubertal, but not adult chronic cannabinoid treatment impairs sensorimotor gating, recognition memory, and the performance in a progressive ratio task in adult rats. Neuropsychopharmacology 28:1760–1769
Solinas M, Panililio LV, Goldberg SR (2004) Exposure to delta-9-tetrahydrocannabinol (THC) increases subsequent heroin taking but not heroin’s reinforcing efficacy: a selfadministration study in rats. Neuropsychopharmacology 29:1301–1311
Weed MR, Paul IA, Dwoskin LP, Moore SE, Woolverton WL (1997) The relationship between reinforcing effects and in vitro effects of D1 agonists in monkeys. J Pharmacol Exp Ther 283:29–38
Wilcox KM, Rowlett JK, Paul IA, Ordway GA, Woolverton WL (2000) On the relationship between the dopamine transporter and the reinforcing effects of local anesthetics: practical and theoretical concerns. Psychopharmacology (Berl) 153:139–147
Woolverton WL, Ranaldi R, Wang Z, Ordway GA, Paul IA, Petukhov P, Kozinowski A (2002) Reinforcing strength of a novel dopamine transporter ligand: pharmacodynamic and pharmacokinetic properties. J Pharmacol Exp Ther 303:212–217
Conditioned Defensive Burying in Rats
Broekkamp CL, Rijk HW, Joly-Gelouin D, Lloyd KL (1986) Major tranquillizers can be distinguished from minor tranquillizers on the basis of effects on marble burying and swim-induced grooming in mice. Eur J Pharmacol 126:223–229
Craft RM, Howard JL, Pollard GT (1988) Conditioned defensive burying as a model for identifying anxiolytics. Pharmacol Biochem Behav 30:775–780
DeBoer SF, Koolhaas JM (2003) Defensive burying in rodents: ethology, neurobiology and psychopharmacology. Eur J Pharmacol 463:145–161
deBoer SF, Slangen JL, van der Gugten J (1990) Plasma catecholamine and corticosterone levels during active and passive shock-prod avoidance behavior in rats: effects of chlordiazepoxide. Physiol Behav 47:1089–1098
deBoer SF, van der Gugten J, Slangen JL (1991) Behavioural and hormonal indices of anxiolytic and anxiogenic drug action in the shock prod defensive burying/avoidance paradigm. In: Olivier B, Mos J, Slangen JL (eds) Animal models in psychopharmacology. Birkhäuser Verlag, Basel, pp 137–159
Diamant M, Croiset G, de Zwart N, de Wied D (1991) Shockprod burying test in rats: autonomic and behavioral responses. Physiol Behav 50:23–31
Fernandez-Guasti A, Lopez-Rubalcava C (1998) Modification of the anxiolytic action of 5-HT1A compounds by GABAbenzodiazepine agents in rats. Pharmacol Biochem Behav 60:27–32
Gacsályi I, Schmidt E, Gyertyán I, Vasar E, Lang A, Haapalinna A, Fekete M, Hietala J, Syvälahti E, Tuomainen P, Männistö P (1997) Receptor binding profile and anxiolytictype activity of deramciclane (EGIS-3886) in animal models. Drug Dev Res 40:333–348
Njung’e K, Handley SL (1991a) Evaluation of marble-burying behavior as a model of anxiety. Pharmacol Biochem Behav 38:63–67
Njung’e K, Handley SL (1991b) Effects of 5-HT uptake inhibitors, agonists and antagonists on the burying of harmless objects by mice; a putative test for anxiolytic agents. Br J Pharmacol 104:105–112
Pinel JPJ, Treit D (1978) Burying as a defensive response in rats. J Comp Physiol Psychol 92:708–712
Pinel JPJ, Treit D (1983) The conditioned defensive burying paradigm and behavioral neuroscience. In: Robinson T (ed) Behavioral approaches to brain research. Oxford Press, New York, pp 212–234
Treit D (1985) Animal models for the study of anti-anxiety agents. A review. Neurosci Biobehav Rev 9:203–222
Treit D, Pinel JPJ, Fibiger HC (1981) Conditioned defensive burying: a new paradigm for the study of anxiolytic agents. Pharmacol Biochem Behav 15:619–626
Wiersma A, Bohus B, Koolhaas JM, Nobel A (1996) Corticotropin-releasing hormone microinfusion of in the central amygdala enhances active behavior responses in the conditioned defensive burying paradigm. Stress 1:113–122
Taste Aversion Paradigm
Agüero A, Arnedo M, Gallo M, Puerto A (1993) The functional relevance of the lateral parabrachial nucleus in lithium chloride-induced aversion learning. Pharmacol Biochem Behav 45:973–978
Agüero A, Gallo M, Arnedo M, Molina F, Puerto A (1996) Effects of lesions of the medial parabrachial nucleus (PBNm): taste discrimination and lithium-chloride-induced aversion learning after delayed and contiguous interstimulus intervals. Psychobiology 24:265–280
Bardo MT, Valone JM (1994) Morphine-conditioned analgesia using a taste cue: dissociation of taste aversion and analgesia. Psychopharmacology (Berl) 114:269–274
Bevins RA, Delzer TA, Bardo MT (1996) Characterization of the conditioned taste aversion produced by 7-OH-DPAT in rats. Pharmacol Biochem Behav 53:695–699
Bienkowski P, Kuca P, Piasecki J, Kostowski W (1997) 5-HT3 receptor antagonist, tropisetron, does not influence ethanolinduced conditioned taste aversion and conditioned place aversion. Alcohol 14:63–69
Brockwell NT, Eikelboom R, Beninger RJ (1991) Caffeine-induced place and taste conditioning: production of dose-dependent preference and aversion. Pharmacol Biochem Behav 38:513–517
Davies BT, Wellman PJ (1990) Conditioned taste reactivity in rats after phenylpropanolamine, d-amphetamine or lithium chloride. Pharmacol Biochem Behav 36:973–977
De Beun R, Lohmann A, de Vry J (1996) Conditioned taste aversion and place preference induced by the calcium channel antagonist nimodipine in rats. Pharmacol Biochem Behav 54:657–663
Ervin GN, Birkemo LS, Johnson MF, Conger LK, Mosher JT, Menius JA Jr (1995) The effects of anorectic and aversive agents on deprivation-induced feeding and taste aversion conditioning in rats. J Pharmacol Exp Ther 273:1203–1210
Exton MS, von Horsten S, Voge J, Westermann J, Schult M, Nagel E, Schedlowski M (1998) Conditioned taste aversion produced by cyclosporine A: concomitant reduction of lymphoid organ weight and splenocyte proliferation. Physiol Behav 63:241–247
Gauvin DV, Holloway FA (1992) Ethanol tolerance developed during intoxicated operant performance in rats prevents subsequent ethanol-induced conditioned taste aversion. Alcohol 9:167–170
Glowa JR, Shaw AE, Riley AL (1994) Cocaine-induced conditioned taste aversion: comparisons between effects in LEW/N and F344/N rat strains. Psychopharmacology (Berl) 114:229–232
June HL, June PL, Domangue KR, Hicks LH, Lummis GH, Lewis MJ (1992) Failure of Ro15–4513 to alter an ethanol-induced taste aversion. Pharmacol Biochem Behav 41:455–460
Land CL, Riccio DC (1997) d-Cycloserine, a positive modulator of the NMDA receptor, enhances acquisition of a conditioned taste aversion. Psychobiology 25:210–216
Lin HQ, McGregor IS, Atrens DM, Christie MJ, Jackson DM (1994) Contrasting effects of dopamine blockade on MDMA and d-amphetamine conditioned taste aversion. Pharmacol Biochem Behav 47:369–374
Lipinski WJ, Rusiniak KW, Hilliard M, Davis RE (1995) Nerve growth factor facilitates conditioned taste aversion learning in normal rats. Brain Res 692:143–153
McAllister KHM, Pratt JA (1998) GR205171 blocks apomorphine and amphetamine-induced conditioned taste aversions. Eur J Pharmacol 353:141–148
Mele PC, McDonough JR, McLean DB, O’Halloran KP (1992) Cisplatin-induced conditioned taste aversion: attenuation by dexamethasone but not by zacopride or GR38032F. Eur J Pharmacol 218:229–236
Miller JS, Kelly KS, Neisewander JL, McCoy DF, Bardo MT (1990) Conditioning of morphine-induced taste aversion and analgesia. Psychopharmacology (Berl) 101:472–480
Mosher JT, Hohnson MF, Birkemo LS, Ervin GN (1996) Several roles of CCKA and CCKB receptor subtypes in CCK-8-induced and LiCl-induced taste aversion conditioning. Peptides 17:483–488
Mucha RF (1997) Preference for tastes paired with a nicotine antagonist in rats chronically treated with nicotine. Pharmacol Biochem Behav 56:175–179
Neisewander JL, McDougall SA, Bowling SL, Bardo MT (1990) Conditioned taste aversion and place preference with buspirone and gespirone. Psychopharmacology (Berl) 100:485–490
Parker LA (1994) Aversive taste reactivity: reactivity to quinine predicts aversive reactivity to lithium-paired sucrose solution. Pharmacol Biochem Behav 47:73–75
Parker LA, Gillies T (1995) THC-induced place and taste aversions in Lewis and Sprague–Dawley rats. Behav Neurosci 109:71–78
Rabin BM, Hunt WA (1992) Relationship between vomiting and taste aversion learning in ferrets: studies with ionizing radiation, lithium chloride, and amphetamine. Behav Neural Biol 58:83–93
Rudd JA, Ngan MP, Wai MK (1998) 5-HT3 receptors are not involved in conditioned taste aversions induced by 5-hydroxytryptamine, ipecacuanha or cisplatin. Eur J Pharmacol 352:143–149
Shoaib M, Stolerman IP (1996) The NMDA antagonist dizocilpine (MK801) attenuates tolerance to nicotine in rats. J Psychopharmacol 10:214–218
Sobel BFX, Wetherington CL, Riley AL (1995) The contribution of within-session averaging of drug- and vehicle-appropriate responding to the graded dose–response function in drug discriminating learning. Behav Pharmacol 6:348–358
Swank MW, Schafe GE, Bernstein IL (1995) c-Fos induction in response to taste stimuli previously paired with amphetamine or LiCl during taste aversion learning. Brain Res 673:251–261
Thiele TE, Roitman MF, Bernstein IL (1996) c-Fos induction in rat brainstem in response to ethanol- and lithium chlorideinduced conditioned taste aversions. Alcohol Clin Exp Res 20:1023–1028
Turenne SD, Miles C, Parker LA, Siegel S (1996) Individual differences in reactivity to the rewarding/aversive properties of drugs: assessment by taste and place conditioning. Pharmacol Biochem Behav 53:511–516
Van Haaren F, Hughes CE (1990) Cocaine-induced conditioned taste aversions in male and female Wistar rats. Pharmacol Biochem Behav 37:693–696
Willner J, Gallagher M, Graham PW, Crooks GB Jr (1992) Nmethyl-d-aspartate antagonist D-APV selectively disrupts taste-potentiated odor aversion learning. Behav Neurosci 106:315–323
Yamamoto T (1993) Neural mechanisms of taste aversion learning. Neurosci Res 16:181–185
Cued and Contextual Fear Conditioning
Anagnostaras SG, Maren S, Sage JR, Goodrich S, Fanselow MS (1999) Scopolamine and Pavlovian fear conditioning in rats: dose-effect analysis. Neuropsychopharmacology 21:731–744
Brown JS, Kalish HI, Farber IE (1951) Conditioned fear as revealed by magnitude of startle response to an auditory stimulus. J Exp Psychol 41:317–328
Cambon K, Venero C, Berezin V, Bock E, Sandi C (2003) Posttraining administration of a synthetic peptide ligand of the neural cell adhesion molecule, C3d, attenuates long-term expression of contextual fear conditioning. Neuroscience 122:183–191
Célérier A, Pierard C, Beracochea D (2004) Effect of ibotenic acid lesions of the dorsal hippocampus on contextual fear conditioning in mice: comparison with mammillary body lesions. Behav Brain Res 151:65–72
Contarino A, Baca L, Kennelly A, Gold LH (2002) Automated assessment of conditioning parameters for context and cued fear in mice. Learn Mem 9:89–96
Crestani F, Keist R, Fritschy JM, Benke D, Vogt K, Prut L, Blüthmann H, Möhler H, Rudolph U (2002) Trace fear conditioning involves hippocampal á5 GABAA receptors. Proc Natl Acad Sci U S A 99:8980–8985
DeLorey TM, Lin RC, McBrady B, He X, Cook JM, Lameh J, Loew GH (2001) Influence of benzodiazepine binding site ligands on fear-conditioned contextual memory. Eur J Pharmacol 426:45–54
Eckart K, Jahn O, Radulovic J, Tezval H, van Werven L, Spiess J (2001) A single amino acid serves as an affinity switch between the receptor and the binding protein of corticotrophin-releasing factor: implications for the design of agonists and antagonists. Proc Natl Acad Sci U S A 98:11142–11147
Fendt M, Fanselow MS (1999) The neuroanatomical and neurochemical basis of conditioned fear. Neurosci Biobehav Rev 23:743–770
Fischer A, Sananbenesi F, Schrick C, Spiess J, Radulovic J (2003) Regulation of contextual fear conditioning by baseline and inducible septo-hippocampal cyclin-dependent kinase 5. Neuropharmacology 44:1089–1099
Gould T, Feiro O, Moore D (2004) Nicotine enhances trace cued fear conditioning but not delay cued fear conditioning in C57BL/6 mice. Behav Brain Res 155:167–173
Gupta RR, Sen S, Diepenhorst LL, Rudick CN, Marebn S (2001) Estrogen modulâtes sexually dimorphic contextual fear conditioning and hippocampal long-term potentiation (LTP) in rats. Brain Res 888:336–365
Kishimoto J, Radulovic J, Radulovic M, Lin CR, Schrick C, Hooshmand F, Hermanson O, Rosenfeld MG, Spiess J (2000) Deletion of Crhr2 reveals an anxiolytic role for corticotropin-releasing hormone receptor-2. Nat Genet 24:415–419
Kudo K, Qiao CX, Kanba S, Arita J (2004) A selective increase in phosphorylation of cyclic AMP response element-binding protein in hippocampal CA1 region of male, but not female, rats following contextual fear and passive avoidance conditioning. Brain Res 1024:233–243
Laurent-Demir C, Jaffard R (2000) Paradoxical facilitatory effect of fornix lesions on acquisition of contextual fear conditioning in mice. Behav Brain Res 107:85–91
Lu Y, Wehner JM (1997) Enhancement of contextual fear-conditioning by putative (±)-á-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor modulators and N-methyl-d-aspartate (NMDA) receptor antagonists in DBA/2 J mice. Brain Res 786:197–207
Maciejak P, Taracha E, Lehner M, Szyndler J, Bidzinski A, Skórzewska A, Wislowska A, Zienowicz M, Plaznik A (2003) Hippocampal mGluR1 and consolidation of contextual fear conditioning. Brain Res Bull 62:39–45
Malkani S, Rosen JB (2001) N-Methyl-d-aspartate receptor antagonism blocks contextual fear conditioning and differentially regulates early growth response-1 messenger RNA expression in the amygdala: implications for a functional amygdaloid circuit of fear. Neuroscience 102:853–861
Maren S (1998) Effects of 7-nitroindazole, a neuronal nitric oxide synthase (nNOS) inhibitor, on locomotor activity and contextual fear conditioning in rats. Brain Res 804:155–158
McKay BE, Lado WE, Martin LJ, Galic MA, Fournier NM (2002) Learning and memory in agmatine-treated rats. Pharmacol Biochem Behav 72:551–557
Mesches MH, Gemma C, Veng LM, Allgeier C, Young DA, Browning MD, Bickford PC (2004) Sulindac improves memory and increases NMDA receptor subunits in aged Fischer 344 rats. Neurobiol Aging 25:315–324
Phillips RG, LeDoux JE (1992) Differential contribution of amygdala and hippocampus to cued and contextual fear conditioning. Behav Neurosci 106:274–285
Radulovic J, Kammermeier J, Spiess J (1998) Generalization of fear responses in C57BL/6 N mice subjected to one-trial foreground contextual fear conditioning. Behav Brain Res 95:179–189
Radyushkin K, Anokhin KL, Meyer BI, Jiang Q, Alvarez-Bolado G, Gruss P (2005) Genetic ablation of the mammillary bodies in the Foxb 1 mutant mouse leads to selective deficit of spatial working memory. Eur J Neurosci 21:219–229
Riedel G, Sandager-Nielsen K, Macphail EM (2002) Impairment of contextual fear conditioning in rats by Group I mGluRs: reversal by the nootropic nefiracetam. Pharmacol Biochem Behav 73:391–399
Roberts AJ, Krucker T, Levy CL, Slanina KA, Sutcliffe JG, Hedlund PB (2004) Mice lacking 5-HT7 receptors show specific impairments in contextual learning. Eur J Neurosci 19:1913–1922
Sienkiewicz-Jarosz H, Maciajak P, Bidziński A, Szyndler J, Siemątkowski M, Czlonkowska A, Lehner M, Plaźnik A (2003) Exploratory activity and a conditioned fear response: correlation with cortical and subcortical binding of the α4β2 nicotinic receptor agonist [3H]-epibatine. Pol J Pharmacol 55:17–23
Stiedl O, Radulovic J, Lohmann R, Birkenfeld K, Palve M, Kammermeier J, Sananbenesi F, Spiess J (1999) Strain and substrate differences in context- and tone-dependent fear conditioning of inbred mice. Behav Brain Res 104:1–12
Stiedl O, Misana I, Spiess J, Ögren SO (2000) Involvement of the 5-HT1A receptors in classical fear conditioning in C57BL/6 J mice. J Neurosci 20:8515–8527
Sullivan GM, Apergis J, Gorman JM, LeDoux JE (2003) Rodent Doxapram model of panic: behavioral effects and c-fos immunoreactivity in the amygdala. Biol Psychiatry 53:863–870
Takahashi H (2004) Automated measurement of freezing time to contextual and auditory cues in fear conditioning as a simple screening method to assess learning and memory in rats. J Toxicol Sci 29:53–61
Tezval H, Jahn O, Todorovic C, Sasse A, Eckart K, Spiess J (2004) Cortagine, a specific agonist of corticotrophin-releasing factor receptor subtype 1, is anxiogenic and antidepressive in the mouse model. Proc Natl Acad Sci U S A 101:9468–9473
Tovote P, Meyer M, Pilz PKD, Ronnenberg A, Ögren SO, Spiess J, Stiedl O (2005) Dissociation of temporal dynamics of heart rate and blood pressure responses elicited by conditioned fear but not acoustic startle. Behav Neurosci 119:55–65
Võikar V, Rossi J, Rauvala H, Airaksinen MS (2004) Impaired behavioural flexibility and memory in mice lacking GDNF family receptor α2. Eur J Neurosci 20:308–312
Walker P, Carrive P (2003) Role of ventrolateral periaqueductal gray neurons in the behavioral and cardiovascular responses to contextual conditioned fear and poststress recovery. Neuroscience 116:897–912
Wehner JM, Keller JJ, Keller AB, Piciotto MR, Paylor R, Booker TK, Beaudet A, Heinemann SF, Balogh SA (2004) Role of neuronal nicotinic receptors in the effects of nicotine and ethanol on contextual fear conditioning. Neuroscience 129:11–24
Zhang WN, Murphy CA, Feldon J (2004) Behavioral and cardiovascular responses during latent inhibition of conditioned fear measurement by telemetry and conditioned freezing. Behav Brain Res 154:199–209
Plasma Catecholamine Levels During and After Stress
deBoer SF, deBeun R, Slangen JL, van der Gugten J (1990a) Dynamics of plasma catecholamine and corticosterone concentrations during reinforced and extinguished operant behavior in rats. Physiol Behav 47:691–698
deBoer SF, Slangen JL, van der Gugten J (1990b) Plasma catecholamine and corticosterone levels during active and passive shock-prod avoidance behavior in rats: effects of chlordiazepoxide. Physiol Behav 47:1089–1098
Krieman MJ, Hershock DM, Greenberg IJ, Vogel WH (1992) Effects of adinazolam on plasma catecholamine, heart rate and blood pressure responses in stressed and non-stressed rats. Neuropharmacology 31:33–38
Livesey GT, Miller JM, Vogel WH (1985) Plasma norepinephrine, epinephrine and corticosterone stress responses to restraint in individual male and female rats. Neurosci Lett 62:51–56
Natelson BH, Creighton D, McCarty R, Tapp WN, Pittman D, Ottenweller JE (1987) Adrenal hormonal indices of stress in laboratory rats. Physiol Behav 39:117–125
Taylor J, Harris N, Krieman M, Vogel WH (1989) Effects of buspirone on plasma catecholamines, heart rate and blood pressure in stressed and non-stressed rats. Pharmacol Biochem Behav 34:349–353
Vogel WH, Miller J, DeTurck KH, Routzahn BK (1984) Effects of psychoactive drugs on plasma catecholamines during stress in rats. Neuropharmacology 23:1105–1109
Plasma Corticosterone Levels Influenced by Psychotropic Drugs
Aulakh CS, Wozniak KM, Hill JL, DeVane CL, Tolliver TJ, Murphy DL (1988) Differential neuroendocrine responses to the 5-HT agonist m-chlorophenylpiperazine in fawnhooded rats relative to Wistar and Sprague–Dawley rats. Neuroendocrinology 48:401–406
Aulakh CS, Hill JL, Murphy DL (1993) Attenuation of hypercortisolemia in fawn-hooded rats by antidepressant drugs. Eur J Pharmacol 240:85–88
Broqua P, Baudrie V, Laude D, Chaouloff F (1992) Influence of the novel antidepressant tianeptine on neurochemical, neuroendocrinological, and behavioral effects of stress in rats. Biol Psychiatry 31:391–400
Groenink L, Van der Gugten J, Mos J, Maes RAA, Olivier B (1995) The corticosterone-enhancing effects of the 5-HT1A receptor antagonist, (S)-UH301, are not mediated by the 5-HT1A receptor. Eur J Pharmacol 272:177–183
Koenig JI, Gudelsky GA, Meltzer HY (1987) Stimulation of corticosterone and β-endorphin secretion in the rat by selective 5-HT receptor subtype activation. Eur J Pharmacol 137:1–8
Korte SM, Smit J, Bouws GAH, Koolhaas JM, Bohus B (1991) Neuroendocrine evidence for hypersensitivity in serotonergic neuronal system after psychological stress of defeat. In: Olivier B, Mos J, Slangen JL (eds) Animal models in psychopharmacology, Advances in pharmacological sciences. Birkhäuser Verlag, Basel, pp 199–203
Nash JF, Meltzer HY, Gudelsky GA (1988) Antagonism of serotonin receptor mediated neuroendocrine and temperature responses by atypical neuroleptics in the rat. Eur J Pharmacol 151:463–469
Rittenhouse PA, Bakkum EA, O’Connor PA, Carnes M, Bethea CL, van de Kar LD (1992) Comparison of neuroendocrine and behavioral effects of ipsapirone, a 5-HT1A agonist, in three stress paradigms: immobilization, forced swim and conditioned fear. Brain Res 580:205–214
Benzodiazepine Dependence
File SE, Hitcott PK (1991) Benzodiazepine dependence. In: Briley M, File SE (eds) New concepts in anxiety. McMillan Press, London, pp 237–255
Benzodiazepine Tolerance and Dependence in Rats
Boisse NR, Periana RM, Guarino JJ, Kruger HS, Samorski GM (1986) Pharmacological characterization of acute chlordiazepoxide dependence in the rat. J Pharmacol Exp Ther 239:775–783
Bonnafous C, Lefevre P, Bueno L (1995) Benzodiazepine-withdrawal- induced gastric emptying disturbances in rats: evidence for serotonin receptor involvement. J Pharmacol Exp Ther 273:995–1000
File SE (1985) Tolerance to the behavioral actions of benzodiazepines. Neurosci Biobehav Rev 9:113–121
France CP, Gerak LR (1997) Discriminative stimulus effects of flumazenil in Rhesus monkeys treated chronically with chlordiazepoxide. Pharmacol Biochem Behav 56:447–455
Gallaher EJ, Henauer SA, Jacques CJ, Hollister LE (1986) Benzodiazepine dependence in mice after ingestion of drug-containing food pellets. J Pharmacol Exp Ther 237:462–467
Goudie AJ, Leathley MJ, Cowgill J (1994) Assessment of the benzodiazepine-like dependence potential in rats of a putative 5-HT1A agonist anxiolytic S-20499. Behav Pharmacol 5:131–140
Lamb RJ, Griffiths RR (1984) Precipitated and spontaneous withdrawal in baboons after chronic dosing with lorazepam and CGS 9896. Drug Alcochol Depend 14:11–17
Löscher W, Hönack D, Faßbender CP (1989) Physical dependence on diazepam in the dog: precipitation of different abstinence syndromes by the benzodiazepine receptor antagonists Ro 15–1788 and ZK 93426. Br J Pharmacol 97:843–852
Lukas SE, Griffiths RR (1982) Precipitated withdrawal by a benzodiazepine receptor antagonist (Ro 15–1788) after 7 days of diazepam. Science 217:1161–1163
McNicholas LF, Martin WR, Sloan JW, Wala E (1988) Precipitation of abstinence in nordiazepam- and diazepam-dependent dogs. J Pharmacol Exp Ther 245:221–224
Nath C, Patnaik GK, Saxena RC, Gupta MB (1997) Evaluation of inhibitory effect of diphenhydramine on benzodiazepine dependence in rats. Indian J Physiol Pharmacol 41:42–46
Nutt DJ, Costello MJ (1988) Rapid induction of lorazepam dependence with flumazenil. Life Sci 43:1045–1053
Patel JB, Rinarelli CA, Malick JB (1988) A simple and rapid method of inducing physical dependence with benzodiazepines in mice. Pharmacol Biochem Behav 29:753–754
Piot O, Betschart J, Stutzmann JM, Blanchard JC (1990) Cyclopyrrolones, unlike some benzodiazepines, do not induce physical dependence in mice. Neurosci Lett 117:140–143
Ryan GP, Boisse NR (1983) Experimental induction of benzodiazepine tolerance and physical dependence. J Pharmacol Exp Ther 226:100–107
Stephens DN, Schneider HH (1985) Tolerance to the benzodiazepine diazepam in an animal model of anxiolytic activity. Psychopharmacology 87:322–327
Treit D (1985) Evidence that tolerance develops to the anxiolytic effect of diazepam in rats. Pharmacol Biochem Behav 22:383–387
Vellucci SV, File SE (1979) Chordiazepoxide loses its anxiolytic action with long-term treatment. Psychopharmacology (Berl) 62:61–65
Yanagita T (1983) Dependence potential of zopiclone studied in monkeys. Pharmacology 27(Suppl 2):216–227
Genetically Modified Animals in Psychopharmacology
Anagnostopoulos AV, Mobraaten LE, Sharp JJ, Davisson MT (2001) Transgenic and knockout databases: behavioral profiles of mouse mutants. Physiol Behav 73:675–689
Costentin J (1998) From gene to behavior, a new method for elaboration of new psychotropic agents. Ann Pharm Fr 56:60–67
Crnic LS (1996) Transgenic and null mutant animals for psychosomatic research. Psychosom Med 58:622–632
Mayford M, Mansuy IM, Müller RU, Kandel ER (1997) Memory and behavior: a second generation of genetically modified mice. Curr Biol 7:R580–R589
Picciotto MR, Wickmanm K (1998) Using knockout and transgenic mice to study neurophysiology and behavior. Physiol Rev 78:1131–1163
Special Reports on Genetically Altered Animals Useful for Evaluation of Drugs Against Anxiety
Bilkei-Gorzo A, Racz H, Michel K, Zimmer A, Klingmüller D, Zimmer A (2004) Behavioral phenotype of preproenkephalin-deficient mice on diverse congenic backgrounds. Psychopharmacology (Berl) 176:343–352
Gross C, Santarelli L, Brunner D, Zhuang X, Hen R (2000) Altered fear circuits in 5-HT1A receptor KO mice. Biol Psychiatry 48:1157–1163
Heisler LK, Chu HM, Brennan JT, Danao JA, Bajwa P, Parsons LH, Tecott LH (1998) Elevated anxiety and antidepressant-like responses in serotonin 5-HT1A mutant mice. Proc Natl Acad Sci U S A 95:15049–15054
Holmes A (2001) Targeted gene mutation approaches to the study of anxiety-like behavior in mice. Neurosci Behav Rev 25:261–273
Knapp DJ, Sim-Selley LJ, Breese GR, Overstreet DH (2000) Selective breeding of 5-HT1A receptor-mediated responses: application to emotion and receptor action. Pharmacol Biochem Behav 67:701–708
Miyakawa T, Yamada M, Duttaroy A, Wess J (2001) Hyperactivity and intact hippocampus-dependent learning in mice lacking the M1 muscarinic acetylcholine receptor. J Neurosci 21:5239–5250
Montag-Sallaz M, Montag D (2003) Severe cognitive and motor coordination deficits in Tenascin-R-deficient mice. Genes Brain Behav 2:20–31
Parks CL, Robinson PS, Sibille E, Shenk T, Toth M (1998) Increased anxiety in mice lacking the serotonin 1A receptor. Proc Natl Acad Sci U S A 95:10734–10739
Picciotto MR, Caldarone BJ, Brunzell DH, Zachariou V, Stevens TR, King SL (2001) Neuronal nicotine acetylcholine receptor subunit knockout mice: physiological and behavioral phenotypes and possible clinical implications. Pharmacol Ther 92:89–108
Quinlan JJ, Firestone LL, Homanics GE (2000) Mice lacking the long splice variant of the gamma 2 subunit of the GABAA receptor are more sensitive to benzodiazepines. Pharmacol Biochem Behav 66:371–374
Ramboz S, Oosting R, Amara DA, Kung HF, Blier P, Mendelson M, Mann JJ, Brunner D, Hen R (1999) Serotonin receptor 1A knockout. An animal model of anxiety related disorder. Proc Natl Acad Sci U S A 95:14476–14481
Rupniak NM, Carlson EJ, Webb JK, Harrison T, Porsolt RD, Roux S, d Felipe C, Hunt SP, Oates B, Wheeldon B (2001) Comparison of the phenotype of NK1R−/− mice with pharmacological blockade of the substance P (NK1) receptor in assays for antidepressant and anxiolytic drugs. Behav Pharmacol 12:497–508
Saudou F, Amara DA, Dierich A, LeMeur M, Ramboz S, Segu L, Buhot MC, Hen R (1994) Enhanced aggressive behavior in mice lacking 5-HT1B receptor. Science 265:1875–1878
Schramm NL, McDonald MP, Limbird LE (2001) The á2A-adrenergic receptor plays a protective role in mice behavioral models of depression and anxiety. J Neurosci 21:4875–4882
Trillat AC, Malagié I, Bourin M, Jacquot C, Hen R, Gardier AM (1998) Homozygote mice deficient in serotonin 5-HT1B receptor and antidepressant effect of selective serotonin reuptake inhibitors. C R Sceances Soc Biol Fil 192:1139–1147
Wilson W, Voigt P, Bader M, Marsden CA, Fink H (1996) Behavior of the transgenic (mREN2) rat. Brain Res 729:1–9
Yamada K, Iida R, Miyamoto Y, Saito K, Sekikawa K, Seishima M, Nabeshima T (2000) Neurobehavioral alterations in mice with a targeted deletion of the tumor necrosis factor-alpha gene: implications for emotional behavior. J Neuroimmunol 111:131–138
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this entry
Cite this entry
Kallman, M.J. (2016). Tests for Anxiolytic Activity. In: Hock, F. (eds) Drug Discovery and Evaluation: Pharmacological Assays. Springer, Cham. https://doi.org/10.1007/978-3-319-05392-9_27
Download citation
DOI: https://doi.org/10.1007/978-3-319-05392-9_27
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-05391-2
Online ISBN: 978-3-319-05392-9
eBook Packages: Biomedical and Life SciencesReference Module Biomedical and Life Sciences